Effects of tumor necrosis factor-alpha on cell cycle regulatory genes expression in C6 Glioma cells. by Wong, Kin Ling. & Chinese University of Hong Kong Graduate School. Division of Biochemistry.
Effects of Tumor Necrosis Factor-Alpha on Cell Cycle 
Regulatory Genes Expression in C6 Glioma Cells 
By 
Wong Kin Ling, B. Sc. (Hons) 
A Thesis submitted to the Graduate School in Partial Fulfillment of the 
Requirements for the Degree of Master of Philosophy in Biochemistry 
©The Chinese University of Hong Kong 
July, 2002 
•The Chinese University of Hong Kong holds the copyright of this thesis. Any persons(s) 
intending to use a part or whole of the materials in the thesis in a proposed publication 









m I I 
Abstract 
The levels of cytokines, including tumor necrosis factor-a (TNF-a), were 
increased in the central nervous system after brain injury, and astrocyte proliferation as 
well as glial scar formation were also observed at the injured site later. The scar 
formed inhibited neuron regeneration, and thus recovery. 
The aim of this study was to examine the effects of TNF-a and some P-
adrenergic ((3-AR) drugs on the expression of certain cell cycle regulatory genes and/ 
or proteins in C6 cells. C6 cells have many properties similar to those of cultured 
astrocytes. p-AR compounds were tested because they had been shown to be related 
to astrocyte proliferation and that we previously found that TNF-a could induce the 
expression of both PiAR and P2AR receptor in C6 cells. The methods used were 
reverse transcription-polymerase chain reaction (RT-PCR) and Western blotting. 
We found that TNF-a induced the expression of a number of cell cycle 
regulatory genes, particularly cyclin D2, cyclin-dependent kinase-4 (cdk-4), cyclin E, 
cyclin-dependent kinase inhibitors (ckis). These stimulations were rather cytokine 
specific as the effects of interleukin-6 (IL-6) and interferon-丫 (IF-y) were very weak or 
almost none, and that of IL-la and IL-ip were weaker than those of TNF-a. Studies 
with specific TNF-a receptor subtype antibodies revealed that TNF-a exerted its 
induction effects by interacting with both receptor subtypes: TNF-a receptor 1 (TNF-
Rl) and receptor 2 (TNF-R2). As the level of TNF-R2 in normal C6 cells was very 
low and that the TNF-a induced the expression of cdk-4 protein and p21, a cki, 
mainly by interacting with TNF-R2, this provided a plausible explanation for the 
ii 
inhibition of TNF-a-induced proliferation observed in TNF-R2 antiserum-treated 
cells. 
Though TNF-a could induce the expression of both PiAR and P2AR 
expression, and P-AR agonists could induce C6 cell proliferation, TNF-a did not 
induce C6 cell proliferation directly through this process. This was because P-AR 
antagonists failed to inhibit the expression of most cell cycle regulatory genes. 
Moreover, p-AR agonists, particularly P2AR, were very effective in inducing the 
expression of most cell cycle regulatory genes. This suggested (3-AR agonists induced 
the expression of these genes via a different pathway. 
Our findings suggested that manipulations of cell cycle regulatory genes, 
particular cyclin D2 and pi5, expression at appropriate time could be an effective 
approach to control astrogliosis observed in brain injury and this could be a beneficial 




(TNF-a ) )的水平增加。並且在傷口患處可發現星形K質細胞的增生及形 
成神經勝質症。並且這K質症會阻礙神經元的再生，以致及後的復原。 





轉錄酵素/聚合酵素鏈鎖反應(RT-PCR)和蛋白質轉印(Western B l o t ) � 
我們的實驗結果証實TNF-a能引起調節細胞循環基因的表達。週期 
素D2，週期素依賴性激晦4(cdk-4)，週期素E和週期素依賴性激晦抑制 
劑 (cki)的表達特殊地明顯。因爲白介素 -6(IL-6)和干擾素-Y(IF-Y)的影 
響是非常微弱，並且白介素- l a ( I L - l a )和白介素 - i p ( I L - i p )的影響是比 
較T N F - a的弱，所以我們推斷這現象是特定於細胞激素。根據特定 
TNF-a受體的實驗証明，TNF-0C對上述表達是透過兩對TNF-oc受體： 






雖然T N F - a能夠誘發P - A R受體一型及受體二型的表達，和P - A R 
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CHAPTER 1. INTRODUCTION 
1.1. Events happened in brain injury 
Brain injury can be divided into two major types: stroke (ischemia/ 
hemorrhage) and trauma (McNaughton and Harwood, 2002). There are two major 
events happened after brain injury: initial insult and secondary delayed cascades of 
injury. In the latter, several cellular changes can be observed which include: (1) 
diffused cell death mediated by the glutamate and intracellular calcium released 
(Siesjo, 1992); (2) intense inflammatory responses which involve activation of 
microglia, macrophages, T and B lymphocytes, and neutrophils (Benveniste, 1992; 
Bush et al , 1999; Ghimikar et al, 1998; Schnell et al, 1999b); (3) secondary 
neuronal damage involves delayed cell death; and (4) reactive astrocytes forming a 
glial scar which blocks axonal regeneration and hinders recovery (Fawcett and Asher, 
1999; Lo et al., 2001). The complex structure of the brain and complicated structural 
and biochemical changes often increase the difficulty of therapeutic treatment in brain 
injury (Barone and Feuerstein, 1999). 
The brain is protected by the skull and three interface-barriers: the blood brain 
barrier (BBB) formed by blood vessels of the brain, choroids plexus forming the 
blood-cerebrospinal fluid barrier (BCSFB), and arachnoid layer of the menings 
forming the blood-arachnoid barrier. The BBB is the major barrier and due to its 
structural property, hydrophilic substances have low permeability, only gases and 
small lipophilic molecules can diffuse through it and the others are transferred 
through carrier-mediated mechanism (Lo et al., 2001). In injured brain, the biphasic 
openings of the BBB made it different to ensure the delivery of water-soluble drug to 
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the injured site and at appropriate time (Lo et al., 2001; Schnell et al., 1999a; Stahel et 
al , 2000). 
Besides structural changes, the decrease in ATP production in neurons can 
cause the failure of certain high-energy inquiry processes e.g. sodium and potassium 
ATPase pump and results in cellular edema (Barone and Feuerstein, 1999). Moreover, 
influx of calcium induced by the released excitatory amino acids, such as glutamate, 
cause excitotoxic cascade. Accumulation of calcium also causes deleterious activation 
of a variety of enzymes that are important for up-regulation of damaging proteases 
and DNases (Mattson and Scheff, 1994; Siesjo, 1992). 
Furthermore, cytokines released by the injured cells trigger the inflammatory 
action of neutrophils, monocytes, and macrophages, which could cause further 
damage by releasing proteases, free radicals and vasoconstrictive mediators. These 
would amplify the oxidative stress and programmed cell death at the injured sites 
(Mattson and Scheff, 1994). 
Nowadays, many therapeutic strategies had been proposed. Therapeutic agents 
for stroke and trauma include calcium channel blockers, corticosteroids and 
antioxidants, glutamate receptor antagonists (Bondy and LeBel, 1993; Clausen and 
Bullock, 2001), opioid receptor antagonists, thyrotropin-releasing hormone analogs, 
anti-inflammatory (e.g. anti-TNF-a and -IL-ip agents) (Barone and Feuerstein, 1999), 
and modulators of apoptosis (Mattson and Scheff, 1994). 
However, most of these are not very effective, and some of possible reasons 
are (1) lack efficient drug delivery systems; (2) narrow therapeutic time window; and 
(3) appropriate drug delivery to specific areas of damaged brain (Barone and 
Feuerstein, 1999). 
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1.2. An alternative approach based on neuronal regeneration 
Therefore, other approaches have been considered and one of them is neuron 
regeneration. In the past, it was believed that neurons could not regenerate after brain 
damage (Alonso and Privat, 1993; Sivron and Schwartz, 1995). However, recent 
evidence showed that neurons could regenerate after injury when the unfavorable 
environment is removed (Li and Raisman, 1995), and one of the conditions which 
blocks neuron regeneration is due to glial scar formation (Barone and Feuerstein, 
1999; Fawcett and Asher, 1999). 
Glial scar is formed by glia through various reactive reactions that not only 
prevent secondary injury but also block both axon regeneration and remyelination 
(Reier and Houle, 1988; Rudge and Silver, 1990). During gliosis, glia recruit 
microglia, oligodendrocytes, oligodendrocyte precursors, meningeal cells, astrocytes, 
and stem cells and all these produce molecules that inhibit or prevent axon 
regeneration and remyelination (Berry et al., 1983). 
Many cell types play different roles at critical time periods following brain 
injury to form a glial scar. Within hours of injury, macrophages and microglia present 
at the injury site cause inflammatory responses (Koshinaga et al, 2000). After three to 
five days, oligodendrocyte precursors are detected within the injury site and their 
level peaks at day seven following injury then slowly decline within two weeks. 
Lastly, astrocytes arrive at the glial scar where they fill the remaining vacated space 
(Dusart et al., 1991). All cell types, which recruit for glial reaction, were inhibitory to 
axon regeneration at different levels. As the astrocytes are linked with each other by 
tight junctions and surrounded by extracellular matrix (Hertz et al., 1990), axon 
regeneration is severely inhibited (Fawcett and Asher, 1999). Besides the physical 
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barrier of astrocytes formed (Liuzzi and Lasek, 1987), studies found that certain 
astrocytes cell surface-sulfated proteoglycans, e.g. thy-1 glycoprotein, and 
oligodendroglia-associated proteins can inhibit neuron growth (Bandtlow et al., 1990; 
Snow et al., 1990; Tiveron et al., 1992). 
As mentioned before, astrocytes are one of the major cell types to form the 
glial scar, it is surprising that the roles played by astrocytes attracted most interest. 
For example, quinolinic acid (QA), a tryptophan metabolite, had been used to induce 
neuronal degeneration (Schwarcz et al., 1983). It was found that the density of 
proliferating and non-proliferating microglial cells as well as astrocytes in the 
striatum and substantia nigra pars reticulata (SNr) after injection of QA were 
increased. Furthermore, QA could cause (1) short period of glial activation and 
proliferation in the SNr; and (2) long lasting astrogliosis without proliferation (Dihne 
et al., 2001). These findings clearly showed the importance of astrocytes and 
astrocytes proliferation in axonal regeneration. 
As astrocytes are the major glial cells in the central nervous system (CNS), 
their fates after brain injury and functions are briefly described in the next section. 
1.3. Fate of astrocytes after brain injury 
1.3.1. General information of astrocytes 
Astrocyte is the most abundant cell type in the central nervous system (CNS) 
with cell markers: glial fibrillary acidic protein (GFAP), vimentin, S-100 protein, and 
glutamine synthetase, and these have been used as markers of astrocyte proliferation. 
There are two types of astrocytes: fibrillary and protoplasmatic astrocytes. Fibrillary 
astrocytes are GFAP positive, while protoplasmatic astrocytes are not. After 
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activation, the GFAP expression is increased and this has been used as an indicator 
for the presence of reactive astrocytes (Ridet et al., 1997). 
1.3.2. Functions of astrocytes 
Astrocytes play many important functions in the normal CNS. For example, 
they are responsible for physical support, brain development and metabolism, guiding 
axonal development, and establishing homeostatic mechanisms in the neuropil and at 
the BBB and BCSFB (Hertz et al., 1990; Kimelberg and Norenberg, 1989). Studies 
showed that astrocytes were one of the cell types that produced basic fibroblast 
growth factor (bFGF) which was involved in the development and differentiation of 
the nervous system (Ferrara et al., 1988). Thus, astrocytes play important structural 
and functional role in the normal CNS. 
One of the functions of astrocytes in brain injury is to form scar tissue via 
astrogliosis. This is indicated by the marked increase in GFAP expression. 
Astrogliosis prevents the CNS from further damage (Ferrara et al., 1988; Little and 
O'Callagha, 2001; Rostworowski et al., 1997). For example, after brain QA 
intoxication, a decrease in GFAP-immunoreactivity in astrocytes was detected at early 
times. This was due to (1) astrocytic cell death occurred after an excitotoxic injury, 
and/or (2) GFAP-immunoreactivity was altered by changes in extracellular 
environment. But at later times, dense astrogliosis with proliferating astrocytes were 
found ill dorsal and medial striatum. Active astrogliosis was found in the entire 
striatum in 30 days post intoxication (Dihne et al., 2001), and astrogliosis still 
persisted even 1 year after excitotoxic striatal injury (Bjorklund et al., 1986). 
Moreover, increase in GFAP immunoreactivity was detected in the cortex and corpus 
c alio sum and were more rapid than in the striatum. These suggest diffusion of factors 
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that stimulate astrocytes proliferation from the striatum, the primary injury site, to the 
cortex and corpus callosum (Bjorklund et al., 1986). However, the route(s) is (are) 
still unknown; nor are the factors involved are clearly understood. 
As astrocyte proliferation is one of the processes of astrogliosis, the factors 
that induce astrocyte proliferation have been under investigation, and the suspected 
ones include neurotransmitters, neuropeptides, cytokines, and growth factors 
(Beaujouan, 1991; Giulian and Lachman, 1985; Mantyh et al, 1995, Richardson et al., 
1988). Among these factors, TNF-a is one of the major factors that induce astrocytes 
proliferation following brain injury (Selmaj et al., 1990). For example, microinjection 
of TNF-a into a neonatal mouse brain caused astrogliosis (Balasingam et al., 1994). 
Also, studies showed that TNF-a protein and mRNA production were increased after 
closed head injury, and TNF-a peaked at four hours after injury then declined. TNF-a 
was not only produced by inflammatory-related cells, but also by reactive astrocytes 
(Shohami et al., 1997). These clearly show that TNF-a is one the major factor in 
astroglosis. Besides TNF-a, other growth factors and cytokines produced by 
astrocytes upon activation include basic fibroblast growth factor, neuron growth 
factor, IL-1, and IL-6 (Mattson and Scheff, 1994; Selmaj et al., 1990). Some of these 
factors are known to promote neuron growth, while others inhibit neuron growth (Lu 
et al., 1991). Thus, a simple reduction of these factors may not be an ideal therapeutic 
treatment for brain injury. 
Reactive astrogliosis has been suggested to help regulating neurotransmitter 
levels, repair the extracellular matrix, control the blood-CNS interface, control of 
transport processes, and trophic support to the damaged cells (Ghimikar et al., 1998; 
Hatten et al., 1991). In addition to the above changes, alteration in production of 
proteases, protease inhibitors, cell surface matrix and other molecules were also 
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observed in reactive astrocytes. For example, the oxidoreductive enzyme activities are 
increased in reactive astrocytes. It might be one of the reasons that astrocytic 
processes far away from injury were able to support axon regeneration but local injury 
site became inhibitory to axon regeneration (Fawcett and Asher, 1999). However, the 
pathway leading to astrogliosis is still unknown. It has been reported that some of 
these molecules, for example TNF-a, are major candidates leading to astrocytes 
proliferation and astrogliosis (Komyei et al., 2000; Ridet et al., 1997; Selmaj et al, 
1991; Selmaj et al., 1990). 
1.4. Factors relate to astrocytes proliferation 
Following brain injury, different neuroprotection and neurotoxic factors, 
notably cytokines, are released (Mattson and Scheff, 1994). Cytokines released by 
those intense inflammatory responded cells include TNF-a, interleukin-1 (IL-1), 
interferon y (IF-y), and interleukin-6 (IL-6). However, the roles of these factors in 
astrogliosis are still unclear. 
IL-6 is produced by astrocytes, macrophages, and microglia in brain injury. 
IL-6 is neurotrophic as it can support survival of neurons in culture (Hama et al., 1989) 
and induce the proliferation of cerebral endothelial cells (Fee et al., 2000). Also, it 
triggers the differentiation of B-cells into immunoglobulin (Ig)-producing plasma 
cells. IL-6 receptors, however, are present in astrocytes and neurons but not in 
microglia of normal and injured brain (Klein et al., 1997). In astrocytes, IL-6 can only 
change the morphology of fibrillary astrocytes but not the overall GFAP 
immunoreactivity (Klein et al., 1997). However, in acute brain injury, increase in IL-6 
production was only observed transiently at days 3-5 after injury. Moreover, long-
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term exposure to IL-6 had been shown to reduce hippocampal new neuron production, 
but had no effect on progenitor cell distribution and gliogenesis (Vallieres et al., 
2002). These findings suggest that IL-6 and other pro-inflammatory cytokines have 
dual roles on brain injury. Because of these, IL-6 was included in the present study. 
IL-1 is another cytokine produced by astrocytes, macrophages, and microglia 
in brain injury. IL-1 shows ability to promote T-cell proliferation (Smith et al., 1980). 
Both IL-la and IL-1 (3 are attributed to activation of astrocytes and microglia in 
disease conditions. As a cytokine central to the inflammatory process, IL-la favors 
inflammatory processes by increasing adhesion of leukocytes to endothelial cells in 
the CNS (Libby et al., 1986). Thus, the effects of both IL-la and IL-ip were tested in 
this study. 
Compare to TNF-a, IL-6, and IL-1, IF-y is the last cytokine recruited in brain 
injury (Morganti-Kossmann et al., 1992). IF-y is produced by lymphocytes and it 
triggers reactive gliosis (Merrill et al., 1992). Study showed IF-y has dual functions to 
protect against infection, but changes to neurotoxic in secondary immune-mediated 
pathology (Rudin et al., 1997). Therefore, the effect of this cytokine on cell cycle 
regulatory gene expression was examined. 
1.4.1. TNF-a 
TNF-a is one of the major cytokines released during brain injury. It is so 
named because of its cytotoxic properties on tumor cells (Imamura et al., 1987). TNF-
a is a 17 kDa protein and the active form is a 52 kDa homotrimer. TNF-a exerts its 
biological effects through interaction with two kinds of receptors, TNF-a receptor 1 
(TNF-Rl, p55) and TNF-a receptor 2 (TNF-R2, p75) with a lower and higher binding 
affinity, respectively. TNF-Rl is expressed on almost all somatic cells, whereas TNF-
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R2 is expressed mainly on leukocytes and endothelial cells. There are 28% identities 
between their extracellular domains but no homology between the intracellular 
domains of the two-receptor subtypes and they have different signaling pathways 
mediating different biological responses (Tartaglia and Goeddel, 1992). These two 
receptors can work alone or work in pairs. Both receptors involve in N F K B activation 
which in turn relates to cell proliferation. Many studies showed TNF-Rl is the 
primary signaling receptor for TNF-a on most cell types (Chen and Goeddel, 2002; 
Kanaly et al., 1999; Tartaglia et al., 1991). And it has been postulated that the role of 
the TNF-R2 is primary to enhance signaling through the TNF-Rl by recruiting and 
delivering TNF-a to the lower affinity TNF-Rl (Wong et al, 1992). Moreover, a 
number of studies showed that TNF-Rl triggers apoptosis (Itoh and Nagata, 1993), 
while TNF-R2 responsible for the generation of signals which are sufficient to induce 
cellular proliferation and N F K B activation (Aggarwal, 1992; Baker and Reddy, 1998). 
The roles of these two receptors are different in different cell types. In 
neuronal cells, membrane-associated TNF-a and TNF-R2 contribute to cell death 
(Sipe et al., 1998). In human airway smooth muscle cells, TNF-Rl mainly mediates 
TNF-a-induced effects, such as airway smooth muscle cells proliferation and 
expression of adhesion molecules (Amrani et al., 2001; Amrani et al., 2000a; Amrani 
et al., 2000b; Amrani et al., 1996), while in adipocytes, both TNF-a receptors are 
active, and the TNF-a-induced inhibition of adipogenesis is mediated only by TNF-
Rl (Xu and Hotamisligil, 2001). TNF-Rl is responsible for the regulation of Kupffer 
cells activation in liver and enhances fibrotic processes (Kitamura et al., 2002). 
In the CNS, TNF-a is produced by monocytes, macrophages, T and B 
lymphocytes, neutrophils and mast cells as well as cells in the CNS like neurons, glia, 
and endothelial cells. Many studies suggested that TNF-a plays an immunological 
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and developmental role in the CNS (Barone and Feuerstein, 1999; Shohami et al., 
1999). Production of TNF-a in the CNS can be induced by several cytokines: IL-1, 
IL-2, interferons, and other cytokines. Its production can be suppressed by 
transforming growth factor-(3, IL-4, and IL-6 (Aggarwal, 1992). Moreover, TNF-a 
can stimulate cells, including astrocytes, to produce cytokines, e.g. IL-1, IL-6, and 
TNF-a. 
TNF-a expression is induced in various neurodegradation and inflammation-
related conditions. For example, TNF-a expression in the brain is increased following 
systemic kainic acid administration (Minami et al, 1991), systemic or 
intracerebroventricular administration of lipopolysaccharide endotoxin (Siren et al., 
1992), injection of excitotoxin, ibotenic acid (Alvarez et al., 1994), and in rat 
suffering from traumatic head injury (Fan-et al., 1996). The selective induction in the 
expression of TNF-a once again confirms its important role in brain injury. It has 
been suggested that TNF-a did not affect neuron regeneration directly, but by 
stimulating astrocytes proliferation and astrogliosis (Garcia et al., 1992). 
As discussed before, TNF-a can stimulate astrocyte proliferation, induce glial 
scar formation which is believed to block neuronal regeneration, and thus recovery. 
Therefore, one of the treatments of brain injury is to block the effect of TNF-a 
(Barone and Feuerstein, 1999). However, a number of studies have shown that TNF-a 
also has several beneficial effects. For example, TNF-a facilitated infiltration of cells 
of the immune system to the injured site and enhanced the leukocyte migration by 
expression of adhesion molecules, which enhance leukocytes penetrate through the 
blood brain barrier (Feuerstein et al., 1998; Feuerstein et al., 1994; Morganti-
Kossmann et al., 1992). TNF-a, therefore, plays an important role in inflammatory 
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responses after brain injury. Also, studies showed TNF-a has neuroprotective 
function by stimulating antioxidant pathways and plays key role in injury-induced 
immune response with the suppression of injury-induced microglial activation 
observed in mice lacking TNF-a receptors (Bruce et al., 1996). Thus, another 
reasonable approach in treating brain injury is to modulate the TNF-a-induced 
astrocytes proliferation. Because of the above evidence, the influence of TNF-a on 
cell cycle regulatory genes as well as the role played by its receptor subtypes were 
investigated in this study. 
Our laboratory has been investigating TNF-a-induced proliferation in 
astrocytes and C6 cells. (C6 cells are neoplasmic glial cells). We found that TNF-a-
induced C6 cells proliferation (Liu et al., 1996); and selectively induced the 
expression of TNF-R2 in C6 cells and astrocytes (Huang et al., 1998; Lung et al., 
2001), protein kinase C, P adrenergic receptors (P-ARs) (Lung, 1999; Shan, 2000), 
mitogen-activated protein kinase (MAP kinase), and some early genes: c-fos, c-jun 
(Ho, 2001). These genes are related to C6 cells proliferation, and these previous 
findings prompted us to investigate the effects of TNF-a on the expression of cell 
cycle regulatory genes in C6 cells. 
1.4.2. p adrenergic mechanism and astrocyte proliferation 
Besides TNF-a, (3-adrenergic receptor ((3-AR) substances have been shown to 
be related to astrocytes proliferation as activation of P-ARs can increase the 
expression of GFAP, an astrocyte cell marker (Hodges-Savola et al., 1996; Shao and 
Sutin, 1992). Fujita et al. (1998) found that activation of P-AR in microglia would 
cause an induction of proliferation in astrocytes, while stimulation of P2AR in 
11 
microglia would suppress microglia proliferation and that glial scar formation could 
be suppressed by P-AR antagonists (Fujita et al., 1998; Hodges-Savola et al., 1996). 
The above findings suggest that astrocytes play a more important role than microglia 
in glial scar formation. 
Previous studies showed that P-AR expression was increased following brain 
injury (Salm and McCarthy, 1989). The expression of PiAR and P2AR in astrocytes 
increased after astrocytes activation (Shao and Sutin, 1992). Moreover, P-AR agonists 
and antagonists, affect GFAP immunoreactivity in injured rabbit optic nerve (Hodges-
Savola et al., 1996). These authors found that P-AR agonist could promote astrocytes 
proliferation, while p-AR antagonist suppressed it, and moreover, the suppression of 
GFAP was observed in the presence of propranolol, an P-AR antagonist. 
Another evidence suggesting a close relationship between P-AR and glial scar 
formation was reported by Sutin and Griffith (1993). These authors reported that 
injection of cytotoxic ligand Ricinus communis to the spinal cord in rodent caused 
glial scar formation. They also found that GFAP immunoreactivty was increased by 
11.8% after 7 days of injection and at this time the p-AR density also increased by 
26%. However, when propranolol was applied, the increased in GFAP 
immunoreactivty was decreased and so as the P-AR density. These findings suggest 
3-AR are closely related to astrocytes proliferation. 
3-Adrenergic substances exert their actions by binding to P-ARs. These 
receptors have molecular weights about 46 kDa and there are three main types, 
namely piAR, P2AR, and P3AR. PiAR and P2AR respond to noradrenaline and 
adrenaline and both are expressed in astrocytes (Summers et al., 1997), while P3AR 
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are likely related to lipid metabolism (Harms et al., 1974) which are expressed in 
gastrointestinal tissues but not in the CNS (Manara et al., 1995). 
As we previously found that TNF-a induced Pi and P2AR expression in C6 
cells (Shan, 2000), we hypothesized that the proliferative effect mediated by TNF-a 
and (3-adrenergic compounds are closely related. Therefore, the effects of various Pi 
and P2AR substances on cell cycle related genes expression were also included in this 
study. 
1.5. Cell cycle-related proteins 
To understand how TNF-a and p-AR substances influence astrocytes 
proliferation better, the roles of various proteins in cell cycle regulation are briefly 
described below. Cell cycle-related (regulatory) proteins co-operate at different stages 
of a cell cycle to ensure cell proliferation. There are two major stages in a cell cycle: 
interphase which occupies most of the cycling time, and mitosis which is a cell 
division stage. Mitosis is divided into four phases: prophase, prometaphase, 
metaphase, and anaphase. Interphase can be sub-divided into four phases: Gl, GO, S, 
and G2 phases. Each phase is regulated by specific proteins and each phase perform 
different functions to make sure the forward direction of a cell cycle (Heichman and 
Roberts, 1994). 
Most of the cells at rest are at the GO phase and proceed to the S phase when 
the environment is favorable (Fig. 1.1). In the S phase, DNA replication starts, which 
includes initiation of bidirectional DNA replication, elongation of the new DNA 
strands, and the termination of DNA replication. There is a gap time prior to S phase 
called Gl and a gap time beyond S phase called G2 (Laskey et al., 1989). The Gl 
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Fig. 1.1. A cell cycle consists of two major parts: mitosis and interphase. 
Interphase can be divided into four phases: GO, Gl, S, and G2 phases. Mitosis 
is for cell division while S phase is for DNA synthesis. There are two gap time 
points prior to and beyond to S phase, namely Gl and G2 phase, respectively. 
There is a check point in Gl phase called restriction point which is the time 
point to determine if the environment is suitable or not for cell growth and 
enter S phase. Prior to that point of Gl phase, it is mitogen dependent. 
(Abridge from Santa Cruz. Biotechnology, Inc. Apoptosis tumor suppressor 
and cell cycle research antibodies 2002 catalogue.) 
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phase is the only phase in a cell cycle that is sensitive to mitogen. Several hours prior 
to the S phase, there is a restriction point where cells become mitogen independent. It 
is also the check point for cells to decide whether continue to enter the remaining 
phases of a cell cycle or to enter the GO phase if the condition does not allow cell 
continue to grow. 
For each phase, a specific combination of maturation promoting factor (MPF) 
is responsible for regulation of the duration in each phase with the co-operation of 
other proteins, such as cyclin-dependent kinase inhibitors (ckis) and cyclin-dependent 
kinase activating kinase (Cak) (Palazzo, 2001). 
1.5.1. Maturation promoting factor (MPF) 
MPF are cyclin-cyclin dependent kinase (cdk) complexes and they are 
composed of cdc-l^ ^"^ (one of the cdk) and cyclins which present specifically in 
different cell cycle phases (Sherr, 1994). The life span of a cyclin is long in the 
interphase but short in mitosis. Therefore, in order to form a MPF, a cyclin is first 
induced and accumulated during the interphase, then complexes with cdc-2 which is 
quite constant, but the MPF formed is inactive. To activate the MPF, both the cdc-2 
and the cyclin are phosphorylated (Fisher and Morgan, 1994). This process is 
activated by cdc-25, but inhibited by p21, a cyclin-dependent kinase inhibitor (cki) 
(Roberts et al., 1994). Then, the inactivated MPF would form again through activation 
by pi3, and then return to the interphase. Summing up, cyclins are stable in cells that 
are arrested in meiosis and mitosis, implying that cyclin degradation is required for 
cells to exit meiosis or mitosis (Joyce et al., 2001). 
In a cell cycle, only G1 phase can be affected by external factors, such as 
cytokines. We, therefore, in this study mainly focused on the effects of various 
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cytokines and |3-AR substances on proteins involved in regulation of the G1 phase. 
Having an idea of the events happen in the G1 phase, the functions of the cyclins, cdk, 
cki, and other proteins that participate in regulating a cell cycle are briefly described 
below. 
1.5.2. Early G1 phase 
Early G1 phase is one of the stages in a cell cycle that is most easily affected 
by extracellular factors that are related to cell proliferation. For example, in cultured 
cells, serum is required in the early G1 phase; but they become serum-independent in 
the late G1 phase and S phase (Baldin et al., 1993). The early G1 phase is also the 
time window for retinoblastoma protein (pRb) actions and the time check point to 
decide whether a cell goes into proliferation, differentiation or senescence. 
Although cell cycle regulatory proteins control a cell cycle, different cell types 
use different combination of cyclin Ds, cdks, and INK4 (one of the family members 
of cki) for G1 regulation (Fig. 1.2). Beyond the G1 phase, cyclin induction occurs 
which causes cdk accumulation and the formation of cyclin D-cdk-4 complex, a 
maturation promoting factor. At early G1 phase, the level of cyclin D-cdk-4 complex 
is lower than that of p27, a cyclin kinase inhibitor, which is expressed, more or less, at 
constant level, and most of this cyclin D-cdk-4 complex is bound to p27 and therefore 
the complex is inactive. However, the increase level of cyclin D-cdk-4/6 at the mid 
G1 phase decreases the cyclin D-cdk-4/6 bound with p27, and this allows cyclin D-
cdk-4/6 to be activated by Cak and the phosphorylation of pRb which results in 
inhibiting pRb action and causes DNA synthesis (Draetta, 1994). 
Also, the promoter of pi6 is negatively regulated by pRb and overexpression 
of pi 6 would inactivate the pRb. As the level of pl6 increases, it binds to cdk-4/6 and 
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Fig. 1.2. Distribution of cyclins, cdk, cki in different phases of a cell cycle. 
Cyclin Dl, D2, and D3 and their kinase partners: cdk2, -4, -5, -6 participate 
in the G1 phase. Their activities are gradually inhibited by pl5, pl6, p21 
and p27 ckis from the mid G1 phase to late G1 phase. From late G1 phase, 
cyclin E and cdk2 participate in the G1 phase regulation. The co-operation 
of cyclin Ds and E trigger pRb phosphorylation and block pRb's action on 
E2F and start DNA synthesis of early genes and the cell enters into S 
phase. When a cell enter S phase, cyclin A and cdk2 replace the action of 
those cyclins and cdks participated in the G1 phase. At G2 and M phase, 
cyclin A, -B and cdc-2 become the responsible regulatory proteins. 
(Abridge from Santa Cruz. Biotechnology, Inc. Apoptosis tumor 
suppressor and cell cycle research antibodies 2002 catalogue.) 
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this causes the dissociation of cyclin D from cdk-4/6 and results in the degradation of 
cyclin D (Weinberg, 1995). 
1.5.3. Retinoblastoma protein (pRb) 
pRb is the gene product of retinoblastoma tumor suppressor gene, and it plays 
an important role throughout a cell cycle. It has more than 12 phosphorylation sites 
and it is regulated by many cell cycle proteins e.g. cyclin D1-cdk-4, cyclin E-cdk-2; 
also cyclins A, D3, and E through phosphorylation (Resnitzky and Reed, 1995). 
There are three members in the retinoblastoma gene family (pRb, pRb2/ pi30, 
and pi07) and they are responsible for growth and tumour suppression. Both pi30 
and pl07 have similar functions (Zhu et al., 1993) and, therefore, pl30 was chosen in 
this study to reflect the level of this gene. These gene members are related to growth 
and differentiation in cooperate with p21, a cyclin kinase inhibitor. Also, they are the 
negative regulators of transition between G1 and S phase. They exert their actions 
through the modulation of several nuclear transcription factors e.g. members of the 
E2F family. These genes participate in many tissues, in the CNS, they are effectors of 
neural differentiation (Galderisi et al., 2001; Paggi et al., 2001). 
pRb has two forms: hypophosphorylated and hyp erpho sphorylated. 
Hyperphosphorylated pRb exists in the transition from G1 to M phase. It is also the 
inactivated form of pRb because of its growth inhibitory function, thus inactivation of 
this protein that causes proliferation (Weinberg, 1995). Hypophosphorylated pRb, the 
active form, can bind to one of the 5 forms of E2F transcriptional factors; particularly 
E2F 1, 2, and 3, while E2F 4 and 5 interact mainly with pl07 and pl30 (Qin et al., 
1994). (Because of this, pl30 was chosen to reflect the level of pRb in a cell cycle.) 
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E2F transcriptional factors involve in the transcription of most cell cycle proteins e.g. 
c-myc and cdc-2. Therefore, hypophosphorylated pRb inhibits E2F-related DNA 
synthesis. In a cell cycle, when cyclin Dl-cdk-4 complexes with pRb and this causes 
pRb changes from the hypophosphorylated form to the hyperphosphorylated form, 
thus pRb is released from the E2F and the cell continues into the G1 late phase. 
Many physiologic growth inhibitory signals (e.g. TGF(3, cAMP, contact 
inhibition, radiation) exert their actions by preventing pRb phosphorylation through 
the modulating activities of cdks (e.g. cyclin E-cdk-2), which are proteins responsible 
for pRb phosphorylation specifically. For example, in epithelial cells, TGFp has been 
shown to inhibit growth by influencing cdk-2 in association with p27, increased the 
expression of pi5, a cyclin kinase inhibitor, decreased cdk-4 level, and inhibited 
cyclin E-cdk2 activity. And these cause G1 arrest (Sanchez and Dynlacht, 1996). 
1.5.4. Cyclin-dependent kinase (cdk) activating kinase (Cak) 
Cak is a complex composes of cyclin H, cdk-7 and MAT-1 (Acevedo-Duncan 
et al , 2002; Drapkin et al., 1996; Fisher et al., 1995; Fisher and Morgan, 1994). The 
major function of MAT-1 is to facilitate the association of cyclin H and cdk-7. Cak 
can catalyze most cdks in eukaryotic cells, and it regulates cell cycle by controlling 
transcription and DNA repair (Nigg, 1996). Deregulation or inhibition of Cak reduces 
pRb phosphorylation and cyclin E expression. The phosphorylation of pRb by Cak 
depends on MAT-1 in dose-dependent manner, but independent of cyclin Dl-cdk4 
levels (Wu et al, 2001). 
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1.5.5. Cyclin, cdks and ckis 
As mentioned before (Section 1.5), cyclins, cdks, and ckis are important in 
regulating cell cycle events. Cyclins are the regulatory molecules of cdks and they do 
so by forming complexes. The activity of a cyclin-cdk complex depends on many 
factors. For instance, the periodic accumulation and degradation of specific cyclin as 
well as the presence of a particular cki in the cell cycle. Cyclin-cdk complexes can be 
formed by various combinations of cyclins and cdks, and they trigger different 
biological reactions when interacting with different regulatory proteins found at 
different stages of a cell cycle (Ghiani and Gallo, 2001). For example, cyclin D-cdk-
4/6 complexes regulate G1 phase with the aid of ckis, such as pl5, p21, and p27. A 
cki can bind to a cyclin-cdk complex resulting in inhibiting the complex activity 
(Chen et al., 1999; Draetta, 1994; Roberts et al, 1994). 
1.5.5.1. Cyclins 
The levels of specific cyclins vary at different stages of a cell cycle. They have 
(1) different subcellular localization, (2) different substrate specificities, (3) selective 
interactions with upstream regulatory proteins, and (4) activation of specific cdks at 
different times. 
Cyclins can be divided into four groups according to their appearances in 
different cell cycle phases (Fig 1.3). The levels of G1 cyclins are quite constant during 
the cell cycle, however their levels are controlled by cell size and external growth-
regulatory signals e.g. cytokine. At the Gl/S phase, the levels of cyclins rise but fall 
dramatically at the Gl/S boundary. At the S phase, cyclins are directly responsible for 
stimulating DNA replication and their levels remain high throughout S and G2 phase 
and early mitosis (M) (Fig. 1.3). The M phase cyclins are the last cell cycle cyclins in 
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Fig. 1.3. The level of different cyclins over four cell cycle phases. 
(Abridge from http://www.new-science-press.com/samples/cyclins) 
the sequence, they rise as the cell approaches mitosis and peaks at metaphase. These 
specificities tightly control a cell cycle. Because of these particular features, one can 
trace the state of a cell population. The functions of cyclins at different phases of a 
cell cycle are briefly described below. 
1.5.5.1.1. Cyclin D 
Cyclin D is the growth factor sensor and its induction depends mainly on 
extracellular cues. For example, mitogen withdrawal leads to cessation of cyclin D 
synthesis and cells rapidly exit the cycle. Cyclin D controls mitogen-dependent events 
and causes pRb inactivation (Section 1.5.3). Cyclins D2 and D3 have limited tissue 
distribution compare to cyclin Dl. Also, the levels of these D cyclins vary at different 
time points of Gl phase, cyclin D2 peaks in late Gl, while cyclin D3 peaks during S 
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phase. Both cyclins D2 and D3 can form complexes with cdk-4 or -6 for activities 
(Joyce et al., 2001). 
The life span of cyclin D1 is about 15 minutes and it exerts its action at the 
early to mid-Gl phase (Baldin et al., 1993). For example, micro-injection of antisense 
D1 during that interval causes G1 arrested. Also, overexpression of D1 accelerated the 
G1 progression and decreased serum growth factors dependency as well as the 
decreased in cell size (Quelle et al., 1993). Subcellular localization of cyclin D1 
seems to be controlled by cell cycle. It was found that cyclin D1 presented in nucleus 
only during G1 phase but had never been found during S phase. Moreover, blockage 
of cyclin D1 did not affect cells entry into S phase in pRb" cells (Mamay et al., 2001). 
The synthesis of D cyclins is induced in response to growth factor stimulation. 
However, the D cyclins are also rapidly degraded and their intracellular 
concentrations rapidly fall if growth factors are removed. Thus, as long as growth 
factors are presented through G1 phase, complexes of cyclin D-cdk-4, -6 drive cells 
through the restriction point (Baldin et al., 1993). D cyclins exert its actions by 
forming complexes with cdk-2, -4, -5, or -6. In macrophages and fibroblasts, different 
D cyclins formed complexes with cdk-4 while in peripheral blood T cells they formed 
complexes with cdk-6. Besides D cyclins, cyclin E has an additive effect on 
shortening the G1 interval (Mamay et al., 2001; Resnitzky and Reed, 1995). 
1.5.5.1.2. Cyclin E 
There are two types of cyclin E (cyclin EL, cyclin Es) formed through 
alternative mRNA splicing. Cyclin EL is much more abundant than cyclin Es. Cyclin 
E is required for entry in the S phase in both pRb positive/negative cell systems. 
Cyclin E works at the late G1 to S phases and it is the target of both p21 and p27. 
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Evidence showed that increased expression of cyclin E could shorten G1 phase, 
decreased serum growth factors dependency and decreased cell size. Moreover, its 
level was regulated positively by cdk-2 and negatively by contact inhibition and 
TGPp. However, cyclin E protein level and cyclin E-cdk-2 complex were not affected 
by the lack of pRb. For instance, blocking of cyclin E caused G1 arrested in pRb' cells 
(Ghiani and Gallo, 2001; Ohtsubo et al., 1995). Cyclin E has a rapid turnover rate. Its 
degradation is by two main processes: (1) ubiquitin-dependent proteolysis; and (2) 
phosphorylation by cdk-2 (Ghiani and Gallo, 2001; Ohtsubo et al., 1995). 
1.5.5.1.3. Cyclin A 
Unlike cyclins D and E, cyclin A is involved in the S phase progression. 
Cyclin A steadily accumulates in S and G2 phases. It is needed for S phase entry and 
its role cannot be replaced by cyclin E. During S phase, cyclin A-cdk-2 is responsible 
for E2F-mediated transactivation. Cyclin A and cyclin B maintained the 
hyperphosphorylated state of pRb, the inactivation form of pRb, until the cell enters 
the Gl/Go phase again (Draetta et al., 1989; Girard et al., 1991; Pagano et al., 1992; 
Zindy et al, 1992). 
1.5.5.1.4. Cyclin B 
Cyclin B is synthesized in the late S and early G2 phase. It binds with cdc-2 
for activity. The phosphorylation of cdc-2 by Cak activates cyclin B-cdc-2 complex 
until the end of mitosis (M phase) (Chigbrow and Nelson, 2001). 
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1.5.5.2. Cyclin-dependent kinases (cdks) 
There are several cdks in mammalian cells. They include cdc-2, cdk-2, -3, -4,-
5, and -6. The activities of these proteins but not their levels change in a cell cycle. 
The activity of a cdk depends on (1) association with cyclins; and (2) phosphorylation 
of cdk, a process mediated by Cak. The other regulators of cdk activities are cyclins. 
For example, cdc-2 was found to be associated mainly with cyclins A and B as cdc-2 
mutation caused G2/ M transition arrest. Cdk-2 is mainly associated with cyclins A, B, 
and E as cdk-2 mutation caused Gl arrest (Draetta et al., 1989; Pagano et al., 1992). 
Also, cdc-2 and/or cdk-2 mutations have effects on different phases, and these can be 
rescued by the addition of appropriate cdks. cdk-2 is not cyclin specific, but cdk-4, -5, 
and -6 prefer D cyclins (Draetta et al., 1989; Pagano et al., 1992). Although cdk-3 has 
not been found to be associated with cyclins, cdk-3 mutant caused Gl arrested but not 
acceleration of S, G2 and M phases. Thus, cdk-3 appears to be required for Gl 
progression by interacting with appropriate cyclin partners. On the other hand, both 
cdk-2 and cdk-3 mutants could cause Gl arrested, and it has been suggested they 
played essential roles in Gl/S progression. The function of cdk-5 is suggested not to 
be related to cell division (Hosokawa et al., 1995; Roberts et al., 1994). 
1.5.5.3. Cyclin-dependent kinase inhibitor (cki) 
There were two families: INK4 proteins and p21 family proteins, and their 
functions are to regulate the activity of cyclin-cdk complexes through inhibition. 
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1.5.5.3.1. INK4 proteins (她ibitors of cdk-4 and cdk-6) 
This family includes pl5, pl6, pl8, and pl9. They inhibit cdk-4 and -6 only, 
which cause G1 phase arrest, pi5 and pl6 have similar action and they interact with 
cdk-4 and -6. (Therefore, changes in pi5 were monitored in this study.) examined 
They compete with cyclins D and thereby interfere proliferation in cells possessing 
functional pRb (Rich et al., 1999; Swafford et al., 1997). 
1.5.5.3.2. p21 family proteins 
They include p21, p27, and p57. Only p21 and p27 were studied in this project 
because of their broad functions. 
1.5.5.3.2.1. p21 
p21 blocks the activities of cdk-2, -4，and -6. p21 blocks cell cycle progression 
by inhibiting cdks and thereby inhibits DNA replication in the S phase. The p21 
inhibition of DNA replication could be rescued by the addition of cyclin E or A, but 
not cyclin B or proliferating cell nuclear antigen (Chen et al., 1995; Chen et al., 1999; 
Ghiani et al., 1999). This suggests that the action of cki is phase and cyclin specific. 
1.5.5.3.2.2. p27 
It can regulate cell size and cell number by inactivating several cyclin-cdk 
complexes (e.g. cyclin D-cdks, cyclin E-cdk-2, and cyclin A-cdk-2). p27 exerts its 
action on a cyclin-cdk complex by interacting with cdk-2, -4, and -6, and this 
interaction prevents the activation by Cak (Drapkin et al., 1996). To relief the 
inhibitory effect, the turnover rate of p27 is accelerated by cyclin E-cdk-2 complex. 
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Moreover, overexpression of both p27 and p21 could inhibit pRb phosphorylation by 
cyclin-cdk complexes and this resulted in G1 arrest (Quelle et al., 1993). 
1.6. Apoptosis related proteins 
As increase in cell number can be resulted from accelerated proliferation or a 
decrease in cell death, we therefore also investigated the effects of cytokines and 
3-AR drugs on apoptosis related genes. One of the more important groups of protein 
regulating apoptosis and proliferation is the bcl-2 family proteins. Apoptosis is 
characterized by (1) blebbing of plasma membrane; (2) reduction in cell volume; (3) 
condensation of nucleus; and (4) endonucleoytic cleavage of DNA into nucleosomal-
length fragments. “ 
1.6.1. bcl-2 family 
bcl-2 family is a group of proteins with bcl-2 homology domain(s) which act 
as agonists and antagonists of cell death. Death agonists include Bak, Bax, bcl-Xs, bcl-
xp; and death antagonists include bcl-Xa, bcl-XL, bcl-w and Mcl-l. However, no single 
member alone can be a sole agonist or antagonist and the ratio of death antagonists to 
agonists determined whether a cell would respond to an apoptotic signal or not 
(Suzuki et al., 2000). 
1.6.1.1. bcl-2 
bcl-2 is a 26 kDa protein that represses cell death and is required during 
development. It is localized in the mitochondria, endoplasmic reticulum (ER), and 
nuclear membranes, the vital subcellular organs. It can prevent cell death caused by y-
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irradiation, H2O2, t-butyl hydroperoxide, and menadione (Clark et al.，1999; Esche et 
al., 2001; Lam et al., 1994). Recent studies showed TNF-a promoted the expression 
of bcl-2 in dendritic cells and this inhibited melanoma-induced apoptosis (Esche et al., 
2001). The mechanism of how bcl-2 repressed apoptosis was still poorly understood. 
Studies suggested it might involve the regulation of ER-associated Ca^^ fluxes (Lam 
et al., 1994). In the CNS, an increase in bcl-2, but not bcl-xc/ Bax, was found in tissue 
from traumatic brain injury patients (Clark et al., 1999). This suggests bcl-2 plays an 
important role in brain injury and possibly a valuable therapeutic target. Because of 
the above, the changes of this gene upon cytokines and p-AR drugs treatment were 
monitored in this study. 
1.6.1.2. bcl-x 
bcl-x is separated into two different forms, bcl-XL (long form) and bcl-XG, 
(short form) by alternative splicing (Boise et al., 1993). bcl-XL is an anti-apoptotic bcl-
2 family protein. In the CNS, it is widely expressed in the developing and adult 
neurons system. Evidence also showed that it was important in neuron survival (Bui et 
al., 2001). Moreover, TNF-a induced BCL-XL expression in an NFKB-dependent 
manner (Tamatani et al., 1999). These findings suggest bcl-x: is an important factor 
in CNS development and possibly neuron survival. bcl-XL has different distribution 
compare with bcl-2 (Petros et al., 2001). Because of the above, the changes of this 
gene upon cytokines and p-AR drugs treatment were monitored in this study. 
1.6.1.3. bcl-XG 
bcl-XA is a counterpart of human bcl-XL and it is generated from a spliced 
transcript of bcl-x (Shiraiwa et al., 1996). 
2 7 
1.6.1.4. bcl-w 
bcl-w protein can promote cell survival, bcl-w mRNA was found highly 
expressed in brain which suggested this factor played a role in the nervous system 
(Gibson et al., 1996; Hamner et al., 1999). In this study, we also monitored the 
changes of this gene upon cytokines and p-AR drugs treatment. 
1.6.1.5. Myeloid cell leukemia factor 1 (Mcl-l) 
Mcl-l is a 37 kDa protein that contains all four conserved bcl-2 homology 
domains. It is widely distributed in mitochondrial membranes and a variety of non-
mitochondrial compartments. It is up-regulated by cell survival cytokines and down-
regulated by some death-inducing signals. Mcl-l can bind to wide range of pro-
apoptotics but not antiapoptotic bcl-2 family members (Johnson, 1999). In 
macrophages, the level of Mcl-l was decreased if the survival related to the PI3K/ 
Akt-1 pathway was inhibited (Liu et al., 2001). 
1.7. C6 glioma cell line 
In our previous studies, TNF-R2 and (3-ARs were found to be related to the 
TNF-a-induced proliferation pathway(s) in C6 cells. To understand more how TNF-a 
induces proliferation in astrocytes, we used C6 glioma cells to study the relationship 
between TNF-a, TNF-Rs and (3-ARs on cell cycle regulatory genes expression, with 
an ultimate goal of finding a more favorable environment for enhancement of nerve 
regeneration and prevention of scar formation thus a better treatment for brain injury. 
C6 glioma cell line (ATCC: CCL-107) is cloned from a rat glial tumor 
induced by N-nitrosomethylurea after a series of alternate culture and animal passages. 
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C6 glioma cells had been widely used for analysis astrocytes properties (Frei et al., 
1985; Huang et al., 1998; Guimersen et al., 2000; Lung et al., 2001) as they express S-
100 which is found unique to brain astrocytes and they have many astrocytes-like 
properties, e.g. expression of GFAP and the presence of glutamine synthetase (Benda 
et al., 1968). 
Besides, C6 glioma cells have been used for study glioma, especially drug 
effects. For example, to test the effects of thalidomide, a drug that has therapeutic 
applications in neoplasms, on implanted C6 glioma cells in rats. It was found that 
thalidomide could reduce the tumor size and proliferation (Arrieta et al., 2002). Also, 
C6 cells are used to examine the inhibitory effect of pi6 by retroviral transfer of the 
pi6 cDNA into C6 glioma in rats. These authors found that pi6 arrested C6 cell 
proliferation efficiently (Strauss et al., 2002). 
Moreover, the effects of cytokines on protein expression in C6 cells had been 
studied. It was recently found that IL-ip, TNF-a, and IF-y alone was ineffective, 
whereas their combinations induced nitric-oxide synthase expression (Syapin et al., 
2001). Oshiro et al. (2001) found that IF-y increased major histocompatibility 
complex class-1 expression in C6 cells and this increased C6 cells survival. Moreover, 
TNF-a, IL-ip, and IF-y induced an increase in level of glial-derived neurotrophic 
factor (GDNF) mRNA and protein in C6 cells, whereas IL-2 and IL-6 had no 
significant effects (Appel et al., 1997). The above reports clearly show that C6 cells 
do respond to cytokines, and C6 cells were chosen as the model in this study. 
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1.8. Aim of this project 
Brain injury causes cascades of biochemical changes and also caused neuronal 
damage. To enhance neuronal regeneration, one of the approaches is to block 
astrocyte proliferation which is involved in glia scar formation. The levels of 
cytokines, including TNF-a, were elevated after brain injury, however, their functions 
are still unclear. As TNF-a induces astrocyte proliferation and that astrocytes 
proliferation is a process leading to scar formation, the major aim of this project was 
to understand the pathway/mechanism mediating the induction of candidate genes 
controlling astrocyte proliferation. 
To investigate the effects of TNF-a on C6 cell proliferation, we examined the 
effects of TNF-a on 18 cell cycle-related proteins regulating Gl, S, G2, and M phases 
of a cell cycle, and some bcl-2 family proteins, which are antiapoptotic proteins. The 
concentration of lOOU/ml of TNF-a had been found to exert maximum effect on C6 
cell proliferation (Liu, 1996). A time course study, with or without TNF-a treatment, 
on cell cycle regulatory genes expression was performed to understand the roles 
played by these genes in a cell cycle. 
TNF-a exerts its effect through TNF-Rl and/or TNF-R2. To investigate the 
roles played by these TNF-a receptor subtypes, the effects of TNF-a in the presence 
of specific TNF-Rl or TNF-R2 antiserum towards these 18 cell cycle regulatory 
genes were examined. The concentration of antiserum used was 0.08 |ag/|al which had 
found to block C6 cells proliferation (To, 2000). 
Besides TNF-a, the effects of four other cytokines: IL-6, IL-a, IL-ip, and IF-y 
that were found in injured brain on the expression of these 18 cell cycle regulatory 
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genes and protein expression were also tested. Another reason for choosing these 
cytokines is because IL-6 and IF-y were found to have no significant effect on C6 cell 
proliferation (Liu, 1996). 
As our previous study showed that TNF-a induced the expression of P] and 
P2AR (Shan, 2001), and |3-adrenergic mechanism had been shown to be involved in 
astrocyte proliferation (Section 1.4.2), the effects Pi and P2AR agonists and 
antagonists on these 18 cell cycle regulatory proteins expression were examined. The 
purpose of this study was to elucidate if the TNF-a-induced proliferation via an P-
adrenergic mechanism or these two types of compound induced proliferation through 
different pathways in C6 cells. 
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CHAPTER 2. MATERIALS & METHODS 
2.1. Materials 
2.1.1. Rat C6 glioma cell line 
Rat C6 glioma cells were obtained from the American Type Culture collection 
(U.S.A). They were originally cloned from a ral glial tumor induced by 
N-nitrosomelhylurea after a scries of alternate culture and animal passages (Benda el 
al., 1968). 
2.1.2. Cell culture materials preparation 
2.1.2.1. Complete Dulbecco's Modified Medium (cDMEM) 
The Dulbecco's modified Eagle medium (DMEM) powder with L-glulaminc 
and glucose (Invitrogen, Hong Kong) was dissolved in 800 ml double distilled water 
with 3.7 g sodium bicarbonate added. Then hcat-inaclivatcd fetal bovine scrum 
(Invitrogen, Hong Kong), 10000 U/ml penicillin, 1 ()()()() |.ig/nil streptomycin, 25 
|ig/ml fungizone, (Invitrogen, Hong Kong) were added. The medium was made up to 
1 litre with double distilled water adjust lo pH 7.3 and filtered. The final cDMHM 
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medium contained 10% FBS, 100 U/ml penicillin, 100 |Lig/ml streptomycin and 0.25 
|ag/ml fungizone. The medium was stored at 4°C until use. 
2.1.2.2. Serum-free Dulbecco's Modified Medium (sDMEM) 
The preparation of serum-free DMEM is the same as that of cDMEM, except 
fetal bovine serum was not added to the medium. Therefore, the serum-free DMEM 
contains DMEM, 100 U/ml penicillin, 100 |ig/ml streptomycin, and 0.25 jug/ml 
fungizone. This medium was also stored at 4°C until use. 
2.1.2.3. Phosphate buffered saline (PBS) 
Phosphate buffered saline (PBS) was prepared by dissolving a pack of 
powdered Dulbecco's PBS (In vitro gen, Hong Kong) in 800 ml of NANOpure water, 
Then the pH of PBS was adjusted to 7.4, made up to 1 litre and autoclaved. The 
autoclaved PBS was stored at 4°C until use. 
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2.1.3. Drug preparation 
2.1.3.1. Recombinant cytokines 
Recombinant mouse TNF-a (specific activity: 6X1 (T U/mg), human IL-la 
(specific activity: 5X10^ U/mg), mouse IL-ip (specific activity: 5X10? U/mg), 
mouse IL-6 (specific activity: 1X10^ U/mg), and mouse IF-y (specific activity: 5X10^ 
U/mg) were purchased from Roche (Germany). All of the cytokines were stored in 
aliquots at -20°C until use. 
2.1.3.2. Antibodies 
2.1.3.2.1. Antibodies used in expression analysis 
Anti-TNF-Rl and anti-TNF-R2 antibody (200 ^ig/ml, Santa Cruz Biotechnology, 
Inc., U.S.A.) were diluted with serum-free DMEM before use. 
2.1.4. Antibodies used in Western blotting 
All the primary and corresponding secondary antibodies used in Western 
blotting experiments were shown in (Table 2.1). 
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Table 2.1. Concentrations of different primary and corresponding secondary 
antibodies used in Western blotting experiments. 
Protein of interest Primary antibody Secondary antibody 
actin Goat anti-actin (1:1000), Mouse anti-goat (1:1000), 
Santa Cruz Zymed Laboratories 
cyclin D1 Goat anti-cyclin Dl (1:1000), Mouse anti-goat (1:1000), 
Santa Cruz Zymed Laboratories 
cyclin D3 Goat anti-cyclin D3 (1:1000), Mouse anti-goat (1:1000), 
Santa Cruz Zymed Laboratories 
cdk-4 Goat anti-cdk-4 (1:1000), Rat anti-goat (1:1000), 
Santa Cruz Zymed Laboratories 
cyclin E Goat anti-cyclin E (1:1000), Rabbit anti-goat (1:5000), 
Santa Cruz Zymed Laboratories 
cdk-2 Goat anti-cdk-2 (1:1000), Mouse anti-goat (1:1000), 
Santa Cruz Zymed Laboratories 
p l5 Goat anti-p 15 (1:1000),- Mouse anti-goat (1:1000), 
Santa Cruz Zymed Laboratories 
p27 Goat anti-p27 (1:1000), Goat anti-goat (1:5000), 
Santa Cruz Zymed Laboratories 
p21 Goat anti-p21 (1:1000), Mouse anti-goat (1:1000), 
Santa Cruz Zymed Laboratories 
pl30 Goat anti-pl30 (1:1000), Rabbit anti-goat (1:1000)， 
Santa Cruz Zymed Laboratories 
cyclin H Goat anti-cyclin H (1:1000), Mouse anti-goat (1:1000), 
Santa Cruz Zymed Laboratories 
cyclin B Goat anti-cyclin B (1:1000), Mouse anti-goat (1:1000), 
Santa Cruz Zymed Laboratories 
bcl-2 Goat anti-bcl-2 (1:1000), Mouse anti-goat (1:1000), 
Santa Cruz Zymed Laboratories 
bcl-XL Goat anti-bcl-Xl (1:1000), Mouse anti-goat (1:1000), 
Santa Cruz Zymed Laboratories 
bcl-w Goat anti-bcl-w (1:1000), Goat anti-goat (1:1000), 
Santa Cruz Zymed Laboratories 
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2.1.5. Reagents for RNA isolation 
TRIzol reagent (Invitrogen, Hong Kong) and isopropanol (Promega, U.S.A) 
were stored at 4。C, while chloroform and ethanol (both from AnalaR, England) were 
stored at room temperature until use. 
2.1.6. Reagents for reverse transcription-polymerase chain reaction (RT-PCR) 
Reagents used for reverse transcription (RT) included: deoxynucleotide mix 
(dNTP, 10 mM each dNTP), AMV reverse transcriptase (25 U/|dl), RNase inhibitor 
(50 11尔1), random primer p(dN)6 (2 |ag/ml), magnesium chloride (25 mM). These 
reagents were purchased from Roche, Germany. Nuclease free water was purchased 
from Promega, U.S.A. Reagents used for polymerase chain reaction (PCR) included: 
deoxynucleotide mix (dNTP, 10 mM each dNTP), Tag DNA polymerase (produced 
in E. coli, 5 U/jul) were purchased from Roche, Germany. Specific sense and 
antisense primers were designed using information obtained from GenBank 
Sequence Database. All primers were synthesized by TechDragon, Hong Kong. Table 
2.2 showed the primers used for PCR in this study. Tris-ethylenediaminetetraacetic 
acid disodium salt (TE) buffer was used to reconstitue and dilute PCR primers. The 
TE buffer contained 10 mM Tris (pH 8.0) and 1 mM ethylenediaminetetraacetic acid 
disodium salt (EDTA); these chemicals were purchased from Sigma, U.S.A. 
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Table. 2.2. Primers used in RT-PCR experiments and the predicted sizes of the PGR 
products. 
cDNA interested Reference Primer sequences (5，to 3，） Product size 
source (bp) 
R. norvegicus cytoplasmic beta-actin (Actx), NM_031144 tga gac ctt gca aca ccc cag 201 
mRNA ttc atg agg tag tct gtc agg tcc 
Rattus norvegicus mRNA for cyclin D1，complete D14014 agg age aga agt gcg aag ag 498 
cds tgg aaa gaa agt gcg ttg tg  
R. norvegicus mRNA for cyclin D2, complete cds L09752 ccc gac tcc taa gac cca tc 298 
ggt age aca cag age gat ga 
R. norvegicus mRNA for cyclin D3, complete cds D16309 aca tgg cca gtc agt tcc tc 503 
gta gca gag ggg agg gaa ag  
R. norvegicus cyclin-dependent kinase 4 (cdk4) LI 1007 caa tgt tgt acg get gat gg 505 
mRNA, complete cds gtc gtc ttc tgg agg caa tc 
R. norvegicus mRNA for cyclin E, complete cds D14015 tgg gaa gtt cca age tea ag 502 
tgc cgt ctg tgt gaa gag tc  
R. norvegicus mRNA for cdk2, partial cds D63162 gtt gac ggg aga agt tgt gg 301 
； gca gac acg gtg aga atg g  
R. norvegicus elongation factor SIII pi 5 subunit L29259 acc tat ggt ggc tgt gaa gg 300 
mRNA, complete cds ggc cat cag cag ttc cag 
R. norvegicus mRNA for p27, complete cds D83792 gcc tgg ctc tac tcc act tg 504 
get gac ate caa get ctc ct 
R. norvegicus p21 protein (cipl) gene, complete L41275 cga gac act cag age cac ag 491 
cds ggc get tgg agt gat aga aa  
R. norvegicus pi30, Retinoblastoma-related gene NM_031094 gaa gaa age aga ggc gac ag 300 
(Rb2), mRNA eta ggc cgt cgt gta agg ag 
R. norvegicus mRNA for Cdk-activating kinase X83579 agt ctc gtg ttg acc cca tc 498 
gag ctc aag cag gtc gtc tc 
R. norvegicus cyclin H mRNA, complete cds AF154914 gac teg ata ccc cat gtt gg 496 
ttc eta ctt ccg teg gtc ag 
R. norvegicus cyclin B mRNA, complete cds LI 1995 cca age acc aga tea gac ag 500 
tgc ate tgc aga cga ggt ag  
R. norvegicus Bcl-x (bcl-x) gene, complete cds U10579 aca gca gca gtt tgg atg c 498 
tgt ctg gtc act tcc gac tg 
R. norvegicus Bcl-x^ mRNA, complete cds U72350 gag aag age ctg cct tgt tg 502 
agt tgg tcc ctc agt cat gg 
R. norvegicus Bcl-w (bcl-w) mRNA, complete cds AF096291 aga cac acg ggc tct agt gg 498 
age act gtc ctc act gat gc 
R. norvegicus Mcl-l protein mRNA, complete cds AF115380 gga aga cga cga get gta cc 499 
aaa age cag cag cac att tc 
3 7 
2.1.7. Reagents for Electrophoresis 
6X DNA loading buffer contained 30% (v/v) glycerol, 0.25% (w/v) 
bromophenol blue and 36 mM EDTA (pH 8.5). 5X Tris-boric-EDTA (TBE) buffer 
was prepared by dissolving 54 g Tris base, 27.5 g boric acid and 3.72 g EDTA in 1 
liter double-distilled water, and the pH was adjusted to 8.3. The 100 bp DNA ladder 
marker was from Bio-rad, U.S.A. 
2.1.8. Reagents and buffers for Western blotting 
RIPA buffer was made up of 1 X PBS, 1% Igepal CA-630 (Sigma, U.S.A.), 
0.5% sodium deoxycholate, 0.1% SDS. Protease inhibitors used included, 10 fil/ml 
PMSF (Sigma, U.S.A.), 30 |LLl/ml aprotinin (Sigma, U.S.A.), 10 j^l/ml 100 mM 
sodium orthovanadate (Sigma, U.S.A.). Two X loading buffer contained 0.5 M Tris, 
pH 6.8, 10% (v/v) glycerol, 2% (w/v) SDS, 5% (v/v) 2-p-mercaptoethanol and 
0.03% (w/v) bromophenol blue. One X running buffer was made up of 0.025 M Tris, 
0.19 M glycine and 0.1% (w/v) SDS. Transfer buffer contained 39 mM glycine, 48 
mM Tris, 0.037% (w/v) SDS and 20% (v/v) methanol. PBS for preparation of 
blocking buffer contained 0.058 M sodium hydrogen phosphate, 0.017 M sodium 
dihydrogen phosphate and 0.068 M sodium chloride. Blocking buffer was freshly 
prepared by dissolving 5% non-fat dried milk powder and 0.1% (v/v) Tween®20 
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(Sigma, U.S.A) in PBS. Wash buffer contained PBS plus 0.1% (v/v) Tween®20. 
Western blotting detection reagents (ECL+Plus) were from Amersham Pharmacia 
Biotech, UK. 
2.1.9. Other chemicals and reagents 
All other chemicals were purchased from Sigma, U.S.A. 
2.2. Methods 
2.2.1. Maintenance of C6 cells 
C6 cells were growing in cDMEM medium at 37°C, 5% CO2 in an incubator. 
Cells were sub cultured twice per week. For subculturing, the original medium was 
first removed followed by washing the cells with 10 ml sterile PBS twice. Then, 1 ml 
trypsin-EDTA was added and incubated for 4 min at 37°C in a volume of 10 ml 
cDMEM. Cells were dispersed by repeated pipetting, centrifuged at 1000 rpm for 3 
min to collect the cells. The pellet was dispersed again by repeated pipetting, and 
cells were subcultured in a concentration of 10^ cells/ml in a 75 cm^ culture flask in a 
volume of 20 ml cDMEM. 
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2.2.2. Preparation of cells for assays 
All samples for RT-PCR and Western blotting assays were performed with cells 
of 20 to 50 passages. In these experiments, cells were seeded at 5 x cells/ml in a 
60 mm petri dish in cDMEM medium. At about 70% confluence, the medium was 
replaced by sDMEM and incubated for 24 hours to synchronize the cells at the G � 
phase. 
2.2.3. Drugs preparation 
The five cytokines tested in this study were TNF-a, IL-6, IL-la, IL-ip, and 
IF-y. For TNF-Rl and TNF-R2 monoclonal antibodies treatment experiments, cells 
were treated with 0.08 |Lig/ml, and this amount of antiserum had been found to be 
effective in blocking TNF-a-induced C6 cells proliferation (To, 1999). The six 
3-adrenergic agonists and antagonists tested were common p-adrenergic receptor 
agonist isoproterenol (ISO); common antagonist propanolol (PROP); piAR agonist, 
dobutamine (DOB); piAR antagonist, CGP 20712A (CGP); P2AR agonist, procaterol 
(PROC); and pzAR antagonist, ICI 118,551 (ICI). All the p-AR compounds were 
from Sigma, U.S.A. 
All drugs were prepared and diluted with sDMEM to the desirable 
concentrations before the experiments. For simple reference, the amounts or 
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concentrations of different cytokines or p-AR compounds tested were given in (Table 
2.3). 
2.2.4. Determination of RNA expression by RT-PCR analysis 
2.2.4.1. RNA extraction 
Cells at 5 X lO"^  cells/ml were seeded in a 60 mm petri dish in cDMEM. At about 
70% confluence, the medium was removed and replaced with sDMEM and incubated 
for 24 hours to synchronize the cells at Go phase. The cells were treated with drugs 
for various time periods as described in the text, and treatment was terminated by 
placing the dish on ice. The medium was removed and cells were washed with 20 ml 
cold PBS twice. This was followed by the addition of 1 ml TRIzol reagent 
(Invitrogen, Hong Kong) and incubated for 5 min at room temperature to lyze the 
cells as described before (Shan, 2000). All RNA samples obtained were stored at 
-20�C until use. 
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Table 2.3. Concentrations or amounts of various drugs tested in reverse 
transcription-polymerase chain reaction (RT-PCR) and Western blotting experiments. 
Drugs RT-PCR Western blotting 
TNF-a 100 U/ml 1 OOU/ml 
TNF-Rl 
0 . 0 8 f i g / ^ i l 0 . 0 8 f i g / | L i l 
antibody 
TNF-R2 
0 . 0 8 |Lig/|^l 0 . 0 8 | L i g尔 1 
antibody 
IL-6 (U/ml) 50; 100; 1000; 5000; 10000 50; 100; 1000; 2500; 7500 
I L - l a (pg/ml) 100 100 
IL- ip (pg/ml) 100 100 
IF-y (U/ml) 100 100 
ISO (M) 10.9; 5x10.9; 10"'; 10"'; 10"'; 10"'; 10.4 10"^ ; 10"^ 10"'; 10"^ ; 10"^ ; 10'' 
Prop (M) 10.9; 10.8; 10.7; 10—6; 10.5; 5X10.4; jq-4 10.9; 10.8; 10-7; 10-6; IQ-5. 10.4 
DOB (M) 10.9; 5x10.9; JQ-8. 10-7; 10-6; Q^-5. 10.4 10-9; IQ-S; JQ-7. q^-6. 10"' 
CGP(M) 10-9; 10-8; 10"'； 10.6; 10-5; 10.4; 10-3 10-9; 10-8; 10-7; 10-6; JQ-S. ^  Q-4 
Proc (M) 10.9; 5x10.9; ^q-S. q^-T. ^q-6, jq-S. 10.4 10-9； iq-8. 10-7; 10.6; 10.5; 10-4 
ICI (M) 10-9; 5x10-9; 10-8; 5x10-8; 10—7; 5x10-7; 10-6 10-9; 5x10-9; 10-8; 5x10-8; 10-7; 10-6 
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2.2.4.2. Spectrophotometric Quantitation of DNA and RNA 
The amount and purity of the isolated nucleic acid were determined 
spectrophotometrically. An absorbance at 260 nm of 1 is equivalent to approximately 
40 [ig/m\ of RNA. The purity of nucleic acid was determined by the ratio between 
the absorbances at 260 nm and 280 nm, and only preparations of nucleic acid which 
had OD260/ OD280 value of 1.8 or above were used for RT-PCR studies. A pure RNA 
preparation should have an OD260/ OD280 value of 2.0. 
2.2.4.3. RNA gel electrophoresis 
RNA was separated by 1 to 2% formaldehyde agarose gel, which was prepared 
by dissolving 1 to 2% agarose (w/v) in IX MOPS containing 0.5 昭/ml ethidium 
bromide and formaldehyde. The RNA sample was mixed with appropriate amount of 
6X agarose gel loading buffer to give a IX final concentration and formamide. The 
samples were heated to 60°C for 20 min, then loaded. The voltage was 8 V/cm. The 
RNA band was detected using a gel documentation system (Bio-rad). 
2.2.4.4. Reverse transcription-polymerase chain reaction (RT-PCR) 
One idg of total RNA was reverse-transcribed in a 20 |il reaction mixture 
containing 20 U of AMV reverse transcriptase, 5 mM MgCl�，1 mM of each dNTP, 
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40 U ofRNase inhibitor, 3.2 jag random primer p(dN)6, 10 mM Tris/HCl, pH 8.3 and 
50 mM KCl. The mixture was incubated at 25°C for 10 min, then 42�C for 60 mm, 
heated to 99°C for 5 min and cooled to 4°C for 5 min. The RT samples were 
amplified immediately or stored at -20°C until use. 
PCR was performed in a total volume of 25 |LI1 consisting of 1.5 |LI1 of RT sample, 
0.5 U of Taq DNA polymerase, 1.5 mM MgCl〗，0.2 mM of each dNTP, 0.2 |LIM of 
both sense and antisense oligonucleotides, lOmM Tris/HCl, pH 8.3 and 50 mM KCl 
in a PCR machine (GeneAmp PCR system 9700, PerkinElmer, U.S.A.). The PCR 
conditions were 94°C for 5 min, then 30 cycles of 94°C for 0.5 min, 52°C for Imin, 
72°C for 1 min, followed by final extension of 5 min at 72°C. The sequences of the 
PCR primers used in this study were summarized in Table 2.2. 
2.2.4.5. Separation of PCR products by agarose gel electophoresis 
An 5 |j.l-aliquot of PCR products was loaded with 6 X loading buffer and 
separated on a 2% (w/v) agarose gel. The gel was run in 0.5 X TBE buffer at 125 V 
for one hour and stained with 1 \ig/m\ ethidium bromide solution and photographed 
under UV fluorescence. 
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2.2.4.6. Quantification of band density 
Density of the PGR product was quantified by densitometry using ImageQuant 
(Microsoft) by Molecular Dynamics. The density of the target gene was first 
normalized by dividing its density by that of the P-actin gene then the normalized 
value of the treated sample was divided by the normalized value of the corresponding 
control in the same set of treatment to obtain the relative density value. The higher 
densitometry value suggested higher gene expression. 
2.2.4.7. Restriction enzyme (RE) digestion 
To ensure that all the PGR products were from the amplification of 
corresponding transcripts of the genes of interest, the PGR bands of the predicted 
sizes were further checked by restriction enzyme digestion to see if the PCR products 
contained the predicted restriction sites as described previously (Huang et al. 1998). 
For RE digestion, 20 of PCR products were digested with RE at 37�C for 4 hours 
and separated on a 2% (w/v) agarose gel (Huang et al. 1998). 
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2.2.5. Determination of protein expression by Western blotting 
2.2.5.1. Total protein extraction 
Cells of 5 X 104 cells/ml were seeded in a 120 mm petri dish in cDMEM. At 
about 70% confluence, the medium was removed and replaced with sDMEM with 
1% PSF for 24 hours to synchronize the cells at the G�phase. After drug treatments, 
cells were washed with ice-cold as described in (Section 2.2.4.1). 0.6 ml of RIPA 
buffer (containing freshly prepared protease inhibitors) was added to each dish and 
cells were scraped off with a cell scraper. To ensure cell breakage, the cell lysate was 
forced through a syringe fitted with a 21 gauge needle twice. 10 jul of 10 mg/ml 
PMSF, a protease inhibitor, was added and incubated in ice for 60 minutes. The cell 
lysate was centrifuged at 10,000 x g for 30 min at 4°C and the supematent was either 
stored at -4°C until use or processed for SDS PAGE analysis. The amount of protein 
in each sample was determined by the method of Lowry et al. (1951) using bovine 
serum albumin (Sigma, U.S.A.) as the standard. 
2.2.5.2. Western blotting analysis 
For this study, 20 \xgl\i\ protein sample was electrophoresed in 7.5-10% 
polyacrylamide gel as described in Table 2.4. The gel was run at 100 V for 1.5 hours. 
Table 2.4. The ingredients of 7.5% and 10% separating and stacking SDS-PAGE gel. 
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Separating gel (1 Oml/two gels) Stacking gel (5ml/two  
g f ^  
Percentage of gel 7.5% 10% “ 
30% Acryamide/Bis 2.5ml 3.33ml 0.66ml 
0.5M Tris-Cl 4X (pH - -- 1.26ml 
6.8) 
1.5M Tris-Cl 8X (pH 2.5ml 2.5ml --
8.8) 
IQo/oSDS lOOul lOOul 50ul 
DDH20 4.85ml 4.02ml 3ml 
TEMED lOul lOul lOul 
10% APS 50ul 50ul 25ul 
(O.Olg�lOOul)  
After electrophoresis, the protein bands were transferred onto a Hybond-P 
membrane (Bio-rad, Hong Kong). The non-specific binding sites were blocked by 
immersing the membrane in PBS containing 5% non-fat dried milk powder, 0.1% 
(v/v) Tween® for 1 hour at room temperature on an orbital shaker. The membrane 
was rinsed twice in wash buffer. The membrane was incubated in the diluted primary 
antibody (dilution 1:1000 with 5% non-fat dry milk) for 1 hour at room temperature 
with shaking. The membrane was briefly rinsed with two changes of wash buffer and 
then washed with in wash buffer for 15 min at room temperature. The membrane was 
rinsed for 3x5 minutes with fresh changes of wash buffer at room temperature before 
expose to the secondary antibody. The horse raddish peroxidase (HRP) labelled 
secondary antibody was diluted 1:1000 with 5% non-fat dry milk (Table 2.1). Then, 
the membrane was briefly rinsed with two changes of wash buffer, washed with wash 
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buffer for 15 min at room temperature, and followed by 3x5 minutes rinse with fresh 
wash buffer. The membrane was incubated with ECL+Plus detection solution for 5 
min at room temperature. The final volume of detection reagent was 0.1 ml/cm^. The 
excess detection reagent on the membrane was drained off and covered with a piece 
of SaranWrap. The wrapped blot was covered with an autoradiographic film was 
placed in an X-ray film cassette and exposed for various times and then developed. 
The intensity of each band was semi-quantified using ImageQuant (Microsoft). Data 
treatments were similar these described in Section 2.2.4.2. 
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CHAPTER 3. RESULTS 
3.1. Effects of TNF-a on cell cycle related genes and proteins 
expression 
In a cell cycle, specific proteins are responsible for regulating different phases. 
As G1 phase is the phase that is influenced by external factor, we focus on the effect 
of TNF-a on expression of these genes and/ or proteins which are involved in the 
regulation of G1 phase. The aim is to see if the TNF-a-induced C6 cell proliferation 
is through the regulation of these cell cycle related genes and/ or proteins. The 
proteins that are involved in the regulation of other phases (S, G2, and M) were also 
included in order to allow us to compare the effect of TNF-a on these proteins and 
those in the G1 phase. 
In the following studies, cells were treated with 100 U/ml TNF-a for different 
time periods, and then the genes and proteins of interest were determined by RT-PCR 
and Western blotting, respectively. 
3.1.1. Effects of TNF-a on the time courses of cyclin Dl gene and protein 
expression 
Cyclin Dl is one of the major cyclins responsible for G1 phase regulation. For 
example, application of cyclin Dl antisense caused G1 arrest (Baldin et al., 1993; 
Resnitzky and Reed, 1995). The action cyclin Dl is activated by cdk-2, -4, -5, or —6 to 
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form the respective cyclin-cdk complexes. Following the addition of TNF-a (100 
U/ml), the expression of cyclin D1 RNA was induced at around 0.25, 0.5, and 1 hour, 
then declined. But its expression was increased again at around 4-9 hours, and at 12-
23 hours (Fig. 3.1). In general, the pattern of protein expression followed that of the 
gene but with a slight delay and several very distinct peaks were observed at around 5 
min, 5 to 10, 14 and 19 hours after TNF-a addition (Fig. 3.1). The findings that TNF-
a induced the expression of cyclin D1 gene and protein at very early times after TNF-
a addition supports that TNF-a-induced cell proliferation by influencing the G1 
phase. 
3.1.2. Effect of TNF-a on the time course of cyclin D2 gene expression 
Cyclin D2 has similar function as cyclin D1 and both are responsible for G1 
phase regulation. TNF-a caused a much greater induction of cyclin D2 RNA 
expression. At early times following TNF-a treatment, the induction was greater than 
20 folds and at later times, two distinct peaks were observed at around 13 and 21 
hours (Fig. 3.2). This observation suggested that cyclin D2, like cyclin Dl, is one of 
the target genes of TNF-a induction in C6 cells. As both cyclin Dl and D2 are 
responsible for G1 phase, it is reasonable to suggest that TNF-a exerts its 
proliferative effect by stimulating these regulatory genes in the G1 phase. 
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Fig. 3.1. Effects of TNF-a on the time courses of cyclin D1 gene and 
protein expression. Cells were first synchronized at GO phase then 
treated with 100 U/ml TNF-a for 1 min to 25 hours. RT-PCR and 
Western blotting were performed to analyze the RNA or protein 
expressed as described in Materials and methods. The amounts of PCR 
products were semi-quantified by densitometry and normalized with 
respect to the corresponding |3-actin values. Results were expressed as 
relative densities with respect to the corresponding samples without 
treatment. Data presented were representations of three separate 
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Fig. 3.2. Effect of TNF-a on the time course of cyclin D2 gene 
expression. Methods and data treatments were as described in Fig. 3.1. 
Data presented were representatives of three separate experiments with 
similar results. 
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3.1.3. Effects of TNF-a on the time courses of cyclin D3 gene and protein 
expression 
Cyclin D3, like cyclins D1 and D2, is required for G1 phase regulation. 
However, the degrees of dependence on this cyclin are different in different cell types. 
Cyclin D3 induction was observed at the first hour after TNF-a treatment, but it 
occurred a bit later than those of cyclins D1 and D2. Three prominent major peaks of 
induction occurred at around 7, 14, and 20 hours, respectively. In general, the 
induction level of cyclin D3 was greater than that of cyclin D1 but smaller than that of 
cyclin D2. The cyclin D3 protein showed very obvious induction at the first 10 hours 
(Fig. 3.3). The clear induction of cyclin D3 gene and protein again supports the 
hypothesis than TNF-a exerts its action by stimulating cyclin Ds expression. As these 
three cyclins (cyclin Dl , D2, and D3) are expressed in the G1 phase, it is very likely 
TNF-a exerts its major action at this phase of a cell cycle. In the time course of TNF-
a treatment, we observed that there were three clear peaks of cyclins induction. In 
control C6 cells, the generation time is � 2 0 hours, it might indicate that the cells had 
gone through three cycles. The finding of these peaks of cyclin Ds suggests TNF-a 
could shorten the generation time of C6 cells. 
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Fig. 3.3. Effects of TNF-a on the time courses of cyclin D3 gene and 
protein expression. Methods and data treatments were as described in 
Fig. 3.1. Data presented were representatives of three separate 
experiments with similar results. 
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3.1.4. Effects of TNF-a on the time courses of cdk-4 gene and protein expression 
cdk-4 is required for G1 phase regulation, and its action is to activate cyclin 
Ds. A cdk-4 combines mainly with cyclin D, but not other cyclins, to form cyclin D-
cdk-4 complex at the G1 phase. The level of cdk-4 RNA was induced at around 5 min, 
5 to 9, 13 to 16, and 19 to 23 hours after TNF-a treatment. But its level declined after 
each induction, and the levels of all peak were greater than 2 folds (Fig. 3.4). 
However, the protein level showed no induction in the first 6 hours, but its level was 
rapidly increased afterwards, and prominent inductions were observed at 7 hours by 
� 6 0 folds, remained high until 11 hours then declined. Its level was induced once 
again at 20 hours, but the level was smaller compared to that of the first peak (Fig. 
3.4). As cdk-4 activates cyclin Ds by forming complex, the finding that TNF-a also 
induced the expression of this protein again supports our hypothesis that TNF-a 
exerts its effects by stimulating the G1 phase. 
3.1.5. Effects of TNF-a on the time courses of cyclin E gene and protein 
expression 
Cyclin E is a cyclin that exerts its action at the late G1 phase. It exerts its 
actions by combining with cdk-2 which phosphorylates pRb to induce DNA synthesis. 
Following the addition of TNF-a, the cyclin E RNA expression was first induced at 
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Fig. 3.4(a). Effect of TNF-a on the time course of cdk-4 gene 
expression. Methods and data treatments were as described in Fig. 3.1. 
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Fig. 3.4(b). Effect of TNF-a on the time course of cdk-4 protein 
expression. Methods and data treatments were as described in Fig. 3.1. 
Data presented were representatives of three separate experiments with 
similar results. 
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with similar levels of � 7 folds which occurred at 4 to 9, 12 to 17, and 20 to 24 hours. 
The overall induction level of this gene was greater than those of cyclin Dl and D3, 
but lower than that of cyclin D2 (Fig. 3.2). The induction of cyclin E protein 
expression was observed first at 1 hour after the addition of TNF-a and a much 
greater induction of about 13 folds at 6 hours. Following this major induction, another 
smaller induction of about 3 folds was observed at 14 hours (Fig. 3.5). The 
observation that TNF-a induced the expression of this late G1 phase gene at times 
later than that of some cyclin Ds again supports our thought that TNF-a exerts its 
action by stimulating the G1 phase. 
3.1.6. Effects of TNF-a on the time courses of cdk-2 gene and protein expression 
cdk-2 is a cyclin-dependent kinase which combines with cyclins at different 
cell cycle phases. Its function is to activate cyclins specifically. It should also be noted 
that cell cycle phase cyclins present in specific phase if not combine with cdk will be 
degraded. Thus, cdk-2 has the function of prolonging the half-lives of cyclins. In the 
G1 phase, cdk-2 can combine with cyclins D and E and in the S phase, with cyclin A. 
The cdk-2 RNA expression was rapidly induced 5 min after the addition of TNF-a 
then declined, but maintained at a level of � 3 folds that of the control throughout the 
22 hours of treatment (Fig. 3.6). The induction of cdk-2 protein expression was 
observed at 1 hour with a level of � 2 folds. For the first 13 hours of TNF-a treatment, 
the cdk-2 protein expression remained at the control level then declined below that of 
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Fig. 3.5. Effects of TNF-a on the time courses of cyclin E gene and 
protein expression. Methods and data treatments were as described in 
Fig. 3.1. Data presented were representatives of three separate 
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Fig. 3.6. Effects of TNF-a on the time courses of cdk-2 gene and 
protein expression. Methods and data treatments were as described in 
Fig. 3.1. Data presented were representatives of three separate 
experiments with similar results. 
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prevent cyclins from degradation. The lack of clear induction of this protein may be 
related to the fact that this protein is not phase specific. 
3.1.7. Effects of TNF-a on the time courses of pl5 gene and protein expression 
The pi5 RNA level did not change much in the first 10 hours after the 
addition of TNF-a; greater induction was observed from 15-24 hours (Fig. 3.7). The 
level of pi 5 protein expression was similar to its RNA expression. In the first 6 hours, 
its level was not much induced, possibly because this is the time window in which 
cyclin D-cdk-4 complex exerts its action. At 15 and around 20 hours, the pi5 protein 
level was gradually induced (Fig. 3.7). The lack of significantly induction of pl5 
during the first few hours of TNF-a treatment would allow the TNF-a-induced cyclin 
Ds and cdk-4 complexes to exert their actions at the early G1 phase. This is to enable 
pi5 and other ckis to inhibit the action of cyclin D-cdk-4 complex, a process which 
allows a cell to enter into the late G1 phase. This observation, together with the 
stimulatory action of TNF-a on the expression cyclin Ds and cdk-4, suggest TNF-a 
exerts its proliferative action mainly at the early G1 phase. 
3.1.8. Effects of TNF-a on the time courses of p27 gene and protein expression 
Another protein which regulates the activity of cyclin-cdk complex we 
investigated was p27. As mentioned before, p27 is one of the cki that inhibits cyclin 
D-cdk complex's action. TNF-a seemed to have little effects on p27 RNA expression 
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Fig. 3.7. Effects of TNF-a on the time courses of pl5 gene and protein 
expression. Methods and data treatments were as described in Fig. 3.1. 
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Fig. 3.8. Effects of TNF-a on the time courses of p27 gene and protein 
expression. Methods and data treatments were as described in Fig. 3.1. 
Data presented were representatives of three separate experiments with 
similar results. 
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during the first few hours of TNF-a treatment. The level of p27 remained relatively 
constant throughout the treatment with the exception that a � 2 folds of induction was 
observed at around 15 hours (Fig. 3.8). TNF-a induced p27 protein expression peaked 
at two times points: the first at 4 to 6 hours and the other at around 19 hours (Fig. 3.8). 
The time of the first peak was before the first cyclin D and cdk-4 peaks 
induced by TNF-a (Figs. 3.1-3.4). Also, the time was earlier than that of pi5 
induction (Fig. 3.7). Another point to be noted was that the fold of the TNF-a-induced 
pl5 expression was larger than that of p27 (Figs. 3.7 and 3.8). 
3.1.9. Effects of TNF-a on the time courses of p21 gene and protein expression 
Like pi5 and p27, p21 is a cyclin-dependent kinase inhibitor, but it 
participates in all phases of a cell cycle. The p21 gene level was induced by TNF-a 
throughout the treatment period. For the first 11 hours, the induction level was about 
� 6 folds then gradually increased and peaked at 15-16 hours, and at this time, the 
induction was � 1 4 folds (Fig. 3.9). Similar to the RNA expression level, the p21 
protein level was induced by TNF-a. For the first 10 hours, slight induction of � 1 . 5 
folds was observed. Then, two induction peaks were observed at 13 hours and 20 
hours and at both times the levels were � 2 . 5 folds. Interestingly, both peaks were 
followed by a decline (Fig. 3.9). Comparing the protein expression levels of pi 5, p27, 
and p21, TNF-a seemed to induce pi5 more than the other ckis (Figs. 3.7-3.9). Also, 
TNF-a induced different ckis at different times — p27 at early times while pi5 at later 
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Fig. 3.9. Effects of TNF-a on the time courses of p21 gene and protein 
expression. Methods and data treatments were as described in Fig. 3.1. 
Data presented were representatives of three separate experiments with 
similar results. 
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times (Figs. 3.7 and. 3.8). The smaller induction effect of TNF-a on p21 protein 
expression may be related to the fact that this cki participates in all phases of a cell 
cycle, while the other two mainly at the G1 phase. 
3.1.10. Effects of TNF-a on the time courses of pl30 gene and protein expression 
pi 30 is one of the subunits of pRb, so a change of pi 30 level reflects a change 
in pRb. pRb plays an important role on regulation of DNA synthesis via 
phosphorylation with the help of cyclin D-cdk and/ or cyclin E-cdk. The TNF-a-
induced pi30 RNA expression showed three clear peaks. The first peak reached its 
maximum at 1 hour, the second at � 5 hours and the last at � 1 5 hours. The maximal 
levels of the three peaks were � 3 folds (Fig. 3.10). The protein level of pi 30 showed 
4 peaks at 1, 4, 6, and 13 hours, and the induction was �2 folds. From 14 hours 
onward, the pi30 level was suppressed (Fig. 3.10). Although the levels of different 
phosphorylation states of pRb were not measured in this study, the close correlation 
between the time course of cyclins, cdks and pi30 suggests these proteins play 
important role(s) in aiding TNF-a inducing C6 cell proliferation. 
3.1.11. Effects of TNF-a on the time courses of Cak gene expression 
Cak is the kinase that activates cdks in a cell cycle, cdk is the kinase that is 
involved in the activation of cyclin by forming complex with it. However, a cdk 
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Fig. 3.10. Effects of TNF-a on the time courses of pi30 gene and 
protein expression. Methods and data treatments were as described in 
Fig. 3.1. Data presented were representatives of three separate 
experiments with similar results. 
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will not combine with a cyclin unless it is activated by Cak. Thus, Cak is involved in 
each phase of a cell cycle. From the RNA expression time course, the TNF-a-induced 
Cak gene expression with four clear peaks which occurred at � 5 min, 5 to 9 hours, 13 
to 17 hours, and 20 to 24 hours. The maximum of each peak was � 4 folds. As Cak is 
required to activate cdk for action at different phases of a cell cycle (Fig. 3.11), the 
different peaks observed during the time period of investigation suggest the different 
phases of a cell cycle. In this regard, it is interesting to note that this expression 
pattern is similar to those of cyclins (Figs. 3.1-3.3). 
3.1.12. Effects of TNF-a on the time courses of cyclin H gene and protein 
expression 
Cyclin H is the protein that forms a complex with Cak. The detection of this 
gene may reflect Cak activation. The induction of cyclin H gene was more prominent 
than that of Cak (Fig. 3.10) and levels close to � 2 0 folds were observed (Fig. 3.11). 
Like the induction pattern of Cak, the cyclin H induction can also be divided into four 
peaks, and the pattern was similar to that of Cak (Fig. 3.10). On the other hand, only 
an extremely prominent cyclin H protein expression of >40 folds was observed at 7-
14 hours after TNF-a treatment. The time course of this peak coincided with the 
second peak of Cak gene expression (Figs. 3.10 and 3.11). 
6 8 
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Fig. 3.11. Effect of TNF-a on the time course of Cak gene expression. 
Methods and data treatments were as described in Fig. 3.1. Data 
presented were representatives of three separate experiments with 
similar results. 
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Fig. 3.12. Effects of TNF-a on the time courses of cyclin H gene and 
protein expression. Methods and data treatments were as described in 
Fig. 3.1. Data presented were representatives of three separate 
experiments with similar results. 
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3.1.13. Effects of TNF-a on the time courses of cyclin B gene expression 
Cyclin B is the cyclin that exerts its actions in the M phase. In this phase, 
cyclin B exerts its actions by combining with cdc-2, the cdk that works at the M phase. 
The TNF-a-induced cyclin B RNA expression showed four major peaks. The first 
peak occurred at 15 min with a maximum of �6 folds of the control. The second and 
third peaks had similar peak heights of � 5 folds which occurred at 5 to 8 and 13 to 16 
hours, while the fourth peak of � 3 folds at 19 to 22 hours (Fig. 3.13). The cyclin B 
protein expression pattern was similar to that of the RNA, but the effect was less 
prominent (Fig. 3.13). The levels of these peaks were about 2 folds. As cyclin B 
works at G2 and M phase, it is quite possible that TNF-a treatment shortens the cell 
cycle time in C6 cells. 
3.1.14. Effect of TNF-a on the time course of bcl-2 protein expression 
Thus far, we determined the effects of TNF-a on the cell cycle regulatory 
gene and protein expression and found that the expression of some of these proteins 
could be altered by TNF-a treatment. To understand the action TNF-a in C6 cells 
better, its effects on the bcl-2 family apoptotic proteins were also included in the 
following studies. The major function of these proteins are to prevent or inhibit 
apoptosis or substance-induced cell death. 
bcl-2 is one of the death antagonists in the bcl-2 family. It prevents apoptosis 
by forming complex with those death promoting members of the bcl-2 family. The 
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Fig. 3.13. Effects of TNF-a on the time courses of cyclin B gene and 
protein expression. Methods and data treatments were as described in 
Fig. 3.1. Data presented were representatives of three separate 
experiments with similar results. 
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folds of the control, then the expression was suppressed (Fig 3.14). The lack of 
prominent effect of TNF-a on the expression of this protein, except �3 folds increase 
at 13 hours of treatment, suggest TNF-a does not exert is effect by affecting this gene. 
3.1.15. Effects of TNF-a on the time courses of bcl-XL gene and protein 
expression 
bcl-XL is also one of the death antagonists in the bcl-2 family. It is the larger 
product from the alternative splicing of bcl-x. The shorter product is bcl-Xs which is 
one of the death promoting members in the bcl-2 family. bcl-XL RNA expression, 
upon the addition of TNF-a, showed four major peaks. The first and second peaks 
occurred at 30 min and 5 to 8 hours and their maxima were � 1 8 folds. The third peak 
I 
occurred at 13-17 hours and its maximum was � 2 4 folds. The fourth peak occurred at 
19-24 hours and its maximum was � 1 0 folds (Fig. 3.15). However, the bcl-XL protein 
expression remained at a level similar to that of the control throughout the study 
period (Fig. 3.15). The lack of effect of TNF-a on this protein again suggests that this 
cytokine does not exert its action by altering the level of this bcl-2 family protein. 
3.1.16. Effect of TNF-a on the time course of bcl-Xa gene expression 
bcl-Xa is another bcl-2 family death suppression members. It is a counterpart 
of human bcl-xi. bcl-Xa RNA expression showed four major peaks. The first peak 
occurred at 1 min - 2 hours, the second at 4-9 hours, the third at 12-17 hours and the 
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Fig. 3.14. Effect of TNF-a on the time course of bcl-2 protein 
expression. Methods and data treatments were as described in Fig. 3.1. 
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Fig. 3.15. Effects of TNF-a on the time courses of bcl-XL gene and 
protein expression. Methods and data treatments were as described in 
Fig. 3.1. Data presented were representatives of three separate 
experiments with similar results. 
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fourth at 19-25 hours. All of them had maxima of � 1 0 folds (Fig. 3.16). The high 
level of protein expressed following TNF-a treatment might explain why this 
cytokine induced proliferation in C6 cells. 
3.1.17. Effects of TNF-a on the time courses of bcl-w gene and protein expression 
bcl-w also promotes cell survival. For example, bcl-w mRNA was found 
highly expressed in brain and had been suggested to play a role in the nervous system 
(Gibson et al., 1996; Hamner et al., 1999). As one of the death antagonist members in 
bcl-2 family, bcl-w gene expression was induced by TNF-a. There were four peaks of 
bcl-w induction: the first peak occurred at 15 min and its maximum was � 8 folds; the 
second and fourth peaks at 3-8 and 21-23 hours, respectively and their maximal were 
�9 folds; and the third peak which was highest with a maximum of � 1 4 folds (Fig. 
3.17). However, the bcl-w protein expression showed different pattern. The bcl-w 
protein expression induced by TNF-a occurred at 7-11 hours and the level was � 6 
folds. At other treatment times, the bcl-w protein expression remained at the control 
level (Fig. 3.17). This finding again explained why TNF-a did not cause apoptosis in 
C6 cells. 
3.1.18. Effect of TNF-a on the time course Mcl-l gene expression 
Mcl-l binds to wide range of pro-apoptotic but not antiapoptotic bcl-2 family 
members. It can be up-regulated by cell survival cytokines but down-regulated by 
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Fig. 3.16. Effect of TNF-a on the time course of bcl-Xa gene 
expression. Methods and data treatments were as described in Fig. 3.1. 
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Fig. 3.17. Effects of TNF-a on the time courses of bcl-w gene and 
protein expression. Methods and data treatments were as described in 
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experiments with similar results. 
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some death-inducing signals (Johnson, 1999). Mcl-l is one of death inhibitors in the 
bcl-2 family. The Mcl-l gene expression remained at control level after TNF-a 
treatment throughout the time period study (Fig. 3.18). 
Summing up the results observed in the death suppression proteins, it seems 
that TNF-a does not exert its proliferative effect via the induction of these proteins. 
The reason why TNF-a induces the expression of these proteins in C6 cells is not 
clear. However, this may explain why this cytokine does not induce cell death in C6 
cells. As C6 cells have properties similar to those of astrocytes and that TNF-a level ’ 
is increased at the injured site in the CNS, the induction of these antiapoptotic genes 
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Fig. 3.18. Effect of TNF-a on the time course of Mcl-l gene 
expression. Methods and data treatments were as described in Fig. 3.1. 
Data presented were representatives of three separate experiments with 
similar results. 
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3.2. Effects of TNF-Rl and -R2 on cell cycle related genes and 
proteins expression 
TNF-a exerts its actions by binding to its receptors. In C6 cells, there are two 
receptors subtypes: TNF-Rl which mediates cytotoxicity, while TNF-R2 mediates 
proliferation (Baker and Reddy, 1998). In this study, we used two specific receptor 
antibodies to examine the role played by each receptor subtype in mediating cell cycle 
related genes and proteins expression. Previous study in our laboratory showed that 
0.08 )ig/ml of TNF-R2 antibody was effective in blocking TNF-a-induced 
proliferation (To, 1999). 
1 
In this study, cells were treated with 0.08 }ig/ml TNF-Rl or TNF-R2 antibody 
for different time intervals before the addition of TNF-a and incubated for another 
i 、！ 
two hours. RNA and protein were extracted, and RT-PCR and Western blotting were : 
performed to monitor the cell cycle related RNA and protein expression. j 
丨  
ii 
3.2.1. Effects of blocking TNF-Rl/ -R2 on cyclin Dl gene and protein expression 
Blocking of the TNF-Rl with TNF-Rl antibody did not alter the TNF-a-
induced cyclin Dl gene expression throughout the study. While blocking TNF-R2 
with its specific antibody, did not alter the TNF-a-induced cyclin Dl gene expression 
at the first 20 min, however, the TNF-a-induced cyclin Dl gene expression was 
increased as the blocking time increased. The induction increased to 
8 1 
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twice that of control when the TNF-R2 was blocked for 1 hour and further increased 
to � 4 folds at 2 hours after the addition of TNF-R2 antibody (Fig. 3.19(a)). 
Blocking of the TNF-Rl for 1 min increased the TNF-a-induced cyclin D1 
protein expression, and the induction was � 6 folds, and a maximum induction of �1 3 
folds was observed at 20 min, gradually decreased to � 1 0 folds at 30 min. The TNFoc-
induced cyclin D1 expression was then increased again and at 2 hours, and the 
induction level was � 1 6 folds. The TNF-a-induced cyclin D1 expression increased by 
� 3 folds at 1 hour following TNF-R2 antibody treatment and � 4 folds induction was 
observed at 2 hours (Fig. 3.19(b)). 
Cyclin D1 is one of the proteins that regulate early Gl phase, a stage in the 
cell cycle which depends on mitogen. The above findings suggested blocking neither 
TNF-Rl nor TNF-R2 suppressed the TNF-a-induced cyclin D1 gene expression. 
Although both receptor antibodies increased the TNF-a-induced cyclin D1 protein 
expression, the blocking of TNF-Rl increased the level of cyclin D1 protein much 
more than that with TNF-R2 antibody treatment. It is likely that the expression of this 
protein depends more on TNF-R2. This observation is in agreement with our previous 
observation that TNF-a selectively induced TNF-R2 expression (Lung et al., 1998) 
and that TNF-R2 is closely related to proliferation (Baker, 1998). 
3.2.2. Effects of blocking TNF-Rl/ -R2 on cyclin D2 gene expression 
Cyclin D2 is one of the Gl phase cyclins, and Gl specific cyclins are 
produced in response to growth factor stimulation that triggers cells entering into and 
passage through Gl phase. Blocking the TNP-Rl for 1 min slightly increased the 
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Fig. 3.19(a). Effects of blocking TNF-a receptor subtypes for various 
times on cyclin Dl gene expression. Cells were synchronized at GO 
phase as described in Materials and methods, then treated with 0.08 
|dg/ml of TNF-Rl or TNF-R2 antibody for different time periods as 
indicated and followed by treatment with TNF-a (100 U/ml) for 2 
hours. RNA was extracted and RT-PCR was performed to monitor the 
levels of cyclin Dl gene expressed. The amounts of the PGR products 
were semi-quantified by densitometry and normalized with respect to 
the corresponding P-actin values. Results were expressed as relative 
densities with respect to the sample treated with TNF-a only. Data 
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Fig. 3.19(b). Effects of blocking TNF-a receptor subtypes for various 
times on cyclin Dl protein expression. Cells were synchronized at GO 
phase as described in Materials and methods, then treated with 0.08 
\ig/ml of TNF-Rl or TNF-R2 antibody for different time periods as 
indicated and followed by treatment with TNF-a (100 U/ml) for 2 
hours. Protein was extracted and followed by gel electrophoresis and 
Western blotting. The amounts of protein were semi-quantified by 
densitometry and normalized with respect to the corresponding p-actin 
values. Results were expressed as relative densities with respect to the 
sample treated with TNF-a only. Data presented were representations 
of three separate experiments with similar results. 
8 4 
TNF-a-induced cyclin D2 expression, and maximum induction of � 3 folds was 
observed at 5 min. Blocking of the TNF-Rl longer than 20 min slightly suppressed 
the TNF-a-induced cyclin D2 expression (Fig. 3.20). Blocking the TNF-R2 had 
similar effect as blocking the TNF-Rl, with a significant induction of ~5 folds at 5 
min. However, the TNF-a-induced expression was increased again at 1 hour, and �6 
folds of induction were observed at 2 hours (Fig. 3.20). The above findings suggested 
blocking of either TNF-R subtypes for short periods increased the TNF-a-induced 
cyclin D2 expression. One of the explanations could be that both TNP-Rl and TNF-
R2 may modulate the TNF-a-induced cyclin D2 expression. As blocking of the TNF-
Rl greatly induced the expression of cyclin Dl protein (Fig. 3.19(b)), it seemed that 
TNF-R2 played a more important role in modulating this cell cycle protein expression. 
3.2.3. Effects of blocking TNF-Rl/ -R2 on cyclin D3 gene and protein expression 
Cyclin D3 complexes with cdk-4/6 for action and this complex can 
phosphorylate the pRb and causing it to dissociate from the E2F transcription factor 
complex and resulting in the turning off its transcriptional suppressor activity. 
Blocking the TNF-Rl did not alter the TNF-a-induced cyclin D3 gene 
expression. While blocking TNF-R2 with its specific antibody, did not alter the TNF-
a-induced cyclin D3 gene expression at the first 20 min, however, the TNF-a-induced 
cyclin D3 gene expression was increased as the blocking time increased. The 
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Fig. 3.20. Effects of blocking TNF-a receptor subtypes for various 
times on cyclin D2 gene expression. Methods and data treatments were 
the same as those described in Fig. 3.19(a). Data presented were 
representations of three separate experiments with similar results. 
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induction increased to twice that of control when blocked for 1 hour and further 
increased to � 4 folds at 2 hours (Fig. 3.21(a)). 
The Western results were slightly different. Blocking the TNF-Rl for 1 min 
slightly increased the TNF-a-induced cyclin D3 expression, the induction was slightly 
greater than 1 fold and maximum induction of � 3 folds was observed at 20 min then 
gradually decreased to the control level. At 2 hours after TNF-Rl antibody was added, 
the induction rose to � 3 . 5 folds. Blocking of TNF-R2 increased the TNF-a-induced 
cyclin D3 expression at all the time points studied. About 2 to 3 folds increase in the 
TNF-a-induced cyclin D3 expression was observed from 10 min to 1 hour and was 
further increased to -4.5 folds at 2 hours (Fig. 3.21(b)). 
The above findings suggested blocking either TNF-Rl or TNF-R2 alone had 
no effect on the TNF-a-induced cyclin D3 gene expression at early times. However, 
blocking TNF-R2 for longer times, for example 2 hours, cyclin D3 gene expression 
was enhanced. Blocking of the TNF-Rl had no clear effect on the cyclin D3 protein 
expression at early times, except at 20 min and at 2 hours. However, blocking of 
TNF-R2 increased this protein expression by 2 to 4 folds at all times studied. One of 
the explanations could be that both receptor subtypes played important roles in 
regulating this cell cycle protein. As blocking the TNF-R2 had a greater effect on the 
expression of this protein, it is likely that the induction of this protein is more closely 
related to TNF-Rl. 
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Fig. 3.21(a). Effects of blocking TNF-a receptor subtypes for various 
times on cyclin D3 gene expression. Methods and data treatments were 
the same as those described in Fig. 3.19(a). Data presented were 
representations of three separate experiments with similar results. 
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Fig. 3.21(b). Effects of blocking TNF-a receptor subtypes for various 
times on cyclin D3 protein expression. Methods and data treatments 
were the same as those described in Fig. 3.19(b). Data presented were 
representations of three separate experiments with similar results. 
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3.2.4. Effects of blocking TNF-Rl/ -R2 on cdk-4 gene and protein expression 
cdk-4 exerts its action on cyclins at the early Gl phase. It binds to cyclin Ds 
and forming an active complex that phosphorylates pRb and facilitates DNA synthesis. 
Blocking the TNF-Rl increased the TNF-a-induced cdk-4 gene expression and this 
induction was maintained throughout the treatment. Blocking of TNF-R2 also 
increased the TNF-a-induced cdk-4 gene expression. The induction level maintained 
at � 1 8 folds of the control level in the first hour after TNF-R2 antibody treatment then 
gradually increased to � 3 7 folds at 2 hours (Fig. 3.22(a)). 
Blocking the TNF-Rl also increased the TNF-a-induced cdk-4 protein 
expression and the induction was maintained at � 3 folds throughout the treatment. 
However, blocking the TNF-R2 increased the TNF-a-induced cdk-4 protein 
expression very slightly (Fig. 3.22(b)). 
The findings that blocking either TNF-Rl or TNF-R2 increased TNF-a-
induced cdk-4 protein expression suggested both receptor subtypes could modulate 
the TNF-a-induced cdk-4 gene expression. As blocking of the TNF-R2 only slightly 
increased the TNF-a-induced cdk-4 protein expression, while blocking the TNF-Rl 
increased the cdk-4 protein level, this indicated that TNF-R2 could be more important 
in this induction process. 
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Fig. 3.22(a). Effects of blocking TNF-a receptor subtypes for various 
times on cdk-4 gene expression. Methods and data treatments were the 
same as those described in Fig. 3.19(a) Data presented were 
representations of three separate experiments with similar results. 
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Fig. 3.22(b). Effects of blocking TNF-a receptor subtypes for various 
times on cdk-4 protein expression. Methods and data treatments were 
the same as those described in Fig. 3.19(b). Data presented were 
representations of three separate experiments with similar results. 
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3.2.5. Effects of blocking TNF-Rl/ -R2 on cyclin E gene and protein expression 
Cyclin E activates cdk-2 by forming a complex with it around the start of S 
phase. The activated cyclin E-cdk-2 complex acts to phosphorylate pRb which 
resulting in an irreversible commitment to cell division and transition into S phase. 
Blocking the TNF-Rl increased the TNF-a-induced cyclin E gene expression, 
and the induction was 2 to 3 folds at most of time points studied. Blocking of TNF-R2 
with TNF-R2 antibody had no effect on the TNF-a-induced cyclin E gene expression 
(Fig. 3.23(a)). The addition of TNF-Rl antibody slightly induced the TNF-a-induced 
cyclin E protein expression and this induction was maintained throughout the 
treatment. The maximum induction of � 2 folds was observed at 2 hours. Blocking of 
the TNF-R2 also slightly induced the TNF-a-induced cyclin E protein expression at 
very early time and the inductions maintained at �3 and � 4 folds throughout the study 
period (Fig. 3.23(b)). The above findings suggested both TNF-Rl and TNF-R2 
modulate the TNF-a-induced cyclin E expression. 
3.2.6. Effects of blocking TNF-Rl/ -R2 on cdk-2 gene and protein expression 
cdk-2 binds to cyclin E at late G1 phase, an event which is essential for most 
cells to enter the S phase. Then this protein dissociates away from cyclin E and binds 
to cyclin A at the S phase. Blocking the TNF-Rl did not alter the TNF-a-induced 
cdk-2 gene expression at all the time points investigated. Blocking of TNF-R2 did not 
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Fig. 3.23(a). Effects of blocking TNF-a receptor subtypes for various 
times on cyclin E gene expression. Methods and data treatments were 
the same as those described in Fig. 3.19(a). Data presented were 
representations of three separate experiments with similar results. 
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Fig. 3.23(b). Effects of blocking TNF-a receptor subtypes for various 
times on cyclin E protein expression. Methods and data treatments were 
the same as those described in Fig. 3.19(b). Data presented were 
representations of three separate experiments with similar results. 
95 
alter the TNF-a-induced cdk-2 gene expression at the first 30 min. However, the 
TNF-a-induced cdk-2 gene expression increased as the treatment time increased. The 
induction increased to � 1 . 5 folds of the control at 1 hour and further increased to � 3 
folds at 2 hours (Fig. 3.24(a)). 
Blocking the TNF-Rl did not alter the TNF-a-induced cdk-2 protein 
expression from 1 min to 30 min, but increased to � 2 folds at 1 and 2 hours. Blocking 
of TNF-R2 slightly induced the TNF-a-induced cdk-2 protein expression at very early 
times, and the induction further increased to �3 folds at 2 hours (Fig. 3.24(b)). 
The findings that blocking either the TNF-Rl or TNF-R2 increased the TNF-
a-induced cdk-2 protein expression at 2 hours suggested both receptor subtypes 
modulate the TNF-a-induced c(ik-2 protein expression. As the increase occurred at 2 
hours, this agreed with the role of this protein at the S phase. In view of the fact that 
cdk-2 binds to cyclin E for activity, it is not surprising that the levels of these two 
proteins were affected to similar extents by antibody treatment (Figs. 3.23 and 
3.24(b)). 
3.2.7. Effects of blocking TNF-Rl/ -R2 on pl5 gene protein expression 
pi 5 inhibits the action of cyclin Dl-cdk-4 and cyclin D-cdk-5. This inhibition 
results in the displacement of the p27 assembly factor that is bound to cyclin Dl-cdk-
4 and cyclin D-cdk-5. Therefore as the free p27 level increases and this increases its 
availability to inhibit the action of cyclin E-cdk-2. This process forms another 
regulation mechanism in the G1 phase. 
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Fig. 3.24(a). Effects of blocking TNF-a receptor subtypes for various times on 
cdk-2 gene expression. Methods and data treatments were the same as those 
described in Fig. 3.19(a). Data presented were representations of three separate 
experiments with similar results. 
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Fig. 3.24(b). Effects of blocking TNF-a receptor subtypes for various times on 
cdk-2 protein expression. Methods and data treatments were the same as those 
described in Fig. 3.19(b). Data presented were representations of three separate 
experiments with similar results. 
9 8 
Blocking the TNF-Rl did not alter the TNF-a-induced pi5 gene expression. 
The TNF-a-induced pi5 gene expression was suppressed by the addition of TNF-R2 
antibody from 10 to 30 min. However, an induction of � 3 folds was observed 2 hours 
(Fig. 3.25(a)). 
Blocking the TNF-Rl at 1-2 min and 30 min suppressed the TNF-a-induced 
pl5 protein expression, but at other treatment times, the TNF-a-induced pi5 protein 
expression was induced by � 2 folds. The TNF-a-induced pi5 protein expression was 
slightly increased following the blocking of TNF-R2, except a clear suppression was : 
. J 
I 
observed at 5 min (Fig. 3.25(b)). 
The findings that blocking the TNF-Rl induced pi5 protein level at 10 and 20 
min, while blocking the TNF-R2 suppressed the TNF-a-induced pi5 protein 




3.2.8. Effects of blocking TNF-Rl/ -R2 on p27 gene and protein expression 
p27 is involved in the regulation of Gl-S transition. The protein level ofp27 is 
regulated predominantly by posttranslational mechanisms. Blocking the TNF-Rl from 
2 mm to 2 hours slightly increased the TNF-a-induced p27 gene expression and a 
level of between 1 to 2 folds was maintained. Blocking the TNF-R2 for 1 to 10 min 
did not significantly alter the TNF-a-induced p27 gene expression, this was followed 
by a slight suppression at 20-30 min. But, at 2 hours, an induction of the TNF-a-
induced p27 gene expression of � 3 folds was observed (Fig. 3.26(a)). Blocking the 
TNF-Rl did not alter the TNF-a-induced p27 protein expression throughout the study 
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Fig. 3.25(a). Effects of blocking TNF-a receptor subtypes for various 
times on pi5 gene expression. Methods and data treatments were the 
same as those described in Fig. 3.19(a). Data presented were 
representations of three separate experiments with similar results. 
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Fig. 3.25(b). Effects of blocking TNF-a receptor subtypes for various 
times on pi5 protein expression. Methods and data treatments were the 
same as those described in Fig. 3.19(b). Data presented were 
representations of three separate experiments with similar results. 
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Fig. 3.26(a). Effects of blocking TNF-a receptor subtypes for various 
times on p27 gene expression. Methods and data treatments were the 
same as those described in Fig. 3.19(a). Data presented were 
representations of three separate experiments with similar results. 
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period. Blocking the TNF-R2 from 5 min to 2 hours induced the TNF-a-induced p27 
protein expression by � 2 folds (Fig. 3.26(b)). 
The findings that blocking either TNF-Rl or TNF-R2 did not change the TNF-
a-induced p27 protein expression by much suggest both receptor subtypes did not 
modulate the TNF-a-induced p27 gene expression during the time period studied. As 
blocking of the TNF-R2 slightly increased the TNF-a-induced p27 protein expression, 
this might indicate that TNF-Rl was more important in this induction process. 
3.2.9. Effects of blocking TNF-Rl/ -R2 on p21 gene protein expression 
p21, a member of the cki family, is involved in the regulation of 
phosphorylation of pRb which results in initiating DNA synthesis. And thus p21 is 
important for the regulation of G1 phase. As it also inhibits other cyclin-cdk 
complexes, thus it also plays an important role in controlling DNA synthesis in other I 
I 
phases of a cell cycle. 
Blocking the TNF-Rl did not alter the TNF-a-induced p21 gene expression 
throughout the study period. This suggests that the role of TNF-R2 was relatively 
small. Blocking the TNF-R2 for 1-10 min did not alter the TNF-a-induced p21 
expression. Stimulation of the TNF-a-induced p21 gene expression was observed at 2 
hours after TNF-R2 antibody treatment, and the induction was � 3 . 5 folds (Fig. 
3.27(a)). This suggested TNF-a exerted this effect at the stage of a cell cycle by 
interacting mainly with TNF-Rl. 
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Fig. 3.26(b). Effects of blocking TNF-a receptor subtypes for various 
times on p27 protein expression. Methods and data treatments were the 
same as those described in Fig. 3.19(b). Data presented were 
representations of three separate experiments with similar results. 
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Fig. 3.27(a). Effects of blocking TNF-a receptor subtypes for various 
times on p21 gene expression. Methods and data treatments were the 
same as those described in Fig. 3.19(a). Data presented were 
representations of three separate experiments with similar results. 
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Blocking the TNF-Rl increased the TNF-a-induced p21 protein expression, and 2 
peaks were observed at 5 and 20 min and the inductions were ~3 and � 6 folds, 
respectively. Blocking the TNF-R2 from 2 to 20 min with TNF-R2 antibody slightly 
induced the TNF-a-induced p21 protein expression. However, suppression of the 
TNF-a-induced p21 protein expression was observed when the treatment time was 
prolonged from 1 hour to 2 hours (Fig. 3.27(b)). 
The findings that blocking TNF-R2 suppressed the TNF-a-induced p21 
expression suggested that TNF-Rl was not too important in the expression of this ； 
protein. However, TNF-R2 appeared to play a more important role in modulating the 
TNF-a-induced p21 expression as blocking the TNF-Rl with its monoclonal antibody 
greatly elevated p21 expression. This observation is line with our previous finding 





3.2.10. Effects of blocking TNF-Rl/ -R2 on pl30 gene and protein expression | 
t : •f： i 
丨: 
pi30 is one of the subunits of pRb and it is a substrate for phosphorylation. 
Thus, a change in pl30 level reflects the level of pRb. pRb is responsible for DNA 
synthesis. 
Treatment with TNF-Rl antibody either had no or slight suppressive effects 
on the TNF-a-induced pi30 gene expression. Treatment with TNF-R2 antibody 
slightly increased the TNF-a-induced pi30 expression and this occurred at 1-2 hours 
after the addition of this antibody (Fig. 3.28(a)). Blocking the TNF-Rl and the TNF-
R2 did not alter the TNF-a-induced pl30 protein expression (Fig. 3.28(b)). 
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Fig. 3.27(b). Effects of blocking TNF-a receptor subtypes for various 
times on p21 protein expression. Methods and data treatments were the 
same as those described in Fig. 3.19(b). Data presented were 
representations of three separate experiments with similar results. 
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Fig. 3.28(a). Effects of blocking TNF-a receptor subtypes for various 
times on pi30 gene expression. Methods and data treatments were the 
same as those described in Fig. 3.19(a). Data presented were 
representations of three separate experiments with similar results. 
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Fig. 3.28(b). Effects of blocking TNF-a receptor subtypes for various 
times on pi30 protein expression. Methods and data treatments were 
the same as those described in Fig. 3.19(b). Data presented were 
representations of three separate experiments with similar results. 
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The lack of effects of both receptor subtype antibodies on the TNF-a-induced 
pi30 expression suggests this protein expression was not affected by either TNF-a 
receptor subtype alone. This is not surprising as the activity of pRb is altered by 
phosphorylation. 
3.2.11 Effects of blocking TNF-Rl/ -R2 on Cak gene expression 
The cyclin-dependent kinase (cdk)-activating kinase (Cak) is involved in cell 
cycle control, transcription, and DNA repair. To regulate cell cycling, Cak activates 
cdk by phosphorylation. 
Blocking the TNF-Rl did not alter the TNF-a-induced Cak gene expression 
throughout the study period. Blocking the TNF-R2 induced the TNF-a-induced Cak j 
S 
1 
gene expression and the induction maintained at a range of � 3 folds to that of the ； 
11 ； 
control from 1 min to 1 hour, then increased to � 9 folds at 2 hours (Fig 3.29). | 
The above findings suggested the TNF-R2 did not play an important role in I; 
the TNF-a-induced Cak expression, while the role played by TNF-Rl appeared to be 
more important in the study period. 
3.2.12 Effects of blocking TNF-Rl/ -R2 on cyclin H gene and protein expression 
Cyclin H, cdk-7, and Matl are the three major subunits of cdk-activating 
kinase (Cak). Cak coordinates the progression through a cell cycle by phosphorylating 
cyclin-dependent kinases (cdks) which gives cdks full activity. 
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Fig. 3.29. Effects of blocking TNF-a receptor subtypes for various 
times on Cak gene expression. Methods and data treatments were the 
same as those described in Fig. 3.19(a). Data presented were 
representations of three separate experiments with similar results. 
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Treatment with TNF-Rl antibody did not alter the TNF-a-induced cyclin H 
gene expression. Blocking the TNF-R2 induced the TNF-a-induced cyclin H gene 
expression at very early times (<10 min), this was followed and a gradual induction 
and at 2 hours the induction was � 6 folds (Fig. 3.30(a)). 
Blocking the TNF-Rl did not alter much the TNF-a-induced cyclin H protein 
expression throughout the study period (Fig. 3.30(b)). Blocking the TNF-R2 from 1 to 
20 min increased the TNF-a-induced cyclin H protein expression, this was followed 
by a decline to the control value (Fig. 3.30(b)). ： 
The findings that the blocking TNF-R2 increased the TNF-a-induced cyclin H 
gene and protein expression suggested that TNF-Rl played a more important role in 
modulating the TNF-a-induced cyclin H expression. 
i 
i 




Cyclin B is the main cyclin that involves in G2 and M phase regulation. It 
forms a complex with cdc-2, and this triggers mitosis. 
Blocking the TNF-Rl did not alter the TNF-a-induced cyclin B gene 
expression. Blocking of TNF-R2 from 1 to 30 min did not alter the TNF-a-induced 
cyclin B gene expression. However, the induction level gradually increased to -1.5 
and � 3 . 5 folds at 1 and 2 hours (Fig. 3.31(a)). 
Addition of TNR-Rl antibody stimulated the TNF-a-induced cyclin B protein 
expression by � 2 and -3.5 folds at 2 and 5 min, respectively then reduced at 10 min. 
The induction occurred again at 20 min and a stimulation of � 5 . 5 folds was 
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Fig. 3.30(a). Effects of blocking TNF-a receptor subtypes for various 
times on cyclin H gene expression. Methods and data treatments were 
the same as those described in Fig. 3.19(a). Data presented were 
representations of three separate experiments with similar results. 
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Fig. 3.30(b). Effects of blocking TNF-a receptor subtypes for various 
times on cyclin H protein expression. Methods and data treatments 
were the same as those described in Fig. 3.19(b). Data presented were 
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Fig. 3.31(a). Effects of blocking TNF-a receptor subtypes for various 
times on cyclin B gene expression. Methods and data treatments were 
the same as those described in Fig. 3.19(a). Data presented were 
representations of three separate experiments with similar results. 
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A 
observed. This was followed by a decline to the control level at 30 min and a gradual 
increase to � 5 . 5 folds at 2 hours. 
Blocking the TNF-R2 for 1-2 min stimulated the TNF-a-induced cyclin B 
protein expression by � 2 . 5 folds then reduced to the control level. At 1 to 2 hours 
after the addition of this antibody, the stimulations were -2.2 and �1 . 6 folds, 
respectively (Fig. 3.31(b)). 
The findings that blocking TNF-Rl caused the appearance of two peaks of 
TNF-a-induced cyclin B protein expression suggested TNF-R2 could modulate the 
TNF-a-induced cyclin B protein expression. 
3.2.14. Effects of blocking TNF-Rl/ -R2 on bcl-2 protein expression 
bcl-2 prolongs cell survival and blocks apoptosis in cells induced by c-Myc 
(Bissonnette et al., 1992). Other studies also showed the bcl-2 inhibited death of 
central neural cells induced by multiple toxic agents (Farlie et al., 1995; Zhong et al., 
1993). Because of these, we examined the effect of TNF-a and the roles played by 
TNF-Rl and TNF-R2. 
Blocking the TNF-Rl during the first 10 min had no effect on the TNF-a-
induced bcl-2 protein expression. However, the induction was increased by � 2 folds 
from 20 min to 2 hours. Blocking the TNF-R2 did not significantly alter the TNF-a-
induced bcl-2 protein expression throughout the study period (Fig. 3.32). 
The above findings that blocking the TNF-Rl increased the TNF-a-induced 
bcl-2 expression while blocking the TNF-R2 had no significant effect suggested that 
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Fig. 3.31(b). Effects of blocking TNF-a receptor subtypes for various 
times on cyclin B protein expression. Methods and data treatments 
were the same as those described in Fig. 3.19(b). Data presented were 
representations of three separate experiments with similar results. 
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Fig. 3.32. Effects of blocking TNF-a receptor subtypes for various 
times on bcl-2 protein expression. Methods and data treatments were 
the same as those described in Fig. 3.19(b). Data presented were 
representations of three separate experiments with similar results. 
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the TNF-R2 played a more important role in regulating bcl-2 protein expression, and 
this might explain why this cytokine did not cause apoptosis or cell death in C6 cells. 
3.2.15. Effects of blocking TNF-Rl/ -R2 on bcl-XL gene and protein expression 
BC1-XL is a protein which increases cellular apoptotic threshold and is able to 
form stable complexes with Bax, a protein which promotes apoptosis. In addition to 
bcl-2, bcl-XL plays an important role in the regulation of developmental cell death and 
tissue homeostasis. 
Blocking the TNF-Rl slightly suppressed the TNF-a-induced bcl-x: gene 
expression at all time points investigated, and maximum suppression was observed at 
5 min after TNF-Rl antibody treatment. Blocking the TNF-R2 for 1-5 min also 
suppressed the TNF-a-induced bcl-XL gene expression, and no change was observed 
at 10-30 min and this was followed by an induction of � 1 . 5 and � 2 . 5 folds at 1 and 2 
hours, respectively (Fig. 3.33(a)). 
With reference to protein expression, blocking the TNF-Rl slightly suppressed 
the TNF-a-induced bcl-x: protein expression. While blocking the TNF-R2 increased 
the TNF-a-induced bcl-XL protein expression, and a maximum induction of � 3 folds 
was observed at 20 min following TNF-R2 antibody treatment (Fig. 3.33(b)). 
The findings that blocking the TNF-Rl suppressed the TNF-a-induced bd-x: 
gene and protein expression suggested a minor role of TNF-R2 in mediating the 
action of TNF-a. In contrast, blocking of the TNF-R2 induced the level bcl-x: protein. 
This action is mediated by TNF-Rl. This findings suggested both receptor subtypes 
played differential roles in stimulating the expression of anti-apoptotic proteins, and 
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Fig. 3.33(a). Effects of blocking TNF-a receptor subtypes for various 
times on bcl-XL gene expression. Methods and data treatments were the 
same as those described in Fig. 3.19(a). Data presented were 
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Fig. 3.33(b). Effects of blocking TNF-a receptor subtypes for various 
times on bcl-x: protein expression. Methods and data treatments were 
the same as those described in Fig. 3.19(b). Data presented were 
representations of three separate experiments with similar results. 
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this further explained why this cytokine did not cause apoptosis or cell death in C6 
cells. 
3.2.16. Effects of blocking TNF-Rl/ -R2 on bcl-Xa gene expression 
Bcl-Xa is another bcl-2 family death suppression cell cycle members. 
Blocking the TNF-Rl slightly stimulated the TNF-a-induced bcl-Xa gene 
expression by � 1 folds and this level was maintained throughout the treatment time. 
Blocking the TNF-R2 did not significantly alter the TNF-a-induced bcl-Xa gene 
expression during the first hour, however an induction of � 6 folds was observed at 2 
hours (Fig. 3.34). 
The above findings suggested TNF-Rl played a minor role in modulating bcl-
Xa gene expression as no effect was observed during the first hour of TNF-R2 
I 
antibody treatment. However, TNF-R2 appeared to play a more significant role as 
blocking the TNR-Rl caused a � 2 folds induction of this gene. The fact that both 
receptor subtypes mediated the expression of this gene is in agreement with 
observations that treatment of C6 cells with this cytokine did not cause cell death. 
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Fig. 3.34. Effects of blocking TNF-a receptor subtypes for various 
times on bcl-Xa gene expression. Methods and data treatments were the 
same as those described in Fig. 3.19(a). Data presented were 
representations of three separate experiments with similar results. 
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3.2.17. Effects of blocking TNF-Rl/ -R2 on bcl-w gene and protein expression 
bcl-w is one of the death inhibitors in the bcl-2 family, it maintains cell 
viability by preventing the activation of the cell death effectors, the caspases. 
Blocking the TNF-Rl had no clear effect on the TNF-a-induced bcl-w gene 
expression, except an obvious suppression was observed at 2 hours after TNF-Rl 
antibody treatment. Blocking the TNF-R2 suppressed the TNF-a-induced bcl-w gene 
expression at 1-2 min, followed by an increase at 5-20 min, a suppression at 30 min, 
finally an induction at 2 hours and the induction was � 4 folds (Fig. 3.35(a)). Blocking 
the TNF-Rl caused an elevation of bcl-w protein to � 2 folds at the first hour and 
elevated to � 3 folds at 2 hours. Blocking the TNF-R2 had a slight effect on the TNF-
a-induced bcl-w protein expression (Fig. 3.35(b)). 
The findings that blocking either TNF-Rl or TNF-R2 had slight effects on the 
TNF-a-induced bcl-w expression suggested that both receptor subtypes played minor 
i. 
roles in modulating the TNF-a-induced bcl-w gene and protein expression. | 
3.2.18. Effects of blocking TNF-Rl/ -R2 on Mcl-l gene expression 
Mcl-l, one of the antiapoptotic bcl-2 family members. It inhibits apoptosis by 
binding to Bax (one of the death promoting members in bcl-2 family) and interacting 
with different proapoptotic members, e.g. Bak, Bok, Bik, and Bod. 
Blocking the TNF-Rl slightly increased the TNF-a-induced Mcl-l gene 
expression at all treatment times examined and the induction was � 1 . 5 folds. 
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Fig. 3.35(a). Effects of blocking TNF-a receptor subtypes for various 
times on bcl-w gene expression. Methods and data treatments were the 
same as those described in Fig. 3.19(a). Data presented were 
representations of three separate experiments with similar results. 
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Fig. 3.35(b). Effects of blocking TNF-a receptor subtypes for various 
times on bcl-w protein expression. Methods and data treatments were 
the same as those described in Fig. 3.19(b). Data presented were 
representations of three separate experiments with similar results. 
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Fig. 3.36. Effects of blocking TNF-a receptor subtypes for various 
times on Mcl-l gene expression. Methods and data treatments were the 
same as those described in Fig. 3.19(a). Data presented were 
representations of three separate experiments with similar results. 
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Blocking of the TNF-R2 also showed a similar trend and the level was � 1 . 5 folds 
during the 1-2 hours treatment (Fig. 3.36). 
The findings that blocking either TNF-Rl or TNF-R2 slightly enhanced the 
TNF-a-induced Mcl-l expression suggested that both receptor subtypes could 
modulate the effect of this cytokine and that TNF-a induced proliferation in C6 cells 
not by affecting the expression of this gene, but the induction of this gene might offer 











3.3. Effects of other cytokines (IL-6, IL-la, IL-ip，IFy) on cell cycle 
related genes and proteins expression 
To test the specificity of TNF-a towards the expression of cell cycle 
regulatory proteins, the effects of four other cytokines namely, interleukin 6 (IL-6), 
interleukin 1-a (IL-la), interleukin l-P (IL-1 (3), and interferon y (IF-y) on the 
expression of cell cycle regulatory genes and proteins were examined. IL-6 and IF-y 
were found to be unable to induce C6 cell proliferation, while IL-la and IL-1 (3 were ： 
able to induce C6 cell proliferation but were less potent compared to TNF-a (Liu, ： 
1996). As IL-6 cannot induce C6 cell proliferation, five different concentrations of 
this cytokine were tested to see if there was any concentration dependence. While IL-
l a , IL-ip, and IF-y were tested at fixed concentrations (IL-la and IL-1 (3 at 100 pg/ml, 
and IF-y at 100 U/ml) and time courses examined. These concentrations of IL-la and 
• I 
J 
IL-1 (3 were found to induce C6 cell proliferation with maximal effects (Liu, 1996). ！ 
•丨丨 
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3.3.1. Effects of TNF-a, IL-6, IL-la, IL-ip, IFy on cyclin Dl gene and protein 
expression 
Cyclin Dl is one of the proteins responsible for G1 phase regulation and the 
G1 phase is a phase sensitive to mitogen. Treatment of the cells with different doses 
of IL-6 for 2 hours did not alter the levels of cyclin Dl expression. This finding was 
in agreement with the Western blotting results (Fig. 3.37). On the other hand, IL-la 
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Fig. 3.37. Effects of various concentrations of IL-6 on cyclin Dl gene 
and protein expression. Cells were first synchronized at GO phase as 
described in Materials and Methods and exposed to different 
concentrations of IL-6 as indicated for 2 hours. Then RT-PCR and 
Western blotting were performed to analyze the cyclin Dl gene and 
protein expression. For RT-PCR data, the amounts of PGR products were 
semi-quantified by densitometry and normalized with respect to the 
amount of P-actin in the sample. For Western blotting results, band 
densities were also semi-quantified by densitometry. Data presented were 
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Fig. 3.38(a). Effects of exposure to TNF-a, IL-la, IL-ip, or EF-y for 
various times on cyclin Dl gene expression. Cells were first 
synchronized at GO phase as described in Materials and Methods and 
exposed IL-a (100 pg/ml), IL-ip (100 pg/ml) or IF-y (100 U/ml) for 
various times as indicated. After incubation, RT-PCR was performed to 
analyze the cyclin Dl gene expression. Other details were as described 
in (Fig. 3.37). Data presented were representatives of three separate 
exDeriments with similar results. 
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and IL-lp induced the expression of this gene slightly (Fig. 3.38(a)). Another point to 
be noted was the effect of IL-1 a was much higher, especially at 1 hour (Fig. 3.38(b)). 
IF-Y had little effect on the level of this gene and protein expression (Fig. 3.38(a) and 
(b)). The latter observation was in line with the lack of effect of this cytokine on C6 
cell proliferation (Liu, 1996). 
3.3.2. Effects of TNF-a, IL-6, IL-la, IL-lp, IFy on cyclin D2 gene expression 
As cyclin D2 is one of the cyclins that participates in the early Gl phase, we 
also tested the effects of these cytokines on cyclin D2 RNA expression. IL-6 at 50 
U/ml induced cyclin D2 gene expression by almost 20 folds but the level was greatly 
reduced to � 8 and � 4 folds with increased concentrations of this cytokine (Fig. 3.39). 
IL-la induced cyclin D2 gene expression by about 2 to 4 folds throughout the study 
period with the maximum at 1 hour. IL-1 (3 showed about 7 to 2 folds induction with 
the peak induction of about 7 folds at 0.5 hour. Compared to the induction effect of 
TNF-a on cyclin D2 of about 25 at early times, the induction observed with these 
cytokines were relatively small (Fig. 3.40). Compared to the effects of IL-ls, IF-y 
had no significant effect on the expression of this gene. The lack of effect of IF-y and 
the relative small inductive effects of the other cytokines tested suggested that the 
effect of TNF-a was specific and further indicated that TNF-a exerted its 
proliferative effect by inducing cyclin D2. This thought was also supported by our 
previous observation that TNF-a was the most potent cytokine in inducing C6 cell 
proliferation (Liu, 1996). 
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Fig. 3.38(b). Effects of exposure to TNF-a, IL-la, IL-ip, or IF-y for 
various times on cyclin Dl protein expression. Cells were first 
synchronized at GO phase as described in Materials and Methods and 
exposed IL-a (100 pg/ml), IL-lp (100 pg/ml) or IF-y (100 U/ml) for 
various times as indicated. After incubation, Western blotting was 
performed to monitor the cyclin Dl protein expression. Other details 
were as described in (Fig. 3.37). Data presented were representatives of 
three separate experiments with similar results. 
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Fig. 3.39. Effects of various concentrations of IL-6 on cyclin D2 gene 
expression. Experimental details were as described in (Fig. 3.37). Data 
presented were representatives of three separate experiments with 
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Fig. 3.40. Effects of exposure to TNF-a, IL-1 a, IL-ip, or IF-y for 
various times on cyclin D2 gene expression. Experimental details were 
as described in (Fig. 3.38(a)). Data presented were representatives of 
three separate experiments with similar results. 
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3.3.5. Effects of TNF-a, IL-6, IL-1 a, IL-1 [3, IFy on cyclin E gene and protein 
expression 
Cyclin D3 governs the progression of cells through the Gl phase of a cell 
cycle. Studies with other cell types showed that its level accumulates in cells 
stimulated with growth factors. Also, cyclin D3 appears later than cyclin D1 and 
cyclin D2 in the Gl phase. Thus, these cyclins are good indicators of cells at different 
stages in the Gl phase. 
IL-6, at different concentrations, and IL-1 (3 treatment for various times did not 
alter the level of cyclin D3 gene expression (Figs. 3.41 and 3.42(a)). While IL-1 a 
induced cyclin D3 gene expression by � 4 folds then declined slightly at 4 hours. IF-y, 
however, reduced cyclin D3 gene expression significantly after 1 hour of IF-y 
treatment. The Western result, was similar to that of gene expression (Fig. 3.42(a) and 
(b)). IL-1 a induced gene expression by about 3.6 folds (Fig. 3.42(a)), and it induced 
protein expression by about 2 folds (Fig. 3.42(b)). IL-lp treatment showed two 
induction peaks: one at 0.5 hour and the other at 4 hours; and at these time points, the 
levels were about 3 folds that of the control (Fig. 3.42(a)). TNF-a-induced the gene 
expression the first 2 hours, but it did not alter much the cyclin D3 protein expression 
although its level was slightly higher than the control at the first 2 hours (Figs. 3.41; 
3.42(a) and (b)). 
These findings suggested that cyclin D3 played a more important role in 
mediating IL-1-induced C6 cell proliferation than TNF-a. The lack of effects of IL-6 
and IF-y were in agreement with our previous observation that these two cytokines did 
not induce C6 cells proliferation significantly. 
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Fig. 3.41. Effects of various concentrations of IL-6 on cyclin D3 gene 
and protein expression. Experimental details were as described in (Fig. 
3.37). Data presented were representatives of three separate 
experiments with similar results. 
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Fig. 3.42(a). Effects of exposure to TNF-a, IL-la, IL-ip, or IF-y for 
various times on cyclin D3 gene expression. Experimental details were 
as described in (Fig. 3.38(a)). Data presented were representatives of 
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Fig. 3.42(b). Effects of exposure to TNF-a, IL-la, IL-1 (3, or IF-y for 
various times on cyclin D3 protein expression. Experimental details 
were as described in (Fig. 3.38(b)). Data presented were representatives 
of three separate experiments with similar results. 
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3.3.5. Effects of TNF-a, IL-6, IL-1 a, IL-1 [3, IFy on cyclin E gene and protein 
expression 
cdk-4 is one of the cdks that governs G1 phase progression. The synthesis of 
cdk-4 is affected negatively by growth factors, e.g. transforming growth factor (3, 
which inhibit cdk-4 synthesis, but positively by mitogens. 
IL-6, at different concentrations, did not significantly alter the expression of 
cdk-4 gene (Fig. 3.43). In fact, IL-6 decreased the protein level. Similarly, treatment 
with IF-y for various times caused no changes in this gene and its protein expression 
(Figs. 3.44(a) and (b)). These observations are in line with our previous finding that 
both cytokines were unable to induce C6 cells proliferation (Liu, 1996). However, 
both IL-la and IL-lp induced the expression of this gene slightly especially at early 
time points. The Western blotting results showed that at and after 0.5 hour of 
treatment with IL-la or IL-1|3, the expression of this protein was induced by about 4 
folds, though the gene expression was slightly induced (Figs. 3.44(a) and (b)). The 
level of protein induced by IL-lp maintained at this high level throughout the study 
period, while that induced by IL-la declined after two hours; and at 4 hours, the level 
dropped to that of the control (Fig. 3.44(b)). Compared with these cytokines, TNF-a 
rapidly induced cdk-4 RNA level at 5 min with �2 . 5 folds of induction, but no clear 
change in the protein level was observed during the 4 hours of TNF-a treatment (Fig. 
3.44(a) and (b)). 
These findings suggested that cdk-4 is mainly induced by IL-1 and slightly, 
but significantly, by TNF-a. The lack of effects of IL-6 and IF-y were in line with our 
previous findings that these two cytokines were ineffective in inducing C6 cells 
proliferation. 
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Fig. 3.43. Effects of various concentrations of IL-6 on cdk-4 gene and 
protein expression. Experimental details were as described in (Fig. 
3.37). Data presented were representatives of three separate 
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Fig. 3.44(a). Effects of exposure to TNF-a, IL-la, IL-ip, or IF-y for 
various times on cdk-4 gene expression. Experimental details were as 
described in (Fig. 3.38(a)). Data presented were representatives of three 
separate experiments with similar results. 
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Fig. 3.44(b). Effects of exposure to TNF-a, IL-loc, IL-ip, or IF-y for 
various times on cdk-4 protein expression. Experimental details were as 
described in (Fig. 3.38(b)). Data presented were representatives of three 
separate experiments with similar results. 
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3.3.5. Effects of TNF-a, IL-6, IL-1 a, IL-1 [3, IFy on cyclin E gene and protein 
expression 
Cyclin E, which appears at later time of a cell cycle than cyclin Ds, regulates 
the progression of cells through the Gl phase of a cell cycle. It associates primarily 
with cdk-2. 
Addition of IF-y resulted in no induction on cyclin E gene and protein 
expression, while the other three cytokines caused different degrees of induction on 
cyclin E gene expression (Figs. 3.46(a) and (b)). IL-6 caused a clear induction of 
cyclin E gene expression of � 3 folds, and this induction could be ready observed with 
the lowest concentration, 50U/ml, of IL-6 tested (Fig. 3.45). The protein level was 
also dose-dependent and the highest induction was about 3 folds. The addition of IL-
l a or IL-ip caused a rapid induction of cyclin E gene expression of � 7 to 12 folds, 
and this level was maintained until 4 hours (Figs. 3.46(a) and (b)). The Western 
blotting results were rather dissimilar: both IL-1 a, and IL-ip did not induce cyclin E 
protein expression throughout the study period (Fig. 3.46(b)). As TNF-a can induce 
cyclin E gene expression from 1 min to 2 hours and that this cytokine induced protein 
expression to a level of greater than or about 4 folds throughout the study period, 
while the other cytokines did not alter cyclin E protein expression, except IL-6, we 
suggested TNF-a-induced cyclin E gene expression was cytokines specific. It 
appeared reasonable to conclude that cyclin E induction played an important role in 
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Fig. 3.45. Effects of various concentrations of IL-6 on cyclin E gene 
and protein expression. Experimental details were as described in (Fig. 
3.37). Data presented were representatives of three separate 
experiments with similar results. 
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Fig. 3.46(a). Effects of exposure to TNF-a, IL-la, IL-ip, or IF-y for 
various times on cyclin E gene expression. Experimental details were 
as described in (Fig. 3.38(a)). Data presented were representatives of 
three separate experiments with similar results. 
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Fig. 3.46(b). Effects of exposure to TNF-a, IL-la, IL-lp, or IF-y for 
various times on cyclin E protein expression. Experimental details were 
as described in (Fig. 3.38(b)). Data presented were representatives of 
three separate experiments with similar results. 
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3.3.5. Effects of TNF-a, IL-6, IL-1 a, IL-1 [3, IFy on cyclin E gene and protein 
expression 
cdk-2 is one of cell cycle protein that is directly involved in DNA replication. 
It is activated by cyclin E at late G1 phase then by cyclin A around the start of S 
phase. 
IL-6 had no effects on cdk-2 gene and protein expression, with the exception 
at very high concentrations (Fig. 3.47). Among the other cytokines tested, IL-1(3 
induced cdk-2 gene expression by � 2 . 5 folds from 15 min to 2 hours then declined 
(Fig. 3.48(a)). IL-la and IF-y either had no effect or slightly reduced cdk-2 
expression throughout the study period. TNF-a induced cdk-2 RNA level at 5 min to 
a level � 6 folds of the control then declined to � 2 folds at 2 hours (Fig. 3.48(a)). From 
the Western results, different patterns were observed. Like the RT-PCR results, IL-la 
slightly induced cdk-2 protein expression, while the IL-1(3-induced cdk-2 protein 
expression was much higher and levels between 6 to 12 folds were observed during 
the study period (Fig. 3.48(b)). IF-y greatly induced cdk-2 protein expression, and � 1 2 
to � 2 3 folds induction was observed (Fig. 3.48 (b)). TNF-a induced cdk-2 protein 
level at 1 hour; and at this time, the induction was � 2 folds (Fig. 3.48(b)). 
These findings again suggested the differential potencies of the cytokines 
tested. 
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Fig. 3.47. Effects of various concentrations of IL-6 on cdk-2 gene and 
protein expression. Experimental details were as described in (Fig. 
3.37). Data presented were representatives of three separate 
experiments with similar results. 
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Fig. 3.48(a). Effects of exposure to TNP-a, IL-la, IL-1|3, or IF-y for 
various times on cdk-2 gene expression. Experimental details were as 
described in (Fig. 3.38(a)). Data presented were representatives of three 
separate experiments with similar results. 
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Fig. 3.48(b). Effects of exposure to TNF-a, IL-la, IL-ip, or IF-y for 
various times on cdk-2 protein expression. Experimental details were as 
described in (Fig. 3.38(b)). Data presented were representatives of three 
separate experiments with similar results. 
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3.3.5. Effects of TNF-a, IL-6, IL-1 a, IL-1 [3, IFy on cyclin E gene and protein 
expression 
pi 5 is one of the ckis which is involved in cyclin D-cdk regulation. 
IL-6 did not alter much both the pi5 gene and protein expression at all concentrations 
tested (Fig. 3.49). The other cytokines tested, except TNF-a and IL-la, had no clear 
effect on pl5 gene and protein expression (Figs. 3.50(a) and (b)). The lack of clear 
induction effect on pi5 expression by IL-ip, IF-y and IL-6 suggested this gene played 
a relatively minor role in mediating the proliferation of these cytokines. The findings 
that both TNF-a and IL-la were effective in inducing this gene again supported the 
cytokine specificity in this induction process. 
3.3.8. Effects of TNF-a, IL-6, IL-la, IL-lp, IFy on p27 gene and protein 
expression 
p27 is involved in the regulation of Gl-S transition. The protein level of p27 is 
regulated predominantly by posttranslational mechanisms. For example, in HepG2 
cells, IL-6 mediated inhibition of DNA-synthesis via partial inhibition of p27 
accumulation (Klausen et al., 2000). 
IL-6 showed � 2 folds of induction of gene expression at 50 U/ml and the 
increase was rather gradually as the concentrations increased (Fig. 3.51). TNF-a had 
no observable effect on p27 gene expression. Among the other cytokines tested, IL-ip 
had no effect，while IF-y showed �3 folds of p27 gene induction and this was 
maintained for 3 hours then declined slightly. IL-la showed � 4 folds induction at 15 
152 
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Fig. 3.49. Effects of various concentrations of IL-6 on pi5 gene and 
protein expression. Experimental details were as described in (Fig. 
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Fig. 3.50(a). Effects of exposure to TNF-a, IL-la, IL-1 p, or IF-y for 
various times on pi5 gene expression. Experimental details were as 
described in (Fig. 3.38(a)). Data presented were representatives of three 
separate experiments with similar results. 
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Fig. 3.50(b). Effects of exposure to TNF-a, IL-1 a, IL-1 (3, or IF-y for 
various times on pi5 protein expression. Experimental details were as 
described in (Fig. 3.38(b)). Data presented were representatives of three 
separate experiments with similar results. 
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Fig. 3.51. Effects of various concentrations of IL-6 on p27 gene and 
protein expression. Experimental details were as described in (Fig. 
3.37). Data presented were representatives of three separate 
experiments with similar results. 
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Fig. 3.52(a). Effects of exposure to TNF-a, IL-la, IL-ip，or IF-y for 
various times on p27 gene expression. Experimental details were as 
described in (Fig. 3.38(a)). Data presented were representatives of three 
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Fig. 3.52(b). Effects of exposure to TNF-a, IL-la, IL-1 (3, or IF-y for 
various times on p27 protein expression. Experimental details were as 
described in (Fig. 3.38(b)). Data presented were representatives of three 
separate experiments with similar results.. 
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min after the addition of this cytokines, rose to 〜10 folds at 0.5 hour, maintained at a 
level between 10 to 12 folds until 3 hours then declined to 〜5 folds at 4 hours (Fig. 
3.52(a)). Both IL-1|3 and IL-6 showed no observable induction effect on p27 protein 
expression, while IL-la and IF-y showed � 3 folds increase in p27 protein expression 
between 0.5 to 3 hours after the addition of the cytokine (Fig. 3.52(b)). IF-y caused 〜3 
folds of increase in p27 protein expression throughout the study period (Fig. 3.52(b)). 
The above findings suggested that p27 played a more important role in mediating the 
action of IL-la and IF-y in regulating cell cycling in C6 cells. 
3.3.9. Effects of TNF-a, IL-6, IL-la, IL-ip, IFy on p21 gene and protein 
expression 
p21, one of the ckis that inhibits cyclin D activity, is regulated by p53 tumor 
suppressor protein. At low levels, p21 stabilizes cdk and cyclin D, but at high levels, 
it causes cell cycle arrest by inhibiting cyclin D. 
IL-6, at very high concentrations, caused a very slight stimulation of p21 gene 
induction and little effect on p21 protein level was observed (Fig. 3.53). Among the 
other three cytokines tested, only IF-y induced the expression of this gene. This 
induction was extremely high and levels of about 120 to 160 folds were observed 
(Fig. 3.54(a)). TNF-a also induced p21 gene expression but the maximum level was 
〜8 folds which was much smaller than that induced by IF-y in the first 4 hours (Fig. 
3.54(a)). None of the IL-ls had any effects on p21 gene expression (Fig. 3.54(a)). 
However, the Western results were rather different and no clear induction of p21 
protein expression was observed with these cytokines. For example, although IF-y 
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Fig. 3.53 Effects of various concentrations of IL-6 on p21 gene and 
protein expression. Experimental details were as described in (Fig. 
3.37). Data presented were representatives of three separate 
experiments with similar results. 
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Fig. 3.54(a). Effects of exposure to TNF-a, IL-1 a, IL-lp, or IF-y for 
various times on p21 gene expression. Experimental details were as 
described in (Fig. 3.38(a). Data presented were representatives of three 
separate experiments with similar results. 
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induced p21 gene expression by >100 folds, the Western result showed only 2 folds or 
less increase. TNF-a also showed slightly induction on p21 protein expression (Fig. 
3.54(b)). 
3.3.10. Effects of TNF-a, IL-6, IL-la, IL-lp, IFy on pl30 gene and protein 
expression 
pi30 is one of the subunits in pRb thus a change in pi30 level reflects pRb 
level as well. A, B, D, and E cyclin-cdk complexes all are able to phosphorylate pRb. 
The phosphorylation of pRb is a critical step to initiate D N A synthesis. In the G1 
phase, the pRb phosphorylation is caused by cyclin D-cdk complex but not by the 
cyclin E-cdk complex. 
IL-6 at low concentrations had no effect, but at 1000 U/ml, it induced pi30 
gene expression by 〜3 folds and the induction increased when IL-6 concentration 
increased (Fig. 3.55). However, its effect on pi30 protein level was rather small (Fig. 
3.55). TNF-a induced pl30 R N A expression by about 2 to 3.5 folds of the control 
(Fig. 3.56(a)). The other four cytokines tested also induced pi30 gene expression (Fig. 
3.56). IF-y showed similar induction level as TNF-a (Fig. 3.56(a)). IL-la induced 
pi30 gene expression by 〜4 to 6 folds during the first 3 hours then declined. The 
induction by IL-1 (3 was 〜4 folds at 15 min then increased to and maintained at 〜6 
folds until 3 hours, but at the 4丈^  hour, the level reduced to 〜4 folds (Fig. 3.56(a)). 
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Fig. 3.54(b). Effects of exposure to TNF-a, IL-1 a, IL-1 (3, or IF-y for 
various times on p21 protein expression. Experimental details were as 
described in (Fig. 3.38(b)). Data presented were representatives of three 
separate experiments with similar results. 
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Fig. 3.55. Effects of various concentrations of IL-6 on pi30 gene and 
protein expression. Experimental details were as described in (Fig. 
3.37). Data presented were representatives of three separate 
experiments with similar results. 
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Fig. 3.56(a). Effects of exposure to TNF-a, IL-la, IL-lp, or IF-y for 
various times on pi30 gene expression. Experimental details were as 
described in (Fig. 3.38(a)). Data presented were representatives of three 
separate experiments with similar results. 
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The pi30 protein patterns were slightly different from those of gene expression. IL-6 
had a slight induction at very high concentrations only (Fig. 3.55), while IF-y had no 
effect (Fig. 3.56(b)). IL-lp had a slight induction effect of about 2 folds at 0.5 to 1 
hour, while IL-la induced pi30 protein expression by 〜5 folds at Ihour, maintained 
at a high level of >3 folds until 3 hours then declined (Fig. 3.56(b)). TNF-a also 
induced the protein level of pl30 by more than 2 folds at 0.5 hour and at 4 hours (Fig. 
3.56(b)). The slight effects of IL-6 and IF-y were in agreement with the fact that these 
two cytokines do not have much effect on C6 cells proliferations. The more prominent 
effects of TNF-a, IL-la, and IL-ip on the protein expression suggested that pi30/ 
pRb played a more important role in the proliferative action of these three cytokines. 
The differential effects of these cytokines also supported specific actions of these 
cytokines. 
3.3.11. Effects of TNF-a, IL-6, IL-la, IL-ip, IFy on Cak gene expression 
One of the major events required for the activation of cdk complexes is the 
phosphorylation of this complex by the Cak. Cak is required for the phosphorylation 
and activation of cdk-2, cdc-2, and cdk-4 complexes. 
IL-6 induced Cak gene expression by >10 folds with 50 U/ml, and no further 
induction was observed with higher concentrations of the cytokine (Fig. 3.57). IL-la, 
IL-ip, and IF-丫 showed no observable induction on Cak gene expression. In fact, IF-y 
suppressed Cak gene expression as the concentrations increased (Fig. 3.58). On the 
other hand, the TNF-a induced Cak gene expression with a maximum of 〜4 folds and 
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Fig. 3.56(b). Effects of exposure to TNF-a, IL-la, IL-1 (3, or IF-y for 
various times on pi30 protein expression. Experimental details were as 
described in (Fig. 3.38(b)). Data presented were representatives of three 
separate experiments with similar results. 
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Fig. 3.57. Effects of various concentrations of IL-6 on Cak gene 
expression. Experimental details were as described in (Fig. 3.37). Data 
presented were representatives of three separate experiments with 
similar results. 
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Fig. 3.58. Effects of exposure to TNF-a, IL-1 a, IL-1 (3, or IF-y for 
various times on Cak gene expression. Experimental details were as 
described in (Fig. 3.38(a)). Data presented were representatives of three 
separate experiments with similar results. 
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findings suggested that TNF-a, unlike IF-y, IL-la, and IL-lp, could induce Cak gene 
expression specifically (Fig. 3.58). As Cak is required for the phosphorylation of cdks, 
it is likely that TNF-a induced proliferation in C6 cells by inducing the expression of 
this gene. 
3.3.12. Effects of TNF-a, IL-6, IL-la, IL-ip，IFy on cyclin H gene and protein 
expression 
The cdk-activating kinase, Cak, has been shown to complex with cyclin H. 
Cak is important for activating cdks throughout the cell cycle. 
Addition of IL-6 resulted in no observable induction on cyclin H gene 
expression while it induced cyclin H protein expression when its concentration was 
〉103 U/ml, which was quite high (Fig. 3.59). Both IL-la and IL-1 (3 did not 
significantly alter cyclin H R N A level, while IF-y induced the level by 〜3-6 folds 
(Fig. 3.60(a)). TNF-a greatly increased the expression of this gene by about 18 
folds, and a level of >6 folds was maintained at 4 hours (Fig. 3.60(a)). 
The protein expression patterns were different (Fig. 3.60(b)). TNF-a had no 
effect, while IL-la and IF-y had a slight induction effect at early times. IL-1 [3 
showed a greater stimulation of 3 to 5 folds in the first 3 hours, declined to the 
control level at 4 hours (Fig. 3.60(b)). The high level of cyclin H gene induced by 
TNF-a suggested that this gene played an important role in the TNF-a-induced cell 
proliferation. The lack of corresponding increase in cyclin H protein may be due 
the time interval examined was relative short. The high level of protein observed in 
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Fig. 3.59. Effects of various concentrations of IL-6 on cyclin H gene 
and protein expression. Experimental details were as described in (Fig. 
3.37). Data presented were representatives of three separate 
experiments with similar results. 
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Fig, 3.60(a). Effects of exposure to TNF-a, IL-la, IL-ip, or IF-y for 
various times on cyclin H gene expression. Experimental details were 
as described in (Fig. 3.38(a)). Data presented were representatives of 
three separate experiments with similar results. 
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Fig. 3.60(b). Effects of exposure to TNF-a, IL-la, IL-ip, or IF-y for 
various times on cyclin H protein expression. Experimental details 
were as described in (Fig. 3.38(b)). Data presented were representatives 
of three separate experiments with similar results. 
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the presence of IL-ip suggested the importance of this protein in the action oflL-ip. 
3.3.13. Effects of TNF-a, IL-6, IL-la, IL-ip，IFy on cyclin B gene and protein 
expression 
Cyclin B is involved in both G2 and M phase regulation. And cyclin-
dependent kinase cdk-1 is one of the cdk involved in forming complex with cyclin B 
to trigger the G2/M transition. 
IL-6 did not alter cyclin B R N A expression but it induced cyclin B protein 
expression when its concentrations increased to 1 U / m l which was quite high. And 
〜3-4 folds of increased was observed (Fig. 3.61). Both IL-la and IL-ip did not 
significantly alter cyclin B R N A and protein levels during the 4 hours of treatment 
(Figs. 3.62(a) and (b)). Although IF-y induced cyclin B R N A expression, but it did not 
alter its protein expression (Figs. 3.62(a) and (b)). TNF-a induced cyclin B R N A 
level by 〜6 folds at 15 min after TNF-a treatment (Fig. 3.62(a)), but this cytokine had 
slight effect on the induction of cyclin B protein level (Fig. 3.62(b)). The lack of clear 
relationship between gene and protein levels may be due to the treatment time was 
only 4 hours and the cells had not reach the G2 or M transition yet. Nevertheless, the 
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Fig. 3.61. Effects of various concentrations of IL-6 on cyclin B gene 
and protein expression. Experimental details were as described in (Fig. 
3.37). Data presented were representatives of three separate 
experiments with similar results. 
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Fig. 3.62(a). Effects of exposure to TNF-a, IL-la, IL-ip, or IF-y for 
various times on cyclin B gene expression. Experimental details were 
as described in (Fig. 3.38(a)). Data presented were representatives of 
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Fig. 3.62(b). Effects of exposure to TNF-a, IL-1 a, IL-lp, or IF-y for 
various times on cyclin B protein expression. Experimental details were 
as described in (Fig. 3.38(b)). Data presented were representatives of 
three separate experiments with similar results. 
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3.3.14 Effects of TNF-a, IL-6, IL-la, IL-lp, IFy on bcl-2 protein expression 
bcl-2 prolongs cell survival and blocks apoptosis in some cell types. For 
example, bcl-2 prevented apoptotic death induced by c-Myc (Bissonnette et al, 1992), 
and that bcl-2 inhibited death of central neural cells induced by multiple cytotoxic 
agents (Farlie et al., 1995; Zhong et al., 1993). IL-6, at different concentrations, did 
not alter the level of bcl-2 protein expression (Fig. 3.63). IL-la and IL-lp induced 
bcl-2 protein expression by 〜2.5 folds, so as the effect of IF-y. Likewise, TNF-a had 
no clear effect on this protein (Fig. 3.64). The lack of a clear effect of indicated that 
there was little apoptosis in the study period. The inductive effects, though small, of 
IF-y, IL-la, and IL-lp suggested that these cytokines might offer a mechanism in 
prolonging survival or preventing apoptosis in C6 cells. 
3.3.15. Effects of TNF-a, IL-6, IL-la, IL-lp, IFy on bcl-XL gene and protein 
expression 
Just like bcl-2, bcl-XL acts as a dominant inhibitor of cell death upon growth 
factor withdrawal. bcl-XL is mainly localized in the periphery of mitochondria which 
suggests it prevents cell death by a mechanism similar to bcl-2. 
IL-6 reduced bcl-XL gene expression from 100 U/ml — 5000 U/ml IL-6, but 
had no significant alterations of bcl-XL protein levels were observed (Fig. 3.65). IF-y 
showed 〜3 to 7 folds increased in bcl-x: gene expression throughout the study period 
(Fig. 3.66(a)), but the protein expression did not change much (Fig. 3.66(b)). IL-la 
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Fig. 3.63. Effects of various concentrations of IL-6 on bcl-2 protein 
expression. Experimental details were as described in (Fig. 3.37). Data 
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Fig. 3.64. Effects of exposure to TNF-a, IL-la, IL-ip, or IF-y for 
various times on bcl-2 protein expression. Experimental details were as 
described in (Fig. 3.38(b)). Data presented were representatives of three 
separate experiments with similar results. 
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Fig. 3.65. Effects of various concentrations of IL-6 on bcl-XL gene and 
protein expression. Experimental details were as described in (Fig. 
3.37). Data presented were representatives of three separate 
experiments with similar results. 
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Fig. 3.66(a). Effects of exposure to TNF-a, IL-1 a, IL-lp, or IF-y for 
various times on bcl-XL gene expression. Experimental details were as 
described in (Fig. 3.38(a)). Data presented were representatives of three 
separate experiments with similar results. 
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Fig. 3.66(b) Effects of exposure to TNF-a, IL-la, IL-lp, or IF-y for 
various times on bcl-XL protein expression. Experimental details were 
as described in (Fig. 3.38(b)). Data presented were representatives of 
three separate experiments with similar results. 
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and IL-ip had no clear effect on bcl-XL gene expression (Figs. 3.66(a) and (b)). 
Although IL-la had no effect on the protein expression, IL-ip induced the protein 
expression by about 3 to 24 folds throughout the study period (Fig. 3.66(b)). TNF-a 
increased the expression of this gene by 9 to 18 folds (Fig. 3.66(a)), but no clear effect 
on the protein expression was observed (Fig. 3.66(b)). 
These findings suggested that bcl-x: played a more important role than bcl-2 
in protecting C6 cells from apoptosis following TNF-a treatment. The lack of 
correlation between the protein and gene levels may be due to time delay in protein 
synthesis as the time investigated was relatively short. The high level of protein 
observed with IL-ip suggested that this protein might offer protection against 
apoptosis. 
3.3.16. Effects of TNF-a, IL-6, IL-la, I L - i p , IFy on bcl-Xa gene expression 
Bcl-Xa is another bcl-2 family death suppression members and it is a 
counterpart of the human bcl-XL. 
IL-6 had a very slight induction of bcl-Xa especially at very high 
concentrations (Fig. 3.67). IL-la, IL-ip, and IF-y had no significant effect throughout 
the treatment times tested (Fig. 3.68). However, TNF-a greatly induced bcl-Xa gene 
expression by about >8 folds from 1 min to 2 hours, gradually dropped to 〜4 folds at 
3 hours then increased again to 〜8 folds at 4 hours (Fig. 3.68). 
These findings suggested TNF-a induced the expression of this bcl-2 family 
member, in addition to bcl-x: to protect C6 cells from apoptosis or other unfavorable 
conditions, and this additional induction provided an extra mechanism against 
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Fig. 3.67. Effects of various concentrations of IL-6 on bcl-Xa gene 
expression. Experimental details were as described in (Fig. 3.37). Data 
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Fig. 3.68. Effects of exposure to TNF-a, IL-la, IL-lp, or IF-y for 
various times on bcl-Xa gene expression. Experimental details were as 
described in (Fig. 3.38(a)). Data presented were representatives of three 
separate experiments with similar results. 
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apoptosis. The lack of effects of the other cytokines tested suggested that the effect of 
TNF-a on this gene was specific. 
3.3.17. Effects of TNF-a, IL-6, IL-la, IL-lp, IFy on bcl-w gene and protein 
expression 
bcl-w is one of the death antagonist members of the bcl-2 family that is found 
in many tissues. Study showed bcl-w was involved in the modulation of seizure-
induced brain injury (Henshall et al, 2001). Thus, the expression of this gene was 
included in this study. 
A suppressive effect of IL-6 on bcl-w gene expression was observed with high 
concentrations of this cytokine. The Western results were very similar (Fig. 3.69). All 
other cytokines tested induced the expression of this gene by various extents and 
greatest induction was observed with IL-la at early treatment times (Fig. 3.70(a)). 
The Western results were rather different, TNF-a, IF-y, and IL-1 (3 had slight effect on 
protein expression (Fig. 3.70(b)). IL-la induced bcl-w gene expression by � 3 to 9 
folds throughout the study period. As IF-y, IL-1 a, IL-1 (3, and TNF-a all induced the 
expression of this gene, this suggests that bcl-w could be a common death-
suppression gene induced by cytokines. In view of the observations that TNF-a 
induced the expression of bcl-XL, bcl-Xa and bcl-w, these provided a reasonable 
explanation for the higher proliferative and/or protective effect of TNF-a than the 
other cytokines tested. Among the cytokines tested IL-la was the most potent 
stimulator of bcl-w expression. 
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Fig. 3.69. Effects of various concentrations of IL-6 on bcl-w gene and 
protein expression. Experimental details were as described in (Fig. 
3.37). Data presented were representatives of three separate 
experiments with similar results. 
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Fig. 3.70(a). Effects of exposure to TNF-a, IL-la, IL-lp, or IF-y for 
various times on bcl-w gene expression. Experimental details were as 
described in (Fig. 3.38(a)). Data presented were representatives of three 
separate experiments with similar results. 
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Fig. 3.70(b). Effects of exposure to TNF-a, IL-1 a, IL-lp, or IF-y for 
various times on bcl-w protein expression. Experimental details were as 
described in (Fig. 3.38(b)). Data presented were representatives of three 
separate experiments with similar results. 
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3.3.14 Effects of TNF-a, IL-6, IL-la, IL-lp, IFy on bcl-2 protein expression 
Mcl-l is one of the antiapoptotic members in the bcl-2 family. It is capable of 
suppressing cell death induced by various stimuli. 
Treatment of the cells with different doses of IL-6 for 2 hours did not alter the 
level of Mcl-l expression (Fig. 3.71). Moreover, IL-la, IL-ip, IF-y, and TNF-a 
treatment for various times did not alter the level of Mcl-l gene expression (Fig. 3.72). 
These suggested that Mcl-l was not a major antiapoptotic member in the actions of 
these cytokines. This observation also indicated that these cytokines do not exert their 
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Fig. 3.71. Effects of various concentrations of IL-6 on Mcl-l gene 
expression. Experimental details were as described in (Fig. 3.37). Data 
presented were representatives of three separate experiments with 
similar results. 
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Fig. 3.72. Effects of exposure to TNF-a, IL-la, IL-1 (3, or IF-y for 
various times on Mcl-l gene expression. Experimental details were as 
described in (Fig. 3.38(a)). Data presented were representatives of three 
separate experiments with similar results. 
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3.4. Effects of P-ARs on cell cycle related genes expression 
p-ARs have also been shown to be related to astrocytes proliferation as 
activation of |3-AR can increase the expression of GFAP, an astrocyte cell marker 
(Hodges-Savola et al., 1996). Also, Fujita et al. (1998) found that activation of p-AR 
in microglia could induce proliferation in astrocytes. 
In our laboratory, we had showed that TNF-a induced P-AR expression (Shan, 
2000). As described in Section 3.1, TNF-a triggered certain cell cycle regulatory 
genes expression, we therefore studied whether adrenergic mechanism was involved 
in the induction of these cell cycle genes in C6 cells. 
In this study, cells were treated with different concentrations of common and 
selective P-AR agonists, and P-AR antagonists in the presence of TNF-a. The issues 
we concentrated on were: (1) whether p-AR agonists alone could induce the 
expression of these genes, and (2) the effects of various p-AR antagonists on the 
effect of TNF-a induction. This strategy would allow us to clarify whether TNF-a 
exerted its action through an (3-adrenergic mechanism. 
To examine the involvement of different P-ARs, different concentrations of 
various specific P-AR agonists and antagonists were tested. W e used six different 
agonists and antagonists and they were: (1) isoproterenol (ISO), a common p-AR 
agoinst; (2) propranolol (PROP), a common P-AR antagonist; (3) dobutamine (DOB), 
a selective PiAR agonists; (4) CGP 20712A (CGP), a selective PiAR antagonist; (5) 
procaterol (PROC), a specific P2AR agonist; and (6) ICI 118,551 (ICI), a specific 
32AR antagonist. 
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In experiments described in this section, cells were either exposed to various 
concentrations of an P-AR agonist for 2 hours or pretreated with different 
concentrations of an P-AR antagonist for 2 hours followed by another 2 hours in the 
presence of TNF-a (100 U/ml). This amount of cytokine had been shown to induce 
maximum proliferation in C6 cells (Liu, 1996). 
3.4.1. Effects of P-AR agonists and antagonists on cyclin Dl gene expression 
Addition of ISO, a common P-AR agonist, induced the expression of cyclin Dl 
R N A and the level induced with different concentrations of agonist added were 〜2 
folds (Fig. 3.73(a)). Pretreatment of cells with PROP, a common P-AR antagonist, 
slightly induced the TNF-a-induced cyclin Dl expression 〜2 folds with the exception 
of 10.9 M of this antagonist at which a suppression was observed (Fig 3.73(b)). In 
order to delineate which (3-AR subtype was involved in mediating the induction of 
cyclin Dl, the effects of selective piAR and P2AR agonists and antagonists were 
examined. D O B , a selective PiAR agonist, induced cyclin Dl expression at low 
concentrations (10'^ -10"^  M ) and the induction levels were about 〜3 folds (Fig. 
3.73(a)). On the other hand, CGP pretreatment did not change the level of TNF-a-
induced cyclin Dl expression (Fig. 3.73(b)). PROC, a selective P2AR agonist, greatly 
induced the expression of cyclin Dl and this induction was inversely proportional to 
the concentrations of agonist added. The lack of effect of (3-AR antagonists on the 
TNF-a induction suggested that this cytokine did not exert its action through an p-
adrenergic mechanism. This finding suggested that P2AR agonist could induce cyclin 
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Fig. 3.73(a). Effects of P-AR agonists on cyclin Dl gene expression. 
Cells were synchronized at GO phase as described in materials and 
methods, then treated with different concentrations of PAR agonist as 
indicated. R N A was extracted by described in Methodologies and RT-
P C R was performed to monitor the levels of cyclin Dl gene expressed. 
The amounts of P G R products were semi-quantified by densitometry 
and normalized with respect to the corresponding P-actin values. 
Results were expressed as relative densities with respect to the 
corresponding samples without any drug treatment. Data presented 
were representations of three separate experiments with similar results. 
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Fig. 3.73(b). Effects of P-AR antagonists on the TNF-a-induced cyclin 
D1 gene expression. Cells were synchronized at GO phase as described in 
materials and methods, then treated with different concentrations of (3-
A R antagonist as indicated and followed by treatment with TNF-a (100 
U/ml) for 2 hours. R N A was extracted by described in materials and 
methods and RT-PCR was performed to monitor the levels of cyclin D1 
gene expressed. The amounts of PCR products were semi-quantified by 
densitometry and normalized with respect to the corresponding |3-actin 
values. Results were expressed as relative densities with respect to the 
corresponding samples treated with TNF-a only. Data presented were 
representations of three separate experiments with similar results. 
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Dl expression. About 18 folds induction was observed with 10'^  M of P R O C (Fig. 
3.73(a)). However, ICI, a selective P2AR antagonist, had no effect on the TNF-a 
induction (Fig. 3.73(b)). This finding contrasted the result of a report that in airway 
smooth muscle cells, where albuterol (100 nM), an P2AR agonist, was found to 
inhibit D N A synthesis and a reduction in cyclin Dl protein level (Stewart et al., 1999). 
The differential actions of P2AR agonists in these cell types may be due to tissue/ cell 
type and/ or drug specificity. 
3.4.2. Effects of p-AR agonists and antagonists on cyclin D2 gene expression 
Cyclin D2 is one of the G1 cyclins that is produced in response to growth 
factor stimulation. Both ISO and P R O C had no significant effect on cyclin D2 
7 5 
expression, but PROP, at concentrations 10" -5X10' M , suppressed the TNF-a-
7 Q ... 
induced cyclin D2. ICI, at concentrations 10' and 10" M , further increased the TNF-
a-induced cyclin D2 expression (Figs. 3.74(a) and (b)). However, D O B , a selective 
PiAR agonist, induced the expression of cyclin D2 gene in a concentration-dependent 
maimer and 〜4 folds stimulation was observed with 10"^  M . While higher 
concentration of D O B (lO—* M ) was inhibitory (Fig. 3.74(a)). CGP, a selective 
inhibitor of piAR, did not alter the TNF-a-induced cyclin D2 expression, except an 
reduction was observed with M (Fig. 3.74(b)). The above findings suggested 
3iAR mechanism is closely associated with cyclin D2 expression, and that the TNF-
a-induced cyclin D2 expression was slightly modulated by an PiAR mechanism. 
However, it should be noted that the concentration of CGP (10""^  M ) added was quite 
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Fig. 3.74(a). Effects of P-AR agonists on cyclin D2 gene expression. 
Methods and data treatments were the same as those described in (Fig. 
3.73(a)). Data presented were representations of three separate 
experiments with similar results. 
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Fig. 3.74(b). Effects of (3-AR antagonists on the TNF-a-induced cyclin 
D2 gene expression. Methods and data treatments were the same as 
those described in (Fig. 3.73(b)). Data presented were representations 
of three separate experiments with similar results. 
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3.4.3. Effects of P-AR agonists and antagonists on cyclin D3 gene expression 
Cyclin D3 combines with cdk-4/6 to form a complex and this complex can 
phosphorylate the pRb causing it to dissociate from the E2F transcription factor 
complex and resulted in turning off transcriptional suppressor activity of pRb. ISO 
induced the cyclin D3 expression by ~6 folds and showed some concentration 
dependence, especially at low concentrations (Fig. 3.75(a)). However, blocking the P-
A R with PROP did not suppress the TNP-a-induced expression of cyclin D3, but 
o c 
rather an increase in induction of up to 〜2.5 folds was observed with 10' to 10" M of 
this p-antagonist. At much higher concentrations of PROP, this antagonist was 
inhibitory (Fig. 3.75(b)). The cyclin D3 gene expression was not altered by the 
application of PiAR agonist or antagonist, except high concentrations (lO'^ -lO'"^  M ) of 
3iAR antagonist were inhibitory (Figs. 3.75(a) and (b)). When PROC, an pzAR 
agonist, was applied, the cyclin D3 gene expression was greatly induced, and about 21 
to 13 folds of increase were observed with 10'^ -10'^  M . Higher concentrations (10"^ -
10—4 M ) of this agonist were inhibitory (Fig. 3.75(a)). The addition of ICI further 
stimulated the effects on the TNF-a-induced cyclin D3 expression, except at very 
high concentrations, which were inhibitory (Fig. 3.75(b)). From the above results, it 
seemed that cyclin D3 gene expression was mediated by an P2AR mechanism as both 
ISO and P R O C stimulated cyclin D3 expression and that the effect of P R O C was 
much higher. Since both Pi- and P2AR antagonists at various concentrations had no 
suppressive effects on the TNF-a-induced cyclin D3 expression, it appeared that the 
action of TNF-a was not mediated through an p-AR mechanism. 
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Fig. 3.75(a). Effect of P-AR agonist on cyclin D3 gene expression. 
Methods and data treatments were the same as those described in (Fig. 
3.73(a)). Data presented were representations of three separate 
experiments with similar results. 
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Fig. 3.75(b). Effects of p-AR antagonists on the TNF-a-induced cyclin 
D3 gene expression. Methods and data treatments were the same as 
those described in (Fig. 3.73(b)). Data presented were representations 
of three separate experiments with similar results. 
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3.4.3. Effects of P-AR agonists and antagonists on cyclin D3 gene expression 
cdk-4 exerts its action on cyclins at G1 phase. It binds to cyclin Ds forming an 
active complex which then phosphorylates pRb and results in facilitating D N A 
synthesis. ISO stimulated the expression of cdk-4 gene by about 2 to 3 folds at low 
concentrations (Fig. 3.76(a)), while pretreatment with various concentrations of PROP 
had no effect on TNF-a action, except at high concentrations of this antagonist (Fig. 
3.76(b)). D O B slightly induced the expression of this gene by about 2 folds, but no 
o 
dose-dependence was observed at concentrations >10" M (Fig. 3.76(a)). CGP, a 
selective PiAR antagonist, at all concentrations tested, had no effect on the TNF-a-
induced cdk-4 expression (Fig. 3.76(b)). P R O C induced the expression of cdk-4 by � 3 
folds in the presence of M . As the concentration of P R O C increased to 10'^  
M - 10—4 M , the induction effects were reduced. ICI, at all concentrations, had no 
effect on the TNF-a-induced expression of cdk-4 (Fig. 3.76(a)). The above findings 
suggested both p-AR mechanisms were closely associated with cdk-4 expression and 
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Fig. 3.76(a). Effects of p-AR agonists on cdk-4 gene expression. 
Methods and data treatments were the same as those described in (Fig. 
3.73(a)). Data presented were representations of three separate 
experiments with similar results. 
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Fig. 3.76(b). Effects of P-AR antagonists on the TNF-a-induced cdk-4 
gene expression. Methods and data treatments were the same as those 
described in (Fig. 3.73(b)). Data presented were representations of 
three separate experiments with similar results. 
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3.4.3. Effects of P-AR agonists and antagonists on cyclin D3 gene expression 
Cyclin E activates cdk-2 to form the cyclin E-cdk-2 complex around the start 
of S phase, and this phosphorylates pRb resulting in an irreversible commitment to 
cell division and transition into S phase. ISO, at all concentrations tested, increased 
the expression of cyclin E gene by about 2 folds (Fig. 3.77(a)). PROP pretreatment 
did not reduce the TNF-a-induced cyclin E expression, except at very high 
concentrations (Fig. 3.77(b)). D O B , a selective PiAR agonist, did not alter cyclin E 
gene expression (Fig. 3.77(a)). CGP, a selective PiAR antagonist, did not suppress the 
TNF-a-induced cyclin E gene expression and an inhibitory effect observed at very 
high concentration (10—4 M ) (Fig. 3.77(b)). PROC, a selective P2AR agonist, 
significantly increased cyclin E gene expression by about 4 to 6 folds at 
concentrations of 10"^  to 10"^  M (Fig. 3.77(a)), but ICI, a selective P2AR antagonist, 
did not alter the TNF-a-induced cyclin E gene expression (Fig. 3.77(b)). The above 
findings suggested p-AR mechanism, particularly that of P2AR, was associated with 
cyclin E expression. As all P-AR antagonists had no significant effects on the TNF-a 
induction, this suggested that TNF-a did not exert its effect on cyclin Dl expression 
through an P-AR action. 
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Fig. 3.77(a). Effects of P-AR agonists on cyclin E gene expression. 
Methods and data treatments were the same as those described in (Fig. 
3.73(a)). Data presented were representations of three separate 
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Fig. 3.77(b) Effects of (3-AR antagonists on the TNF-a-induced cyclin 
E gene expression. Methods and data treatments were the same as those 
described in (Fig. 3.73(b)). Data presented were representations of 
three separate experiments with similar results. 
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3.4.3. Effects of P-AR agonists and antagonists on cyclin D3 gene expression 
cdk-2 binds to cyclin E at late G1 phase which is an event essential for most 
cells to enter S phase. Then, cdk-2 dissociates away from cyclin E, and binds to cyclin 
A at the S phase. ISO, at 10"^  M , induced the expression of cdk-2 gene by about 2 
folds, and the effect was concentration-dependent and a maximum induction was 
observed at 10'^  to 10'^  M of ISO then declined as the concentration increased (Fig. 
3.78(a)). PROP significantly reduced the TNF-a-induced cdk-2 expression at 10"^  一 
5X10.5 M (Fig 3 78(b)). However, at 10.4 M no significant inhibition was observed. 
D O B , a selective PiAR agonist, at 5X10.9 M started to induce the expression of cdk-2 
8 5 
gene by about 2 folds and this effect was concentration-dependent, and at 10" to 10' 
M the induction was about 4 folds. Then the induction dropped to the control level as 
the concentration of D O B increased to lO'^^M (Fig. 3.78(a)). CGP, a selective PiAR 
antagonist, showed no suppression on the TNF-a-induced cdk-2 gene expression. 
However, an inhibitory effect was observed, when its concentration was greater than 
10-6 M , and at 10.4 M , the TNF-a-induced cdk-2 expression was almost totally 
o 
inhibited (Fig. 3.78(b)). PROC, at concentrations greater than 10" M inhibited cdk-2 
gene expression, and at 10"^  - 10—4 M an almost total inhibition was observed (Fig. 
3.78(a)). ICI, at low concentrations had no effects on the TNF-a-induced cdk-2 gene 
expression, while at higher concentrations, an inhibitory effect was observed (Fig. 
3.78(b)). The findings that both ISO and D O B , a selective Pi A R agonist, induced cdk-
2 expression suggested an PiAR mechanism was closely associated with cdk-2 
expression. However, neither P R O C nor CGP had any effect on the TNF-a-induced 
cdk-2 expression, and these suggested TNF-a did not exert its effects on cdk-2 
expression through an p-AR action. The inhibitory action of PROC, the P2AR agonist 
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Fig. 3.78(a). Effects of p-AR agonists on cdk-2 gene expression. 
Methods and data treatments were the same as those described in (Fig. 
3.73(a)). Data presented were representations of three separate 
experiments with similar results. 
211 
5 ， • PROP 
i I 
I C G P 
： … C I 
4 1—- .1 ---
.右3 ^  
s 
> 丨 • I 
^ I 
(D 
p^  2 J ^  
0 -I “ 1 1 1 i 」 
-10 -9 -8 -7 -6 -5 -4 
p-AR antagonist concentration (log M ) 
Fig. 3.78(b). Effects of p-AR antagonists on the TNF-a-induced cdk-2 
gene expression. Methods and data treatments were the same as those 
described in (Fig. 3.73(b)). Data presented were representations of 
three separate experiments with similar results. 
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tested, was unclear, so are the inhibitory effects of the P-AR antagonists at high 
concentrations. 
3.4.7. Effects of P-AR agonists and antagonists on pi5 gene expression 
pi 5 inhibits the action of cyclin Dl-cdk-4 and cyclin D-cdk-5. This inhibition 
results in the displacement of the p27 assembly factor that binds to cyclin Dl-cdk-4 
and cyclin D-cdk-5, and this process is another regulation in the G1 phase. ISO, 
suppressed pi5 gene expression. PROP showed no effects on the TNF-a-induced pi5 
gene expression, and a suppression of the TNF-a-induced pi5 gene expression was 
observed at lO'^ M^ (Figs. 3.79(a) and (b)). Addition of D O B did not alter the pl5 gene 
expression (Fig. 3.79(a)). C G P showed no clear trend on the TNF-a-induced pi5 gene 
expression, but a suppression of the TNF-a-induced pi5 gene expression observed at 
10-7 and 10—4 M , but at of CGP, the TNF-a-induced pi5 expression was 
induced by about 2 folds (Fig. 3.79(b)). Addition of P R O C induced the expression of 
pl5, and 〜2 folds was observed with 10"^ -10"^  M of PROC. The induction of pl5 
dropped as the P R O C concentration was increased, and a suppression was observed 
when the concentration of P R O C increased to lO'^-lC'^M (Fig. 3.79(a)). Pretreatment 
Q 0 
of cells with 10" -10" M ICI reduced the TNF-a-induced pi5 expression, while 
treatment with higher concentrations of ICI did not alter the TNF-a-induced pi5 
expression (Fig. 3.79(b)). Based on the above observations, particularly the P2AR 
agonist could induce pi5 expression, and this suggested an P2AR mechanism was 
closely associated with pi5 expression. While CGP suppressed the TNF-a-induced 
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Fig. 3.79(a). Effects of P-AR agonists on pi5 gene expression. 
Methods and data treatments were the same as those described in (Fig. 
3.73(a)). Data presented were representations of three separate 
experiments with similar results. 
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Fig. 3.79(b). Effects of (3-AR antagonists on the TNF-a-induced pi5 
gene expression. Methods and data treatments were the same as those 
described in (Fig. 3.73(b)). Data presented were representations of 
three separate experiments with similar results. 
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pi5 expression, particularly at low concentrations, and this suggested the importance 
of an PiAR action on TNF-a-induced pi5 expression. However, this thought 
contrasted the observation that ISO, at most of the concentrations tested, inhibited pi 5 
expression (Fig. 3.79(a)). It was unclear if the effect observed was not due to the 
pharmacological actions of these compounds. The lack of clear effects of the 
antagonists tested suggested that the TNF-a-induced pi5 expression was not 
mediated through an P-AR mechanism. 
3.4.8. Effects of P-AR agonists and antagonists on p27 gene expression 
p27 is one of the ckis that inhibits the activities of cyclin E-cdk-2 and cyclin 
A-cdk-2 but play a role in the assembly of cyclin Dl-cdk-4. In oligodendrocyte 
progenitors, ISO caused an accumulation of this ckis and resulted in G1 arrest (Ghiani 
et al., 1999). ISO induced p27 expression by 〜2 folds and showed no concentration-
dependence (Fig. 3.80(a)). However, blocking the (3-AR with PROP did not suppress 
the TNF-a-induced expression of p27, except an almost complete inhibitory effect 
was observed with 10'^  M of PROP, and a stimulation of about 2 folds was observed 
at concentrations greater than 10'^  M (Fig. 3.80(b)). D O B , at low concentrations, 
induced p27 gene expression by 〜2-3 folds (Fig. 3.80(a)). CGP showed no alteration 
in the TNF-a-induced p27 gene expression (Fig. 3.80(b)). Addition of P R O C greatly 
stimulated the p27 gene expression, and at 10"^  M the stimulation was about 18 folds 
and this stimulation decreased as concentration increased (Fig. 3.80(a)). However, 
blocking the P2AR with ICI did not suppress the TNF-a-induced expression of 
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Fig. 3.80(a). Effects of p-AR agonists on p27 gene expression. 
Methods and data treatments were the same as those described in (Fig. 
3.73(a)). Data presented were representations of three separate 
experiments with similar results. 
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Fig. 3.80(b). Effects of p-AR antagonists on the TNF-a-induced p27 
gene expression. Methods and data treatments were the same as those 
described in (Fig. 3.73(b)). Data presented were representations of 
three separate experiments with similar results. 
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p27 (Fig. 3.80(b)). Based on the above observations, P2AR agonist P R O C could 
induce p27 expression, which was more effective than ISO and D O B , and these 
suggested a greater role of an P2AR mechanism in p27 expression. The findings that 
both ICI and C G P did not suppress the TNF-a-induced p27 expression suggested that 
both Pi and P2AR did not participate actively in the action of TNF-a in p27 
expression. The induction effect of PROP at concentrations of 10'^  to 10'^  M was 
unclear at present. 
3.4.9. Effects of P-AR agonists and antagonists on p21 gene expression 
p21 is one of members in the cki family. It is involved in the regulation of 
phosphorylation of the pRb and this allows cells to exit from the G1 phase of the cell 
cycle. In oligodendrocyte progenitors, ISO caused an accumulation of p21, and this 
resulted in G1 arrest (Ghiani et al., 1999). Addition of ISO induced the expression of 
p21 R N A and the level induced with different concentrations of agonist added were 
〜2 folds (Fig. 3.81(a)). Pretreatment of cells with PROP had no significant effect on 
the TNF-a-induced p21 expression, except at high concentrations (Fig. 3.81(b)). In 
order to delineate which P-AR subtype was involved in mediating the induction of 
this gene, the effects of selective PiAR and P2AR agonists and antagonists were 
examined. D O B had no observable effects on p21 gene expression (Fig. 3.81(a)). 
Pretreatment of cells with CGP had no significantly effect on the TNF-a-induced p21 
expression with the exception of lO""^  M of this antagonist (Fig. 3.81(b)). P R O C 
greatly induced the expression of p21 and this induction was inversely proportional to 
the concentration of agonist added. About 10 folds of induction were observed 
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Fig. 3.81(a). Effects of p-AR agonists on p21 gene expression. 
Methods and data treatments were the same as those described in (Fig. 
3.73(a)). Data presented were representations of three separate 
experiments with similar results. 
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Fig. 3.81(b). Effects of P-AR antagonists on the TNF-a-induced p21 
gene expression. Methods and data treatments were the same as those 
described in (Fig. 3.73(b)). Data presented were representations of 
three separate experiments with similar results. 
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with 10-9-10—7 M PROC. The induction was gradually decreased to the control level 
when the concentration of P R O C was increased to SxlO'^ -lO""^  M (Fig. 3.81(a)). 
However, ICI had no effect on the TNF-a-induced p21 gene expression (Fig. 3.81(b)). 
As none of the P-AR antagonists had any significant effects on the TNF-a-induced 
gene expression and this suggested that TNF-a did not exert its effect on p21 
expression through an P-AR action. 
3.4.10. Effects of (3-AR agonists and antagonists on pl30 gene expression 
pRb is phosphorylated during specific phases of a cell cycle, and it is the 
target of many compounds that affect cell proliferation/apoptosis. As pi30 is a 
subunit of pRb, therefore the expression of this gene reflects the level of pRb. In this 
connection, it is interesting to note that albuterol (100 nM), an P2AR agonist, inhibited 
D N A synthesis and reduced pRb phosphorylation (Stewart et al., 1999). ISO, at 
concentrations of 10"^ -10'^  M , induced pi30 gene expression by 〜3 folds. The 
induction effects of ISO decreased as the ISO concentration increased to 10—5-10—4 M 
(Fig. 3.82(a)). PROP did not alter the TNF-a-induced pi30 expression with exception 
when 10—5-5X10-4 M PROP (Fig. 3.82(b)). The DOB-induced pl30 gene expression 
was concentration dependent. Its induction effect increased to about 2.5 folds at 10'^  
M , elevated to 〜3.5 folds at lO'^-lO'^M then slightly dropped to 〜2 folds when the 
D O B concentration was increased to 10 ^  M (Fig. 3.82(a)). CGP showed no clear 
trend on the TNF-a-induced pl30 expression, except at M CGP where a 
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Fig. 3.82(a). Effects of P-AR agonists on pi30 gene expression. 
Methods and data treatments were the same as those described in (Fig. 
3.73(a)). Data presented were representations of three separate 
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Fig. 3.82(b). Effects of P-AR antagonists on the TNF-a-induced pi30 
gene expression. Methods and data treatments were the same as those 
described in (Fig. 3.73(b)). Data presented were representations of 
three separate experiments with similar results. 
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suppression was observed (Fig. 3.82(b)). P R O C did not induce pl30 expression and a 
suppressive effect was observed at concentrations greater than 10'^  M (Fig. 3.82(a)). 
ICI increased the TNF-a-induced expression of pi 30 by 〜2 folds at concentrations of 
10.9 to 10-7 M Higher concentrations M ) of ICI were inhibitory (Fig. 
3.82(b)). Based on the observations, both ISO and D O B could induce pl30 expression, 
this suggested an piAR mechanism was closely associated with pi30 expression. 
Neither common P-AR and PiAR antagonists had significant suppression effect on 
the TNF-a induction and this would suggest that P-AR mechanism is not involved in 
the TNF-a action. The stimulating action of ICI at low concentrations was unclear. 
3.4.11. Effects of P-AR agonists and antagonists on Cak gene expression 
The cyclin-dependent kinase (cdk)-activating kinase (Cak) is involved in cell 
cycle control, transcription, and D N A repair. To regulate cell cycling, Cak activates 
cdk which is involved in the regulation of cell cycle in each specific phases. ISO 
induced the expression of Cak gene about 〜3 folds and no clear concentration-
dependence was observed. However, high concentrations of ISO reduced the level to 
that of the control (Fig. 3.83(a)). PROP, a common P-AR inhibitor, reduced the TNF-
a-induced Cak expression and a maximum reduction was observed with 1 M of 
PROP (Fig. 3.83(b)). D O B , PiAR agonist, had no significant effect on Cak gene 
expression (Fig. 3.83(a)). Blocking the PiAR with CGP did not suppress the TNF-a-
induced expression of Cak, except an inhibitory effect was observed with high 
concentrations this PiAR antagonist (Fig. 3.83(b)). PROC, a selective P2AR agonist, 
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Fig. 3.83(a). Effects of P-AR agonists on Cak gene expression. 
Methods and data treatments were the same as those described in (Fig. 
3.73(a)). Data presented were representations of three separate 
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Fig. 3.83(b). Effects of P-AR antagonists on the TNF-a-induced Cak 
gene expression. Methods and data treatments were the same as those 
described in (Fig. 3.73(b)). Data presented were representations of 
three separate experiments with similar results. 
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concentrations greater than 10"^  M , an inhibitory effect was observed (Fig. 3.83(a)). 
Blocking the P2AR with ICI did not suppress the TNF-a-induced expression of Cak, 
except an inhibitory effect was observed with high concentrations of this P2AR 
antagonist (Fig. 3.83(b)). Based on the above observations, D O B slightly induced but 
P R O C inhibited while ISO, a common P-AR agonist, induced Cak expression, 
suggested an p-AR mechanism was closely associated with Cak expression. The 
apparently opposite effects of the Pi and P2AR agonist on the expression of this gene 
suggested that both Pi and P2AR played regulatory, possibly opposite, roles in the 
expression of this gene. Moreover, none of the P-AR antagonists at low 
concentrations, had significant suppressive effects on the TNF-a induction, and this 
suggested that TNF-a did not exert its effect on Cak expression through an P-AR 
action. The inhibitory effects of the three antagonists, at high concentrations may be 
due pharmacological actions of these drugs. 
3.4.12. Effects of p-AR agonists and antagonists on cyclin H gene expression 
Cyclin H, cdk-7, and Matl are the three major subunits of cdk-activating 
kinase (Cak). The function of Cak is to phosphorylate cyclin-dependent kinases (cdks), 
which coordinates progression through the eukaryotic cell cycle and gives cdk full 
activity. ISO induced cyclin H gene expression � 2 folds at 10"^  M . A maximum 
induction level of 〜5 folds was observed at 10'^  M , and a decline to the control level 
was observed when the concentration of ISO increased to lO'^ -lO'^ M^ (Fig. 3.84(a)). 
PROP did not suppress the TNF-a-induced cyclin H expression, except a slightly 
inhibition was observed at high concentrations of this antagonist (Fig. 3.84(b)). D O B , 
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Fig. 3.84(a). Effects of P-AR agonists on cyclin H gene expression. 
Methods and data treatments were the same as those described in (Fig. 
3.73(a)). Data presented were representations of three separate 
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Fig. 3.84(b). Effects of P-AR antagonists on the TNF-a-induced cyclin 
H gene expression. Methods and data treatments were the same as 
those described in (Fig. 3.73(b)). Data presented were representations 
of three separate experiments with similar results. 
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a selective PiAR agonist, induced cyclin H gene expression in by about 15 folds at 10' 
8 • Q C 
M . This induction was maintained at concentrations of 10 -10 M , but a reduction 
of about 3 folds was observed at lO""^  M (Fig. 3.84(a)). C G P did not suppress the 
TNF-a-induced cyclin H expression, except a slightly inhibition was observed at high 
concentrations of this antagonist (Fig. 3.84(b)). P R O C also induced cyclin H gene 
expression. About 9 folds induction was observed with 10'^  M P ROC. A maximum 
induction of about 12 folds was observed at lO'^-lO'^M. The induction level gradually 
dropped to that of the control level at 10"^  M and increased again at M to about 7 
folds (Fig. 3.84(a)). ICI did not suppress the TNF-a-induced cyclin H expression, 
except at high concentration of this antagonist (Fig. 3.84(b)). Based on the above 
observations that ISO, D O B and P R O C could induce cyclin H expression, and this 
suggested both pi and P2AR mechanisms were closely associated with cyclin H 
expression. As none of p-AR antagonists had any significant effect on the TNF-a 
induction and this would suggest that TNF-a did not exert its effect on cyclin H 
expression through an P-AR action. 
3.4.13. Effects of P-AR agonists and antagonists on cyclin B gene expression 
Cyclin B is one of the cyclins that involves in G2 and M phase regulation. It 
forms complex with cdc-2 and triggers mitosis. ISO slightly induced cyclin B gene 
expression. The induction level remained at about 2 folds, except an inhibitory effect 
was observed at high very concentrations (Fig. 3.85(a)). Pretreatment of cells with 
PROP had no significantly effect on the TNF-a-induced cyclin B expression with the 
exception of 5X10'^-10'^M of this antagonist where an inhibitory effect was observed 
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Fig. 3.85(a). Effects of P-AR agonists on cyclin B gene expression. 
Methods and data treatments were the same as those described in (Fig. 
3.73(a)). Data presented were representations of three separate 
experiments with similar results. 
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(Fig. 3.85(b)). D O B , a selective PiAR agonist, greatly induced the expression of 
cyclin B. At 5X10'^ M D O B , it induced the level by about 2 folds and increased to 
-12 folds in the presence of 10'^  to 10"^  M . At lO'V D O B , cyclin B induction level 
dropped to 〜2 folds (Fig. 3.85(a)). Pretreatment of cells with C G P increased the TNF-
a-induced cyclin B expression by about 2 folds, but at lO""^  M of this antagonist, an 
inhibition was observed (Fig. 3.85(b)). PROC, at concentrations greater than 10"^  M , 
induced cyclin B expression by 〜3 folds (Fig. 3.85(a)). Pretreatment of cells with low 
concentrations of ICI had no significantly effect on the TNF-a-induced cyclin B 
expression, but at concentrations of 5X10"^-10'^ M , an inhibition was observed (Fig. 
3.85(b)). Based on the observations that all agonists could induce cyclin B expression 
and that the effect with D O B was greatest, and these suggested an P-AR mechanism, 
especially PiAR, was closely associated with cyclin B expression. Neither PROP nor 
ICI had any significant effects on the TNF-a induction, and this suggested that the 
TNF-a effect was not mediated by an P-AR action. The further increase in the 
presence of CGP, an piAR antagonist, was unclear. 
3.4.14. Effects of P-AR agonists and antagonists on bcl-XL gene expression 
BC1-XL is able to increase the cellular apoptotic threshold thus reduces the 
chance of apoptosis. In addition to bcl-2, bcl-XL has an important role in the regulation 
of developmental cell death and tissue homeostasis. ISO did not significantly alter 
bcl-XL gene expression, except an inhibitory effect was observed at high 
concentrations (Fig. 3.86(a)). Pretreatment of cells with PROP had no significantly 
effect on the TNF-a-induced bcl-XL expression with the exception at lO""^  M of this 
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Fig. 3.85(b). Effects of P-AR antagonists on the TNF-a-induced cyclin 
B gene expression. Methods and data treatments were the same as those 
described in (Fig. 3.73(b)). Data presented were representations of 
three separate experiments with similar results. 
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Fig. 3.86(a). Effects of P-AR agonists on bcl-XL gene expression. 
Methods and data treatments were the same as those described in (Fig. 
3.73(a)). Data presented were representations of three separate 
experiments with similar results. 
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antagonist, where an inhibition was observed (Fig. 3.86(b)). D O B slightly induced 
gene expression by about 2 folds at concentrations greater than 10'^  M (Fig. 3.86(a)). 
Pretreatment of cells with C G P had no significantly effect on the TNF-a-induced bcl-
XL expression with the exception at IC'^M of this antagonist, where an inhibition was 
observed (Fig. 3.86(b)). The P2AR agonist had a similar pattern as that with PiAR 
agonist on bcl-x: gene expression; it induced the gene expression by about 2 folds at 
o 
10" M (Fig. 3.86(a)). Pretreatment of cells with ICI increased the TNF-a-induced bcl-
XL expression 〜3 folds at concentrations of 10'^  to 10'^  M then declined to that of the 
control at 10"^ -10"^  M (Fig. 3.86(b)). The observations that both D O B and P R O C 
could induce bcl-x: expression suggested an p-AR mechanism, particularly P2AR, 
was closely associated with bcl-XL expression. The lack of effect of ISO, a common 
agonist, might be due the selectivity sensitivity. The lack of effects of ISO and D O B 
suggested that TNF-a did not exert its effect on bcl-XL expression through an P-AR 
action. The increase observed in the presence of low concentrations of ICI was 
unclear, 
3.4.15. Effects of P-AR agonists and antagonists on bcl-Xa gene expression 
Bcl-Xa is another bcl-2 family death suppression members. ISO, a common P-
A R agonist, greatly induced bcl-Xa gene expression by 〜16 to 12 folds at low 
concentrations. Its induction effect gradually declined to 〜2 folds at 10.4 M (Fig. 
3.87(a)). Pretreatment of cells with low concentrations of PROP had no significantly 
effect on the TNF-a-induced bcl-Xa expression with the exception at 1 0 " ^ - M of 
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Fig. 3.86(b). Effects of p-AR antagonists on the TNF-a-induced bcl-XL 
gene expression. Methods and data treatments were the same as those 
described in (Fig. 3.73(b)). Data presented were representations of 
three separate experiments with similar results. 
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Fig. 3.87(a). Effects of P-AR agonists on bcl-Xa gene expression. 
Methods and data treatments were the same as those described in (Fig. 
3.73(a)). Data presented were representations of three separate 
experiments with similar results. 
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this antagonist (Fig. 3.87(b)). DOB, a selective piAR agonist, induced bcl-Xa gene 
expression by about 11 to 8 folds in the presence of 5X10"^ to 10'^  M , then declined to 
the control level at 10"^  M and increased to 〜3 folds at 10—4 M D O B (Fig. 3.87(a)). 
However, C G P did not alter the TNF-a-induced bcl-Xa gene expression at all 
concentrations tested (Fig. 3.87(b)). PROC, at low concentrations, slightly induced 
the gene expression by about 3 folds (Fig. 3.87(a)). Pretreatment of cells with low 
concentrations of ICI increased the TNF-a-induced bcl-Xa expression by about 2 folds, 
but this was reduced to al level below that of the control at 10"^  M of this antagonist 
(Fig. 3.87(b)). The observations that D O B and P R O C could induce bcl-Xa expression 
suggested an p-AR mechanism was closely associated with bcl-Xa expression. The 
lack of effect of ISO might be related to drug sensitivity. Both PROP and CGP had no 
significant effect on the TNF-a induction, and this would suggest that TNF-a did not 
exert its effect on bcl-Xa expression through an p-AR action. The increase in the 
presence of ICI was unclear. 
3.4.16. Effects of p-AR agonists and antagonists on bcl-w gene expression 
bcl-w is one of the death inhibitors in the bcl-2 family, it maintains cell 
viability by preventing the activation of the cell death effectors, the caspases. ISO 
induced bcl-w gene expression by 〜5 to 6 folds at 10'^ -10'^  M while at 10-4 M the 
level dropped to that of the control (Fig. 3.88(a)). Pretreatment of cells with PROP 
had no significantly effect on the TNF-a-induced bcl-w expression, with the 
exception that at 5X10'^ M and higher this antagonist was inhibitory (Fig. 3.88(b)). 
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Fig. 3.87(b). Effects of P-AR antagonists on the TNF-a-induced bcl-Xa 
gene expression. Methods and data treatments were the same as those 
described in (Fig. 3.73(b)). Data presented were representations of 
three separate experiments with similar results. 
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Fig. 3.88(a). Effects of p-AR agonists on bcl-w gene expression. 
Methods and data treatments were the same as those described in (Fig. 
3.73(a)). Data presented were representations of three separate 
experiments with similar results. 
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Fig. 3.88(b). Effects of P-AR antagonists on the TNF-a-induced bcl-w 
gene expression. Methods and data treatments were the same as those 
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concentrations an inhibitory effect of bcl-w gene expression was observed (Fig. 
3.88(a)). Pretreatment of cells with C G P had no significantly effect on the TNF-
ainduced bcl-w expression with the exception at lO'^ -lO'^ M^ of this antagonist (Fig. 
3.88(b)). P R O C induced bcl-w gene expression 〜2 folds was observed at 5X10"^ M 
PROC, increased to 〜5 to 6 folds at lO'^ -lO""^  M (Fig. 3.88(a)). Pretreatment of cells 
with low concentrations of ICI increased the TNF-a-induced bcl-w expression, while 
at 5X10-7-10-6 M , the effect was inhibitory (Fig. 3.88(b)). The observations that both 
ISO and P R O C induced bcl-w expression suggested an P2AR mechanism was closely 
associated with bcl-w expression. The lack of effects of PROP and C G P on the TNF-
a induction suggested that TNF-a did not exert its effect on bcl-w expression through 
an P-AR action. Interestingly, a biphasic effect ICI was observed - low concentrations 
being stimulatory while high concentrations inhibitory. This suggested P2AR could 
regulate the action of TNF-a on bcl-2 family genes. 
3.4.17. Effects of P-AR agonists and antagonists on Mcl-l gene expression 
Mcl-l is one of the antiapoptotic bcl-2 family members. It inhibits apoptosis 
by binding to Bax (one of the death promoting members in bcl-2 family) and interacts 
with different proapoptotic member, e.g. Bak, Bok, Bik, and Bod. ISO induced Mcl-l 
gene expression by 〜4 to 5 folds at concentrations from 10'^  to 10"^  M , then declined 
to the control level when the concentrations of ISO added was higher than 10'^  M (Fig. 
3.89(a)). Pretreatment of cells with PROP had no significantly effect on the TNF-a-
induced Mcl-l expression, while at lO'^ -lO'^ M^, it was inhibitory (Fig. 3.89(b)). D O B 
did not significantly alter Mcl-l gene expression, except at 10"^  M where an almost 
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Fig. 3.89(a). Effects of P-AR agonists on Mcl-l gene expression. 
Methods and data treatments were the same as those described in (Fig. 
3.73(a)). Data presented were representations of three separate 
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Fig. 3.89(b). Effects of P-AR antagonists on the TNF-a-induced Mcl-l 
gene expression. Methods and data treatments were the same as those 
described in (Fig. 3.73(b)). Data presented were representations of 
three separate experiments with similar results. 
245 
complete inhibition was observed (Fig. 3.89(a)). Pretreatment of cells with C G P had 
no significantly effect on the TNF-a-induced Mcl-l expression with the exception at 
10.4 M (Fig. 3.89(b)). PROC, at most of the concentrations tested, slightly induced 
Mcl-l gene expression by 〜1.5 folds (Fig. 3.89(a)). Pretreatment of cells with ICI had 
no significantly effect on the TNF-a-induced Mcl-l expression, except at 5X10"^-10"^ 
M where it was inhibitory (Fig. 3.89(b)). The observations that neither D O B nor 
P R O C could induce Mcl-l expression while ISO greatly stimulated Mcl-l expression 
suggested an p-AR mechanism was associated with the expression of this gene. The 
lack of effects of the other two selective agonists may be due to the sensitivities of 
this mechanism to these two agonists. The lack of effects of the antagonists tested 
suggested that the TNF-a-induced Mcl-l expression was not related to an |3-AR 
mechanism. 
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CHAPTER 4. DISCUSSION & CONCLUSION 
Brain injury is a very common neurological disorder but effective therapeutic 
treatments are still lacking. At present, one of the commonly adopted treatments 
mainly concerns with prevention of further damage, enhancement of neuronal 
regeneration and reduction of glial scar formation (Reier and Houle, 1988; Rudge and 
Silver, 1990). During astrogliosis, glia recruit microglia, oligodendrocytes, 
oligodendrocyte precursors, meningeal cells, astrocytes, and stem cells, and all of 
them produce molecules that inhibit or prevent axon regeneration and remyelination 
(Berry et al., 1983). This explains why astrogliosis or scar formation has attracted a 
lot of attentions. Astrocytes, one of the major cell types that trigger scar formation, 
were increased after brain injury. Also, because of the important roles played by 
astrocytes in both normal and injured brain, astrocytes have become one of the major 
targets for treatment of brain injury (Fawcett and Asher, 1999). However, the 
substance that induced astrocytes proliferation is still under intense investigation. 
TNF-a whose level was found to be increased after injury had been found to be one 
of the candidates that involved actively in astrocytes proliferation (Garcia et al., 1992). 
To understand the mechanism of TNF-a-induced astrocytes proliferation, we used C6 
glioma cells which have many properties similar to those of cultured astrocytes 
(Benda et al., 1968) as a model to study the role of TNF-a on the regulation of 18 cell 
cycle regulatory genes in order to understand the mechanism involved in the TNF-a-
induced proliferation in astrocytes. 
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4.1. Effects of TNF-a on the induction of cell cycle regulatory genes/proteins 
expression 
W e observed that TNF-a induced the expression of cell cycle regulatory genes 
and/or proteins (Section 3.1). The genes/proteins we concentrated on were those of 
the Gl phase. This was because these genes have been shown to be modified by 
mitogens (Baldin et al., 1993). In line with this, we found that TNF-a induced the 
expressions of some Gl phase genes: cyclins Dl, D2, D3，cdk-4, cyclin H, Cak and 
ckis (pi5, p27, and p21) by at least or greater than 2 folds at very early times after 
TNF-a treatment (Figs. 3.1 - 3.4; 3.7 - 3.9 and 3.11 - 3.12). Among the three D 
cyclins tested, TNF-a induced the expression of cyclin D2 most (Fig. 3.2), a 
regulatory protein that exerts its action specifically at early Gl phase, and this would 
imply that TNF-a exerted its action mainly through the induction of this cyclin, and 
this occurred at very early times after TNF-a addition. The reason why TNF-a 
induced cyclin D2 more than the other cyclin Ds was unclear but this might be due to 
cell specificity. For example, human alpha-thrombin, a growth factor, induced the 
proliferation of human myeloid leukemia U937 cells by increasing the expression of 
cyclin Dl (Naldini et al., 2002), while in Drosophila embryonic cells, cyclin D-cdk 
complex was not the major early Gl regulator during embryogenesis (Meyer et al., 
2002). As cyclin D requires cdk-4 for activity (Baldin et al., 1993), our finding that 
cdk-4 was increased at very early times after TNF-a treatment (Fig. 3.4) suggested 
that the D cyclins were active. Another point to be noted was that the Cak is needed to 
activate the cdk (Nigg, 1996). Our finding that cyclin H, one of the subunit of active 
Cak complex, was also induced at very early times (Figs. 3.11 and 3.12), again 
supported that the cyclin-cdk-4 complex was active. 
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The actions of ckis are to allow cells to enter into the S phase. In line with this, 
we found that TNF-a induced the expressions of the three ckis (pi5, p27, and p21) 
examined though by different degrees and at different times. p21 was induced most 
and this cki had been reported to be involved in all phases of a cell cycle (Chen et al., 
1995). pi5 which had been shown to be involved mainly at G1 (Rich et al.，1999; 
Swafford et al., 1997), was induced as early as 1 min after TNF-a treatment (Fig. 3.7). 
Since pervious findings showed that most mitogens, including cytokines, stimulated a 
cell cycle at the G1 phase, and our study showed that TNF-a exerted its induction 
effects on G1 phase genes, we suggested that the TNF-a induced C6 cells 
proliferation by exerting its effect on the G1 phase. Another point supporting this 
conclusion was that the other phases of cell cycle are not readily alter by external 
stimuli (Baldin et al., 1993). 
In addition to the findings that many G1 phase genes were induced at early 
times after TNF-a addition, we also observed some of these genes showed cyclic 
inductions. For example, cyclin D2 gene expression at early times following TNF-a 
treatment the induction was greater than 20 folds and at later times. Two distinct 
peaks were observed at around 13 and 21 hours (Fig. 3.2). Cyclin D3 induction 
though also occurred at the first hour after TNF-a treatment, but it occurred a bit later 
than those of cyclins D1 and D2. Cyclin D3 had been shown to exert its action later 
than those of the other D cyclins. Three prominent major peaks of induction of this 
cyclin occurred at around 7, 14, and 20 hours respectively (Fig. 3.3). It has been 
reported that the generation time for C6 cells was about 20 hours. Our findings that 
these G1 phase genes showed more than one induction peak following TNF-a 
treatment suggested that this cytokine shortened the generation time of C6 cells. 
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4.2. Effects of TNF-a on bcl-2 family apoptotic inhibitor genes expression 
TNF-a also induced some of the bcl-2 family members cell death inhibiting 
genes. This agreed with our previous finding that TNF-a induced C6 cell proliferation 
and not apoptosis (Liu, 1996). bcl-Xa was induced most, we suggested this was the 
main target of bcl-2 family gene that TNF-a exerted its action in preventing apoptosis 
following cytokine treatment. The first peak occurred at 1 min - 2 hours, the second at 
4-9 hours, the third at 12-17 hours and the fourth at 19-25 hours. All of them had 
maximum of 〜10 folds (Fig. 3.16). 
In addition to bcl-Xa, TNF-a also induced bcl-2, bcl-XL, and bcl-w expression 
(Figs. 3.14; 3.15 and 3.17). The time points of TNF-a induction for bcl-2 protein 
expression occurred at 13 and 14 hours (Fig. 3.14), bcl-XL at 7 hours (Fig. 3.15), and 
bcl-w at 7-11 hours (Fig. 3.17), The induction of these death inhibitory genes by 
TNF-a treatment might offer a greater protection against apoptosis in C6 cells treated 
with this cytokine. And this might explain why TNF-a did not cause apoptosis in C6 
cells. On the other hand, TNF-a did not induce Mcl-l gene expression (Fig. 3.18). 
This could be due to that Mcl-l was an important actinomycin D-induced apoptosis 
inhibitor in multiple myeloma cells (Zhang et al., 2002). This would support the 
thought that the action of TNF-a on antiapoptotic genes in C6 cells was specific. 
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4.3. The TNF-R subtype(s) responsible for the TNF-a-induced cell cycle 
regulatory genes and proteins expression 
Previous study in our laboratory showed that TNF-R2 antiserum treatment 
inhibited C6 cells proliferation (To, 2000) and that TNF-a induced the expression of 
TNF-R2 selectively (Huang et al., 1998). Moreover, TNF-Rl is believed to be 
responsible for cytotoxicity and TNF-R2 for proliferation (Tartaglia and Goeddel, 
1992). To trace the TNF-R subtype responsible for these genes and proteins 
expression, we used two receptor specific antisera to differentiate the role(s) played 
by these two receptor subtypes. W e observed that blocking of either TNF-a receptor 
subtypes affected the expression of most cell cycle regulatory genes and/or proteins. 
These included the cyclins Ds, H, and B (Section 3.2). For example, the expression of 
cyclin D2 gene was induced to a similar extent in the presence of either TNF-R 
antisera suggesting that both subtypes played important roles in this induction. This 
might explain why cyclin D2 gene was greatly induced by TNF-a treatment (Fig. 3.2). 
Closer examination of the genes induced, it appeared that TNF-Rl played a 
more important role and in the expression of cyclins D2, D3, E, H, and B, Cak, as 
well as pl5, and p27 (Figs. 3.20; 3.21; 3.23; 3.25; 3.27; 3.30; and 3.31). On the other 
hand, blocking of the TNF-R2 increased the TNF-a-induced cyclin D3 expression at 
all the time points studied (Fig. 3.21(b)). Blocking of the TNF-R2 also slightly 
induced the TNF-a-induced cyclin E protein expression at very early times and the 
inductions maintained at 〜3 and 〜4 folds throughout the study period (Fig. 3.23(b)). 
However, there were certain genes where TNP-R2 played a more prominent role -
cdk-4 protein, p21 protein, and cyclin B protein. The more prominent role played by 
TNF-Rl in the induction of these cell cycle regulatory genes could be due to the fact 
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that the levels of TNF-R2 in normal cells were rather low, and its level was increased 
after TNF-a induction (Huang et al., 1998). Thus, the blocking of TNF-Rl with its 
specific antiserum would inhibit the induction of these cell cycle related genes to a 
greater extent. 
Another observation concerning the different directions of the gene level and 
its protein was unclear. For example, blocking the TNF-R2 caused a time-dependent 
increase in cyclin Dl gene expression (Fig. 3.19(a)), while blocking the TNF-Rl 
caused a very rapid and prominent increase in cyclin Dl protein level (Fig. 3.19(b)). 
Similarly, both subtypes alone could cause the induction of cdk-2 gene (Fig. 3.24(a)), 
but only TNF-R2 appeared to play an important role in the induction of cdk-4 protein 
(Fig. 3.22(b)). These observations suggested that TNF-R2 played critical role in the 
translation process and/or the degradation of these proteins. The present observations 
seemingly contrasted our previous finding that blocking the TNF-R2 inhibited C6 cell 
proliferation. However, at least two possible reasons might help to explain these 
situations. (1) TNF-R2 level was quite low in normal cells; thus blocking of this 
receptor subtype would increase the chance of inhibition; and (2) TNF-R2 appeared to 
play an extremely important in the expression of certain proteins, e.g. cyclin Dl (Fig. 
3.19(b)) and cdk-4 (Fig. 3.22(b)). Both proteins are required to form cyclin-cdk-4 
complex in early G1 phase. These findings suggested that both receptor subtypes 
played roles in the induction of these genes. 
As for the antiapoptotic genes expression, it was also clear thai both subtypes 
played role(s) in the expression of these genes, with the exception of Mcl-l as the 
expression of this gene was not induced by TNF-a treatment (Fig. 3.18). Mcl-l had 
been shown to be not sensitive to cytokines but sensitive to actinomycin D (Zhang et 
al., 2002). Among the two receptor subtypes, it appeared that TNF-R2 was more 
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important as blocking this subtype inhibited the expression of bcl-2 (Fig. 3.32) and 
bcl-w (Fig. 3.35(b)) proteins. This finding would also explain why TNF-a did not 
cause cell death in C6 cells upon treatment. 
4.4. Is the TNF-a-induced cell cycle regulatory genes and proteins expression 
cytokine specific? 
To confirm the specificity of effects of TNF-a on these genes and proteins, 
four other cytokines (IL-6, IL-la, IL-ip, and IF-y) were also tested. These cytokines 
were chosen as IL-6 and IF-y did not induce C6 cells proliferation, while IL-la and 
IL-1 (3 induced proliferation to a lesser extent (Liu, 1996). There were certain genes 
that were induced by TNF-a but not by other cytokines tested. For example, cyclin 
D1 was induced by TNF-a, IL-la, and IL-lp to similar extents, while IL-6 and IF-y 
were ineffective (Fig. 3.38(a)). Similar findings included cyclin D2 expression (Fig. 
3.40), both IL-la and IL-lp were ineffective, while TNF-a induced cyclin D2 
expression to a higher extent than IL-6. There were cases where other cytokine(s) was 
(were) more effective than TNF-a. For example, IL-la was more potent than TNF-a 
in inducing the expression of cyclin D3, whereas IF-y was almost ineffective (Fig. 
3.42(b)). Both IL-la and IL-1 (3 were much more effective, compared with TNF-a, in 
the induction of cdk-4 protein expression (Fig. 3.44(b)). IL-lp and IF-y were more 
potent than TNF-a in inducing the expression of cdk-2 protein (Fig. 3.46(b)). The 
above findings suggested that the effects of TNF-a were rather specific. 
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The reason behind why IL-6 and IF-y were ineffective in stimulating C6 cells 
proliferation was also quite clear from our study. It is very likely because IL-6 and IF-
y failed to induce the expression of certain cell cycle regulatory genes. These included: 
cyclin Dl (Fig. 3.37), cyclin D3 (Fig. 3.41), cdk-4 (Fig. 3.43), bcl-2 (Fig. 3.63), and 
bcl-w (Fig. 3.69) for IL-6, and cyclin Dl (Fig. 3.38(b)), cyclin E (Fig. 3.46(b)), pl5 
(Fig. 3.50(b)), pl30 (Fig. 3.56(b)), Cak (Fig. 3.58), and Mcl-l (Fig. 3.72) for IF-y. 
The lack of proliferative effect of IL-6 and IF-y could not be due the lack of these 
cytokine receptors as previous studies had shown their presence in C6 cells (Klein et 
al., 1997). 
Another point of interest was that TNF-a was more potent than IL-la and IL-
ip. This could not be due to the differences in the concentrations added as the 
concentrations of these two cytokines were able to induce maximal proliferative effect 
(Liu, 1996). One possible explanation might be related to the differential effects of 
these cytokines. For example, TNF-a was more potent in inducing the expression of 
Cak (Fig. 3.58) and bcl-Xa (Fig. 3.68). 
4.5. The relationship between TNF-a and p adrenergic mechanism in C6 cell 
proliferation 
In astrocytes, p-AR agonist, for example ISO, had been found to stimulate 
proliferation in astrocytes (Hodges-Savola et al., 1996) and in C6 cells (Liu, 1996). 
Moreover, we found that TNF-a induced the expression of both piAR and P2AR 
expression in C6 cells (Shan, 2000). We, therefore, tested whether TNF-a induced C6 
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cell proliferation via an p-adrenergic mechanism and to determine the (3-AR subtype 
that was responsible for P-AR agonist-induced proliferation. Following pretreatment 
of cells with PROP (a common P-AR antagonist), CGP (an Pi A R antagonist), and ICI 
(an P2AR antagonist) then TNF-a treatment, we found that most of the antagonists, at 
low concentrations, failed to inhibit the TNF-a-induced cell cycle related gene 
expression (Section 3.4). In fact, certain antagonists, particularly ICI, further 
stimulated the TNF-a-induced expression of some genes. For example, PROP 
stimulated the expression of cyclin D3 (Fig. 3.75(b)) and p27 (Fig. 3.80(b)), while ICI 
further stimulated the expression of cyclin D2 (Fig. 3.74(b)), and D3 (Fig. 3.75(b)), 
pl30 (Fig. 3.82(b)), bcl-Xa (Fig. 3.87(b)), and bcl-w (Fig. 3.88(b)). On the other hand, 
CGP had no effect on cyclins Ds (Figs. 3.73(b); 3.74(b) and 3.75(b)). These findings 
suggested that TNF-a did not induce the expression these cell cycle regulatory genes 
directly via an (3-adrenergic mechanism. The lack of inhibitory effects of these 
antagonists were unlikely due to the ineffectiveness of these compounds binding to 
their receptors as they are commonly used antagonists and furthermore, their 
respective agonists were effective in inducing the expression of these genes. 
Comparing the effects of three agonists were tested, it appeared that the P2AR 
agonist was most potent. For example, P R O C stimulated the expression of cyclin Dl 
by about 18 folds, while ISO by about 2 folds and D O B by about 3 folds (Fig. 
3.73(a)). Similarly, P R O C induced cyclin D3 by about 24 folds (Fig. 3.75(a)), p27 by 
about 18 folds (Fig. 3.80(a)), cyclin H by about 16 folds (Fig. 3.83(a)). Among these 
genes, cyclins Dl and D3 in association with cdk-4 which was increased by about 3 
folds (Fig. 3.76(a)) were important cell cycle regulatory genes that played important 
role(s) in the G1 phase. Also, p27 which was increased by about 18 folds and p21 
which was induced by about 10 folds were ckis that allowed cells to enter the other 
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phases of a cell cycle. These finding clearly supported the conclusion that P-AR 
agonists, particular P2AR, could induce C6 cell proliferation by interacting with (3-
ARs. 
The effects of these agonists on the anti-apoptotic genes also showed 
differential trends. ISO, the common P-AR agonist, was very potent in inducing these 
genes but P R O C was only slightly less effective. 
The above findings were in line with a report that P2AR agonist could activate 
signal regulated kinases and induce proliferation in HEK293 cells (Schmitt et. al, 
2000). If the findings observed in C6 cells could be extrapolated to astrocytes, this 
would explain that administration of an P-AR antagonist following brain injury had 
beneficial effect (Fujita et al, 1998; Sutin and Griffith, 1993). One possible reason 
being that the elevation of TNF-a at the injured site induced the expression of P-AR 
expression in the surrounding astrocytes and that the administration of an P-AR 
antagonist would inhibit the proliferative action of the P-AR agonist(s) in the 
surrounding, possibly released by the damaged neurons. Thus, the administration of 
an P-AR antagonist would inhibit or reduce astrogliosis. 
4.6. General Discussion 
Results presented earlier revealed that TNF-a, one of cytokine whose level 
was elevated in brain injury, induced the expression of a number of early Gl phase 
cell cycle regulatory genes, particularly cyclin D2, cdk-4, and pi5. These 
observations agree with reports that Gl phase is a phase which is most sensitive to 
external stimuli, such as cytokines (Baldin et al., 1993). The induction of the Gl 
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phase genes as well as other cell cycle regulatory genes could shorten the cell cycle 
time in C6 cells. Moreover, this could be one of the mechanisms whereby TNF-a-
induced C6 cell proliferation. The other could be through induction of |3-AR 
expression, as we previously showed that TNF-a could induce the expression of both 
Pi- and P2AR in a cytokine-specific manner (Shan, 2000). As C6 cells have many 
properties similar to those of astrocytes (Benda et al, 1968), this would provide a 
reasonable explanation for the observation that TNF-a could induce astrogliosis to a 
greater extent than other cytokines and that TNF-a inhibitors, including soluble TNF-
a binding protein, are beneficial in treating brain injury (Wong et al., 1992). 
As to the roles played by the two TNF-Rs in the induction of these cell cycle 
regulatory genes, we found that both subtypes were required as suggested by other 
studies (Baker et al., 1998). Moreover, the .findings that blocking TNF-R2 with its 
specific antiserum were less effective in reducing the stimulatory effect of TNF-a on 
the expression of most cell cycle regulatory genes was in agreement with the general 
belief that TNF-Rl mediates most of the effects of TNF-a and that the role of TNF-
R2 was primarily to enhance signaling through the TNF-Rl by recruiting and 
delivering TNF-a to the lower affinity TNF-Rl (Wong et al., 1994). As the levels of 
TNF-R2 in normal C6 cells (Huang et al., 1998) and astrocytes (Lung et al., 2001) 
were quite low and that their levels were selectively induced by TNF-a treatment, this 
differential levels of the two receptor subtypes might explain the inhibition of 
proliferation following treatment with TNF-R2 antiserum (To, 2000). Another related 
explanation could be related to observations that TNF-R2 played a more prominent 
role in the induction of cdk-4 and p21 proteins. 
The findings that IL-6 and IF-y were unable to stimulate or less effective in 
stimulating cell cycle regulatory genes provided a reasonable explanation for their 
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lack of effects in stimulating C6 cell proliferation. Similarly, the less potent inductive 
effects of IL-la and IL-ip, compared to TNF-a, would explain the difference in their 
proliferative effects in C6 cells. 
4.7. Possible treatments for brain injury 
The complicated events in brain injury and the lack of clear biochemical 
understanding of these processes have made treatments of brain injury very difficult. 
At present, most of the research activities concentrate on axon regeneration, such as 
transplantation and searching for a neuron regeneration enhancing environment. 
Though transplantation is still at its infancy, Rossi et al. (2002) reported that 
transplantated embryonic cerebellar cells could regenerate olivocerebellar axons and 
that they could differentiate into highly organized minicerebella that could mimic the 
cortical compartments presented in normal adult cerebellum. However, further studies 
are required to perfect this approach. 
The other approach is to provide a favorable environment for neuron 
regeneration. One of the research activities is to reduce astrogliosis, a process that is 
believed to block axon regeneration, at appropriate time after injury. Our findings that 
TNF-a and p-AR played an active role in enhancing the induction of a number of 
early G1 phase genes in C6 cells could provide an excellent opportunity for regulating 
astrogliosis. In fact, recent studies by Koguchi et al., (2002) and Nakatsuji et al., 
(2001) had found that overexpression of p27, a cki, could decrease the level of cyclin 
A resulting in an decrease in the ratio of hyperphosphorylated to hypophosphorylated 
pRb, and this caused the slowing down of astrocyte proliferation. Thus, finding a 
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1.7. Effects of TNF-a on the time courses of pl5 gene and protein expression 
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1.7. Effects of TNF-a on the time courses of pl5 gene and protein expression 
TNF-a treatment (h) 
a) RT-PCR 
C 1mm 5 m m 0.25 0.5 1 2 3 4 5 6 7 8 9 10 
11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 
b) Western blotting 
C 0.5 1 2 3 4 5 6 
C 7 8 9 10 11 12 13 14 
" " 厂 、 送 
C 15 16 17 18 19 20 21 22 23 24 
266 
1.7. Effects of TNF-a on the time courses of pl5 gene and protein expression 
TNF-a treatment (h) 
a) RT-PCR 
C 1mm 5min 0.25 0.5 1 2 3 4 5 6 7 8 9 10 
' V 丨 : : : : … ： . : i l t l_ .iiiiiiiiiiiiiiii 
麵s::：：::::::::::.』!&:::::.：,：.：：：：::::::::麵赢灘 _磁__纖_纖1_ 
11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 
b) Western blotting 
C 0.5 1 2 3 4 5 6 
.：；：；：；：；;；；：;：.;； / ‘,… ‘‘“""/ ： // '''''' :...:丨 
C 7 8 9 10 11 12 13 14 
C 15 16 17 18 19 20 2J, 22 23 24 
267 
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1 .3 . Effects of TNF-a on the time courses of cyclin D3 gene and protein 
expression 
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1 .3 . Effects of TNF-a on the time courses of cyclin D3 gene and protein 
expression 
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1 .3 . Effects of TNF-a on the time courses of cyclin D3 gene and protein 
expression 
TNF-a treatment (h) 
a) RT-PCR 
C 1mm 5 m m 0.25 0.5 1 2 3 4 5 6 7 8 9 10 
y 'f - > w . ,叙，， 
11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 
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b) Western blotting 
C 0.5 1 2 3 4 5 6 
、 - “ ” � " � ‘ ••！I'f^lii： -、.;:：•:.;-•:•- .-、：醉. 
C 7 8 9 10 11 12 13 14 
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C 15 16 17 18 19 20 21 22 23 24 
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1 .7 . Effects of TNF-a on the time courses of pl5 gene and protein expression 
TNF-a treatment (h) 
Western blotting 
C 0.5 1 2 3 4 5 6 
“ .:lii_i』 〜铃 •ilfc：;： 广 
C 7 8 9 10 11 12 13 14 
C 15 16 17 18 19 20 21 22 23 24 
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1 .3 . Effects of TNF-a on the time courses of cyclin D3 gene and protein 
expression 
TNF-a treatment (h) 
a) RT-PCR 
C 1mm 5 m m 0.25 0.5 1 2 3 4 5 6 7 8 9 10 
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b) Western blotting 
C 0.5 1 2 3 4 5 6 
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1 .3 . Effects of TNF-a on the time courses of cyclin D3 gene and protein 
expression 
TNF-a treatment (h) 
RT-PCR 
C 1mm 5min 0.25 0.5 1 2 3 4 5 6 7 8 9 10 
：'：'/-'/ /“, V : y �叙 廢 麵 氣 愛 ， . ‘ 3 > ：貪滅 
11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 
274 
1 . 3 . Effects of TNF-a on the time courses of cyclin D3 gene and protein 
expression 
TNF-a treatment (h) 
a) RT-PCR 
C Imin 5mm 0.25 0.5 1 2 3 4 5 6 7 8 9 10 
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11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 
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b) Western blotting 
C 0.5 1 2 3 4 5 6 
C 7 8 9 10 11 12 13 14 
C 15 16 17 18 19 20 21 22 23 24 
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1.18. Effect of TNF-a on the time course Mcl-l gene expression 
TNF-a treatment (h) 
RT-PCR 
C 1mm 5mm 0.25 0.5 1 2 3 4 5 6 7 8 9 10 
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1.19. Effect of TNF-a on the time course P-actin gene expression 
TNF-a treatment (h) 
a) RT-PCR 
C 1mm 5mm 0.25 0.5 1 2 3 4 5 6 7 8 9 10 
11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 
b) Western blotting 
C 0.5 1 2 3 4 5 6 
C 7 8 9 10 11 12 13 14 
|_丨j __隐圓...一 ’ _ _ _ . _     
C 15 16 17 18 19 20 21 22 23 24 
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2. Effects of TNF-Rl and -R2 on cell cycle related genes and proteins 
expression 
2.1. Effects of blocking TNF-Rl/ -R2 on cyclin Dl gene and protein expression 
a) RT-PCR 
TNF-Rl antibody added with different time points (min) before 2 hours TNF-a 
treatment 
C TNF-a 1 2 5 10 20 30 60 120 
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TNF-R2 antibody added with different time points (min) before 2 hours TNF-a 
treatment 
C TNF-a 1 2 5 10 20 30 60 120 
b) Western blotting 
TNF-Rl antibody added with different time points (min) before 2 hours TNF-a 
treatment 
C TNF-a 1 2 5 10 20 30 60 120 
TNF-R2 antibody added with different time points (min) before 2 hours TNF-a 
treatment 




2.3. Effects of blocking TNF-Rl/ -R2 on cyclin D3 gene and protein expression 
RT-PCR 
TNF-Rl antibody added with different time points (min) before 2 hours TNF-a 
treatment 




TNF-R2 antibody added with different time points (min) before 2 hours TNF-a 
treatment 
C TNF-a 1 2 5 10 20 30 60 120 
2 7 9 
2.3. Effects of blocking TNF-Rl/ -R2 on cyclin D3 gene and protein expression 
a) RT-PCR 
TNF-Rl antibody added with different time points (min) before 2 hours TNF-a 
treatment 
C TNF-a 1 2 5 10 20 30 60 120 
� r "f" '"'"ipi 
- ,,, , , , / ) : 〜 , ' 卞 ^ ^ y i ^ f ^ ' i f i ^ f l "-'ik 
TNF-R2 antibody added with different time points (min) before 2 hours TNF-a 
treatment 
C TNF-a 1 2 5 10 20 30 60 120 
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b) Western blotting -
TNF-Rl antibody added with different time points (min) before 2 hours TNF-a 
treatment 
C TNF-a 1 2 5 10 20 30 60 120 
TNF-R2 antibody added with different time points (min) before 2 hours TNF-a 
treatment 
C TNF-a 1 2 5 10 20 30 60 120 
2 8 0 
2.3. Effects of blocking TNF-Rl/ -R2 on cyclin D3 gene and protein expression 
a) RT-PCR 
TNF-Rl antibody added with different time points (min) before 2 hours TNF-a 
treatment 
C TNF-a 1 2 5 10 20 30 60 120 
…二 "，，. i^g藝•羞‘隱:忽鱲^ 
TNF-R2 antibody added with different time points (min) before 2 hours TNF-a 
treatment 
C TNF-a 1 2 5 10 20 30 60 120 
b) Western blotting 
TNF-Rl antibody added with different time points (min) before 2 hours TNF-a 
treatment 
C TNF-a 1 2 5 10 20 30 60 120 
TNF-R2 antibody added with different time points (min) before 2 hours TNF-a 
treatment 
C TNF-a 1 2 5 10 20 30 60 120 
2 8 1 
2.12. Effects of blocking TNF-Rl/ -R2 on cyclin H gene and protein expression 
a) RT-PCR 
TNF-Rl antibody added with different time points (min) before 2 hours TNF-a 
treatment 
C TNF-a 1 2 5 10 20 30 60 120 
TNF-R2 antibody added with different time points (min) before 2 hours TNF-a 
treatment 
C TNF-a 1 2 5 10 20 30 60 120 
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b) Western blotting 
TNF-Rl antibody added with different time points (min) before 2 hours TNF-a 
treatment 
C TNF-a 1 2 5 10 20 30 60 120 
TNF-R2 antibody added with different time points (min) before 2 hours TNF-a 
treatment 
C TNF-a 1 2 5 10 20 30 60 120 
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2.12. Effects of blocking TNF-Rl/ -R2 on cyclin H gene and protein expression 
a) RT-PCR 
TNF-Rl antibody added with different time points (min) before 2 hours TNF-a 
treatment 
c TNF-a 1 2 5 10 20 30 60 120 
r" ' ‘ "”沪 ''-"W" """' '•“ r：'/ ' 勺 ’ ； ‘ ； ^ ^ 办 " ： 環 
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TNF-R2 antibody added with different time points (min) before 2 hours TNF-a 
treatment 
c TNF-a 1 2 5 10 20 30 60 120 
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b) Western blotting 
TNF-Rl antibody added with different time points (min) before 2 hours TNF-a 
treatment 
C TNF-a 1 2 5 10 20 30 60 120 
'�'\/y? '‘：“-p：^- ",''>'、 〜 命 . ”“广 
TNF-R2 antibody added with different time points (min) before 2 hours TNF-a 
treatment 
C TNF-a 1 2 5 10 20 30 60 120 
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2.12. Effects of blocking TNF-Rl/ -R2 on cyclin H gene and protein expression 
a) RT-PCR 
TNF-Rl antibody added with different time points (min) before 2 hours TNF-a 
treatment 
c TNF-a 1 2 5 10 20 30 60 120 
• ‘ , /】'„〜J ‘ , , ,/W z (//,麵效 
TNF-R2 antibody added with different time points (min) before 2 hours TNF-a 
treatment 
C TNF-a 1 2 5 10 20 30 60 120 
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b) Western blotting 
TNF-Rl antibody added with different time points (min) before 2 hours TNF-a 
treatment 
C TNF-a 1 2 5 10 20 30 60 120 
， ' ' . : : 
TNF-R2 antibody added with different time points (min) before 2 hours TNF-a 
treatment 
C TNF-a 1 2 5 10 20 30 60 120 
z iI;；.a,ii.:』_il _ ； _ , ‘、：：、 
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2.12. Effects of blocking TNF-Rl/ -R2 on cyclin H gene and protein expression 
a) RT-PCR 
TNF-Rl antibody added with different time points (min) before 2 hours TNF-a 
treatment 
C TNF-a 1 2 5 10 20 30 60 120 
TNF-R2 antibody added with different time points (min) before 2 hours TNF-a 
treatment 
C TNF-a 1 2 5 10 20 30 60 120 
b) Western blotting 
TNF-Rl antibody added with different time points (min) before 2 hours TNF-a 
treatment 
C TNF-a 1 2 5 10 20 30 60 120 
TNF-R2 antibody added with different time points (min) before 2 hours TNF-a 
treatment 
C TNF-a 1 2 5 10 20 30 60 120 
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2.12. Effects of blocking TNF-Rl/ -R2 on cyclin H gene and protein expression 
a) RT-PCR 
TNF-Rl antibody added with different time points (min) before 2 hours TNF-a 
treatment 
C TNF-a 1 2 5 10 20 30 60 120 
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TNF-R2 antibody added with different time points (min) before 2 hours TNF-a 
treatment 
c TNF-a 1 2 5 10 20 30 60 120 
b) Western blotting 
TNF-Rl antibody added with different time points (min) before 2 hours TNF-a 
treatment 
C TNF-a 1 2 5 10 20 30 60 120 
TNF-R2 antibody added with different time points (min) before 2 hours TNF-a 
treatment 
C TNF-a 1 2 5 10 20 30 60 120 
2 8 6 
2.17. Effects of blocking TNF-Rl/ -R2 on bcl-w gene and protein expression 
a) RT-PCR 
TNF-Rl antibody added with different time points (min) before 2 hours TNF-a 
treatment 
C TNF-a 1 2 5 10 20 30 60 120 
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TNF-R2 antibody added with different time points (min) before 2 hours TNF-a 
treatment 
c TNF-a 1 2 5 10 20 30 60 120 
b) Western blotting 
TNF-Rl antibody added with different time points (min) before 2 hours TNF-a 
treatment 
C TNF-a 1 2 5 10 20 30 60 120 
働 、 耀 ^ ^ ^ m ^ ^ m _ 
TNF-R2 antibody added with different time points (min) before 2 hours TNF-a 
treatment 
C TNF-a 1 2 5 10 20 30 60 120 
譽 ， ^ t e � ^^m mm 
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2.12. Effects of blocking TNF-Rl/ -R2 on cyclin H gene and protein expression 
a) R T - P C R 
TNF-Rl antibody added with different time points (min) before 2 hours TNF-a 
treatment 
C TNF-a 1 2 5 10 20 30 60 120 
TNF-R2 antibody added with different time points (min) before 2 hours TNF-a 
treatment 
C TNF-a 1 2 5 10 20 30 60 120 
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2.12. Effects of blocking TNF-Rl/ -R2 on cyclin H gene and protein expression 
a) RT-PCR 
TNF-Rl antibody added with different time points (min) before 2 hours TNF-a 
treatment 
C TNF-a 1 2 5 10 20 30 60 120 
TNF-R2 antibody added with different time points (min) before 2 hours TNF-a 
treatment 
C TNF-a 1 2 5 10 20 30 60 120 
b) Western blotting 
TNF-Rl antibody added with different time points (min) before 2 hours TNF-a 
treatment 
C TNF-a 1 2 5 10 20 30 60 120 
TNF-R2 antibody added with different time points (min) before 2 hours TNF-a 
treatment 
C TNF-a 1 2 5 10 20 30 60 120 
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2.12. Effects of blocking TNF-Rl/ -R2 on cyclin H gene and protein expression 
a) RT-PCR 
TNF-Rl antibody added with different time points (min) before 2 hours TNF-a 
treatment 
C TNF-a 1 2 5 10 20 30 60 120 
_ _ _ 纖 變 . . . . 一 灣 l i i r . . . . . . . . 一 . . . . . . . i 
","/,/,/ // // //// 
TNF-R2 antibody added with different time points (min) before 2 hours TNF-a 
treatment 
C TNF-a 1 2 5 10 20 30 60 120 
b) Western blotting 
TNF-Rl antibody added with different time points (min) before 2 hours TNF-a 
treatment 
c TNF-a 1 2 5 10 20 30 60 120 
.• „:.,.邏圃^^^^^^^^^^  Jiiili隨麗！編麵.;:, 
TNF-R2 antibody added with different time points (min) before 2 hours TNF-a 
treatment 
C TNF-a 1 2 5 10 20 30 60 120 
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2.14. Effects of blocking TNF-Rl/ -R2 on bcl-2 protein expression 
Western blotting 
TNF-Rl antibody added with different time points (min) before 2 hours TNF-a 
treatment 
C TNF-a 1 2 5 10 20 30 60 120 
TNF-R2 antibody added with different time points (min) before 2 hours TNF-a 
treatment 
C TNF-a 1 2 5 10 20 30 60 120 
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2.12. Effects of blocking TNF-Rl/ -R2 on cyclin H gene and protein expression 
a) RT-PCR 
TNF-Rl antibody added with different time points (min) before 2 hours TNF-a 
treatment 
C TNF-a 1 2 5 10 20 30 60 120 
f , 碼 化 _ 濃 售 輪 . 急 " 赢 i i 'fea:嶺 
TNF-R2 antibody added with different time points (min) before 2 hours TNF-a 
treatment 
C TNF-a 1 2 5 10 20 30 60 120 
b) Western blotting 
TNF-Rl antibody added with different time points (min) before 2 hours TNF-a 
treatment 
C TNF-a 1 2 5 10 20 30 60 120 
輪 ; ' 趣 
TNF-R2 antibody added with different time points (min) before 2 hours TNF-a 
treatment 
C TNF-a 1 2 5 10 20 30 60 120 
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2.12. Effects of blocking TNF-Rl/ -R2 on cyclin H gene and protein expression 
a) RT-PCR 
TNF-Rl antibody added with different time points (min) before 2 hours TNF-a 
treatment 
C TNF-a 1 2 5 10 20 30 60 120 
•:,:。:邊^ I麗__1_嶋illllliiiiilMilH^ 
TNF-R2 antibody added with different time points (min) before 2 hours TNF-a 
treatment 
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2.17. Effects of blocking TNF-Rl/ -R2 on bcl-w gene and protein expression 
a) RT-PCR 
TNF-Rl antibody added with different time points (min) before 2 hours TNF-a 
treatment 
C TNF-a 1 2 5 10 20 30 60 120 
、 ’ ’々’… � % ‘ 〜：露耀篇 
TNF-R2 antibody added with different time points (min) before 2 hours TNF-a 
treatment 
C TNF-a 1 2 5 10 20 30 60 120 
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b) Western blotting 
TNF-Rl antibody added with different time points (min) before 2 hours TNF-a 
treatment 
C TNF-a 1 2 5 10 20 30 60 120 
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TNF-R2 antibody added with different time points (min) before 2 hours TNF-a 
treatment 
C TNF-a 1 2 5 10 20 30 60 120 
294 
2.12. Effects of blocking TNF-Rl/ -R2 on cyclin H gene and protein expression 
a) RT-PCR 
TNF-Rl antibody added with different time points (min) before 2 hours TNF-a 
treatment 
C TNF-a 1 2 5 10 20 30 60 120 
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TNF-R2 antibody added with different time points (min) before 2 hours TNF-a 
treatment 
C TNF-a 1 2 5 10 20 30 60 120 
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2.12. Effects of blocking TNF-Rl/ -R2 on cyclin H gene and protein expression 
a) RT-PCR 
TNF-Rl antibody added with different time points (min) before 2 hours TNF-a 
treatment 
C TNF-a 1 2 5 10 20 30 60 120 
TNF-R2 antibody added with different time points (min) before 2 hours TNF-a 
treatment 
C TNF-a 1 2 5 10 20 30 60 120 
b) Western blotting 
TNF-Rl antibody added with different time points (min) before 2 hours TNF-a 
treatment 
C TNF-a 1 2 5 10 20 30 60 120 
TNF-R2 antibody added with different time points (min) before 2 hours TNF-a 
treatment 
C TNF-a 1 2 5 10 20 30 60 120 
' 考 錄 - 、  、 
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3. Effects of other cytokines (IL-6, IL-la, IL-ip, IFy) on cell cycle 
related genes and proteins expression 
3.1. Effects of TNF-a, IL-6, IL-la, IL-ip, IFy on cyclin Dl gene and protein 
expression 
a) RT-PCR 
IL-6 treatment (U) 
C 50 100 1000 5000 10000 
、 、 、 , 、‘、 ‘ ,, / X '''''' '/ ''' “ ‘ ^ ^  // “‘ “ “‘ , , 々 / , , , , 
“ � � * � ’ - - ' � ’ ’ - ' ' - ‘ ,‘… “'W'U,“, ‘ "�"""’, ''",〜，‘, ‘、,'/”“ 
IL-la treatment (h) 
C 0.25 0.5 1 2 3 4 
‘ I ' I 广、 、％、产、、、、、、、、、、 
IL-lp treatment (h) 
C 0.25 0.5 1 2 3 4 
IF-y treatment (h) 
C 0.5 1 2 3 4 
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b) Western blotting 
IL-6 treatment (U) 
c 50 100 1000 2500 7500 
IL-la treatment (h) 
c 0.25 0.5 1 2 3 4 
…’‘ 
IL-ip treatment (h) 
C 0.25 0.5 1 2 3 4 
_ 麵 _ | _ _ _ _ _ 冰〜‘力”' ； 药 於 。祝:A:,-,-� 
IF-y treatment (h) 
C 0.25 0.5 1 2 3 4 
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3.7. Effects of TNF-a, IL-6, IL-la, IL-ip, IFy on pl5 gene and protein expression 
a) RT-PCR 
IL-6 treatment (U) 
c 50 100 1000 5000 10000 
iiilii^iilipipilM 
__丨_|__|||___|1___||1__:丨:.：..’ . . : . : . . : . . . : : : : : 丨 ： 丨 i 丨 
；lippiplpilpig；；!：;；!；!^^ 
IL-la treatment (h) 
C 0.25 0.5 1 2 3 4 
IL-lp treatment (h) 
C 0.25 0.5 1 2 3 4 
IF-y treatment (h) 
C 0.5 1 2 3 4 
：,, 孤 ， 萬 题 拿 考 
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3.3. Effects of TNF-a, IL-6, IL-la, IL-ip, IFy on cyclin D3 gene and protein 
expression 
a) RT-PCR 
IL-6 treatment (U) 
C 50 100 1000 5000 10000 
IL-la treatment (h) 
C 0.25 0.5 1 2 3 4 
• . 譚 : __r ...:！纖霧.耀鬮ii, • • 广^^^^^  
^mmmMmm&m^^i^^ -：：•：•：•：•：•：•>；； ；^；-. ：滋 11__激_.:::. , . 缚 • 珍 鎮 顔 i . . ,,.；„ . .„,；；,,：..,.,,,；„,...,,；；s^ giiigi：；：®：：：!；^^ ^ 
mi^ffmw^i^^ •：： :;x；：;•；：;>.：.;：: • ？丨:故丨怒丨::•_:::_:..,..::::.:••’_::::?•::•:::+’+:.: ：'：；•：• MiiMWiMi^MM . _::. :::::::’::.:入.:::::.::孩忍站资• •. ：-;>!；；；;：；：；；：：^；：：；：：；：»;^；^ 
IL-ip treatment (h) 
C 0.25 0.5 1 2 3 4 
K 舊 ’ 置 醫•冗鎮響：‘ 響 « m 
IF-y treatment (h) 
C 0.5 1 2 3 4 
I 、 " … ^ S 冗 ： s ： ^ : ⑵ 為 ; 愈 ‘ • 斜 ； ： 地 
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b) Western blotting 
IL-6 treatment (U) 
c 50 100 1000 2500 7500 
IL-la treatment (h) 
C 0.25 0.5 1 2 3 4 
IL-ip treatment (h) 
C 0.25 0.5 1 2 3 4 
“ • �^^^m�, 
IF-y treatment (h) 
C 0.25 0.5 1 2 3 4 
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3.4. Effects of TNF-a, IL-6, IL-1 a, IL-lp, IFy on cdk-4 gene and protein 
expression 
a) RT-PCR 
IL-6 treatment (U) 
c 50 100 1000 5000 10000 
IL-1 a treatment (h) 
C 0.25 0.5 1 2 3 4 
IL-ip treatment (h) 
C 0.25 0.5 1 2 3 4 
二譽’ 零 賢 W …’警：… 
ymmmm^Mkki^..‘‘；,“‘急； ”、： 
IF-y treatment (h) 
C 0.5 1 2 3 4 
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b) Western blotting 
IL-6 treatment (U) 
c 50 100 1000 2500 7500 
IL-la treatment (h) 
C 0.25 0.5 1 2 3 4 
IL-ip treatment (h) 
C 0.25 0.5 1 2 3 4 
IF-y treatment (h) 
C 0.25 0.5 1 2 3 4 
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3.5. Effects of TNF-a, IL-6, IL-la, IL-lp, IFy on cyclin E gene and protein 
expression 
a) RT-PCR 
IL-6 treatment (U) 
C 50 100 1000 5000 10000 
IL-la treatment (h) 
C 0.25 0.5 1 2 3 4 
IL-lp treatment (h) 
C 0.25 0.5 1 2 3 4 
議 讓 _ _ _ _ 1 1 _ _ _讓 _ _議 _ _ ; _ _ 1 _ _ _ _謹 
111111111»^  , : . : z : . : : . , , , , . 』 ^ 〜 l _ _ _ i L .liiii 
IF-y treatment (h) 
C 0.5 1 2 3 4 
i^iiiiPis 
t p 丨 , ； 二 ： 广 二 ： ；‘'、：、/ ：、/、‘-
304 
b) Western blotting 
IL-6 treatment (U) 
c 50 100 1000 2500 7500 
I L - l a treatment (h) 
C 0.25 0.5 1 2 3 4 
^^mHP •^^"•iSiiUHBB. [umpii I - 一 〜 ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ 
I L - i p treatment (h) 
C 0.25 0.5 1 2 3 4 
iflnHHMMHP'' '<mimmm 、^itiiHIIIHiP, m^mippMMMHK 
IF-y treatment (h) 
C 0.25 0.5 1 2 3 4 
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3.6. Effects of TNF-a, IL-6, IL-la, IL-lp, IFy on cdk-2 gene and protein 
expression 
a) RT-PCR 
IL-6 treatment (U) 
C 50 100 1000 5000 10000 
IL-la treatment (h) 
C 0.25 0.5 1 2 3 4 
W" '"""""W “ � � ’ w � � �• 、 響 ： 、；梦’ ：、  
赢 。 、：、I i>、k、:、、，>、<“:v,v、A:?5v 、 J 
IL-ip treatment (h) 
C 0.25 0.5 1 2 3 4 
Y M � … … . / f r , '"德’’ , 
IF-丫 treatment (h) 
C 0.5 1 2 3 4 
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b) Western blotting 
IL-6 treatment (U) 
c 50 100 1000 2500 7500 
:::”_繞摩叙‘•- 爆發 __ 抓’ ‘ .-
IL-la treatment (h) 
C 0.25 0.5 1 2 3 4 
IL-ip treatment (h) 
C 0.25 0.5 1 2 3 4 
IF-y treatment (h) 
C 0.25 0.5 1 2 3 4 
iiip:;？ 、”警、：咖。；顯錄‘‘《V ：  
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3.7. Effects of TNF-a, IL-6, IL-la, IL-ip, IFy on pl5 gene and protein expression 
a) RT-PCR 
IL-6 treatment (U) 
c 50 100 1000 5000 10000 
IL-la treatment (h) 
C 0.25 0.5 1 2 3 4 
IL-ip treatment (h) 
C 0.25 0.5 1 2 3 4 
IF-y treatment (h) 
C 0.5 1 2 3 4 
' 巧 》 ： 涵 像 “ 孤 ii 
‘ ‘ “ '/ ‘ ‘ 'H ‘ 'A '""///'/ ‘. ‘ / “ , mmmrnrn^ ：-：•-.••• ‘ t,',/ / ‘ // .“恶游 
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b) Western blotting 
IL-6 treatment (U) 
c 50 100 1000 2500 7500 
IL-la treatment (h) 
C 0.25 0.5 1 2 3 4 
IL-ip treatment (h) 
C 0.25 0.5 1 2 3 4 
IF-y treatment (h) 
C 0.25 0.5 1 2 3 4 
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3.7. Effects of TNF-a, IL-6, IL-la, IL-ip, IFy on pl5 gene and protein expression 
a) RT-PCR 
IL-6 treatment (U) 
C 50 100 1000 5000 10000 
IL-la treatment (h) 
C 0.25 0.5 1 2 3 4 
IL-ip treatment (h) 
C 0.25 0.5 1 2 3 4 
[ ： , 量 i I 
IF-y treatment (h) 
C 0.5 1 2 3 4 
. = 、 • : : . 靈 置 J S i ^ 讀 』 
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b) Western blotting 
IL-6 treatment (U) 
c 50 100 1000 2500 7500 
IL-1 a treatment (h) 
C 0.25 0.5 1 2 3 4 
• :l_iil_i_r •lililiiii： • ； 聊 變 丨 ： ： ： 丨 • 
IL-ip treatment (h) 
C 0.25 0.5 1 2 3 4 
liiiiiiiiliill' 」;_il________i__:. . :、:;;:____________|_| 疼 卞 : 、 : ， J_i___iiii_i___:H:. 
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< . ‘“‘ 丨丨:::丨:丨：丨丨：:丨:;::;!资丨!S;::怒:wfe;::::::丨. .：,^：.^：.：.：.：.：.^：,•.-•, 
IF-y treatment (h) 
C 0.25 0.5 1 2 3 4 
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3.7. Effects of TNF-a, IL-6, IL-la, IL-ip, IFy on pl5 gene and protein expression 
a) RT-PCR 
IL-6 treatment (U) 
C 50 100 1000 5000 10000 
滅‘城余、U^V^S^�—� , “ � � � . � � , � . . . � . � � � • - � �� -V : 
IL-la treatment (h) 
C 0.25 0.5 1 2 3 4 
； ,…感 … 、 、ifey、、饥、：蘇…、〜.、， 
IL-ip treatment (h) 
C 0.25 0.5 1 2 3 4 
IF-y treatment (h) 
C 0.5 1 2 3 4 
f... 、 . 
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b) Western blotting 
IL-6 treatment (U) 
c 50 100 1000 2500 7500 
IL-la treatment (h) 
C 0.25 0.5 1 2 3 4 
； ： ： ： • 二 ’: ::: ： ： ： ： ： ： ： 錄 丨 I 然 经 : : : : : ： ： 
IL-ip treatment (h) 
C 0.25 0.5 1 2 3 4 
；^iliiilH^  丨：丨※：丨: 
IF-y treatment (h) 
C 0.25 0.5 1 2 3 4 
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3.10. Effects of TNF-a, IL-6, IL-la, IL-1 (3, IFy on pl30 gene and protein 
expression 
a) RT-PCR 
IL-6 treatment (U) 
C 50 100 1000 5000 10000 
IL-1 a treatment (h) 
C 0.25 0.5 1 2 3 4 
:::::：："®:：：::::，'竭海：：：™丨：：:丨:：滋：丨丨::丨：•.. •  . 、 “ “ : ! _ , … 
IL-ip treatment (h) 
C 0.25 0.5 1 2 3 4 
‘:::::：丨::::::::：:::::::™:画、.....“：：：.:.:.1__『:::.:..:.:••••…::!__, , 1 1議 , . •11111 … ,1 
‘ , • ‘ 寧翁:ii45: - , , , 
纏 _ _ _ _ _ 議 _ 醒 1 _ _ 1 _ 乡 I i i l i i i i i l i i * ^ ^ 
IF-y treatment (h) 
C 0.5 1 2 3 4 
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b) Western blotting 
IL-6 treatment (U) 
c 50 100 1000 2500 7500 
、•‘、考、, 、 … 拟 议她欢‘“？ ” 嫩 梦 ' 游 
IL-la treatment (h) 
C 0.25 0.5 1 2 3 4 
響 _ : _ _ _ : -^prn^m^^ -^mm^^： 'm^^m^ 
IL-lp treatment (h) 
C 0.25 0.5 1 2 3 4 
' ： 丨 f ‘ mmm, 穩 腳 , 
IF-y treatment (h) 
C 0.25 0.5 1 2 3 4 
,作 
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3 . 7 . Effects of TNF-a, IL-6, IL-la, IL-ip, IFy on pl5 gene and protein expression 
a) RT-PCR 
IL-6 treatment (U) 
C 50 100 1000 5000 10000 
IL-la treatment (h) 
C 0.25 0.5 1 2 3 4 
- T r - T ‘ W ' ' W梦'."“、,".〈、 
： 纖 … 』 ,i_i 
IL-ip treatment (h) 
C 0.25 0.5 1 2 3 4 
《（< MA,辦‘ ‘ 微 ' 况 厂 乂 ： 湾 广入；''：；K 广"‘？？ 
、二、、- V - . , ‘ \ : 4 ' 、 „ , 急 救 - , ‘ 广 
IF-y treatment (h) 
C 0.5 1 2 3 4 
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3 . 3 . Effects of TNF-a, IL-6, IL-la, IL-ip, IFy on cyclin D3 gene and protein 
expression 
a) RT- P C R 
IL-6 treatment (U) 
C 50 100 1000 5000 10000 
^ ^ ^ ^ ^ ^ ^ ^ ！ ^ 节 一 ― … … . , . . . , , . . „ „ . . , „ „ „ . • 一 … … , 一 . . , … . . . , , … … . . r , 
n w a s i M a a a a i i M M ^ ^ 
IL-la treatment (h) 
C 0.25 0.5 1 2 3 4 
IL-ip treatment (h) 
C 0.25 0.5 1 2 3 4 
、 乂、 cy 、：资厂、、、Ty y v 、、 
IF-y treatment (h) 
C 0.5 1 2 3 4 
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b) Western blotting 
IL-6 treatment (U) 
c 50 100 1000 2500 7500 
IL-la treatment (h) 
C 0.25 0.5 1 2 3 4 
IL-ip treatment (h) 
C 0.25 0.5 1 2 3 4 
IF-y treatment (h) 
C 0.25 0.5 1 2 3 4 
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3 . 3 . Effects of TNF-a, IL-6, IL-la, IL-ip, IFy on cyclin D3 gene and protein 
expression 
a) RT- P G R 
IL-6 treatment (U) 
C 50 100 1000 5000 10000 
IL-la treatment (h) 
C 0.25 0.5 1 2 3 4 
IL-ip treatment (h) 
C 0.25 0.5 1 2 3 4 
IF-y treatment (h) 
C 0.5 1 2 3 4 
w … w - w 、 、胃、、鄉、纟、•““〉、> • 
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b) Western blotting 
IL-6 treatment (U) 
c 50 100 1000 2500 7500 
IL-la treatment (h) 
C 0.25 0.5 1 2 3 4 
IL-ip treatment (h) 
C 0.25 0.5 1 2 3 4 
IF-y treatment (h) 
C 0.25 0.5 1 2 3 4 
320 
3.14. Effects of TNF-a, IL-6, IL-la, IL-ip, IFy on bcl-2 protein expression 
Western blotting 
IL-6 treatment (U) 
C 50 100 1000 2500 7500 
IL-la treatment (h) 
C 0.25 0.5 1 2 3 4 
IL-ip treatment (h) 
C 0.25 0.5 1 2 3 4 
" 急 》 緣 赂 杂 
IF-y treatment (h) 
C 0.25 0.5 1 2 3 4 
. . . . . . : : : : : : : : : ; : : : : : 丨 : 丨 : 丨 : 效 戀 ^ 淡 • 丨::::丨發：丨凝..• .:乂:丨:.:::.:运丨；凝丨丨發丨丨丨丨:丨：逸::丨丨 
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3.15. Effects of TNF-a, IL-6, IL-la, IL-1 (3, IFy on bcl-XL gene and protein 
expression 
a) RT-PCR 
IL-6 treatment (U) 
C 50 100 1000 5000 10000 
IL-la treatment (h) 
C 0.25 0.5 1 2 3 4 
iiiiiiiiiii*^^ 丨 . .... ；ilSiiP^^^  "：111111' llili 
IL-ip treatment (h) 
C 0.25 0.5 1 2 3 4 
雇 二 二 二 :‘.:.:.i .,」...,...,.丨丨法.:.‘.:.?•.,.‘...‘..々 ^^^ ^^  
IF-y treatment (h) 
C 0.5 1 2 3 4 
WmmiiMmmmmim^^mi:::::: 琴 （ 讀 _ : : : : : : : : • 級 . : : ， : : ※ ： 丨 ： 丨 : : 觀 ： . " 灣 導【."•:…..:.:〜”:.:.::] Jiiiik Jill.,: _ , , , , , , : : : : : : < : : : : : : : : : : : : : : : :卿琴 
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b) Western blotting 
IL-6 treatment (U) 
c 50 100 1000 2500 7500 
IL-1 a treatment (h) 
C 0.25 0.5 1 2 3 4 
IL-ip treatment (h) 
C 0.25 0.5 1 2 3 4 
IF-y treatment (h) 
C 0.25 0.5 1 2 3 4 
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3 . 7 . Effects of TNF-a, IL-6, IL-la, IL-ip, IFy on pl5 gene and protein expression 
a) R T - P C R 
IL-6 treatment (U) 
C 50 100 1000 5000 10000 
s"?” “ 礙， - ；: 
IL-la treatment (h) 
C 0.25 0.5 1 2 3 4 
IL-ip treatment (h) 
C 0.25 0.5 1 2 3 4 
IF-y treatment (h) 
C 0.5 1 2 3 4 
、、‘’ 、‘:!急_' ：隱‘ , ‘ — 』 
3 2 4 
3.17. Effects of TNF-a, IL-6, IL-la, IL-1 (3, IFy on bcl-w gene and protein 
expression 
a) RT-PCR 
IL-6 treatment (U) 
C 50 100 1000 5000 10000 
_ _ 丨 , i _ 國 爾 屬 ^ ^ _ _ _ _ 
i i i i i l : - . . , , , , . : , . . . . . . v . . . . . . . .. _丨:_:_缀_：:；：；•.;...： . ；：；,：：：；；：：；：,：  . , ：：mmmmm^- . : : :丨顆通涯 ‘ ‘ ‘ " ‘ ‘ ‘ , ‘ ‘ / • ‘ ‘ 
IL-la treatment (h) 
C 0.25 0.5 1 2 3 4 
IL-ip treatment (h) 
C 0.25 0.5 1 2 3 4 
IF-y treatment (h) 
C 0.5 1 2 3 4 
爾 为 霸 � V r : ' 'V' "(：'' —�:�;:��:::’ 
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b) Western blotting 
IL-6 treatment (U) 
C 50 100 1000 2500 7500 
:: illWIii, :: 
IL-la treatment (h) 
C 0.25 0.5 1 2 3 4 
IL-ip treatment (h) 
C 0.25 0.5 1 2 3 4 
IF-y treatment (h) 
C 0.25 0.5 1 2 3 4 
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3 . 7 . Effects of TNF-a, IL-6, IL-la, IL-ip, IFy on pl5 gene and protein expression 
a) RT-PCR 
IL-6 treatment (U) 
C 50 100 1000 5000 10000 
输 麵 泌 ^ k k 赫 咖 丨 ^ ^ 丨 融 一 ； 基 丨 … , " " . . " M : 丨 。 " 一 . … 二 
IL-la treatment (h) 
C 0.25 0.5 1 2 3 4 
IL-1P treatment (h) 
C 0.25 0.5 1 2 3 4 
IF-y treatment (h) 
C 0.5 1 2 3 4 
p W 響 W 響 纖 w ^ ^ ^ ^ r 、 ” ; : , 
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3 . 3 . Effects of TNF-a, IL-6, IL-la, IL-ip, IFy on cyclin D3 gene and protein 
expression 
a) RT-PCR 
IL-6 treatment (U) 
C 50 100 1000 5000 10000 
lil^l纟霸韓憩：彡资然凝丨丨:i丨:Ii藉霧I赛靈丨丨II麗_靈_翼i黨i赛禁终霜资變：丨黨i_i讀iiiilllPIlP藉譲•靈蘇寒画 
IL-la treatment (h) 
C 0.25 0.5 1 2 3 4 
‘ ‘、’ ‘；、'‘ 、〈广“ ‘‘？, '實 
IL-ip treatment (h) 
C 0.25 0.5 1 2 3 4 
缝 1:《” ‘  - "''‘,"/'' r零T ' • ， 霸 • ‘ “琴厂 
IF-y treatment (h) 
C 0.5 1 2 3 4 
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b) Western blotting 
IL-6 treatment (U) 
c 50 100 1000 2500 7500 
IL-la treatment (h) 
C 0.25 0.5 1 2 3 4 
IL-lp treatment (h) 
C 0.25 0.5 1 2 3 4 
IF-y treatment (h) 
C 0.25 0.5 1 - 2 3 4 
、機鮮、、货#縱•〜、仏;〜份、、、總滅妙、〜、她縱r、:微城：辦'逾 
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4. Effects of P-ARs on cell cycle related genes expression 
4.1. Effects of P-AR agonists and antagonists on cyclin D1 gene expression 
a) Effects of common P-AR agonist/ antagonist with/ without TNF-a on cyclin D1 
gene expression 
ISO treatment only (M) 
C 10-9 5X10-9 10.8 10.7 10-6 10-5 10.4 
P R O P treatment 2h before TNF-a (M) 
TNF-a 10—9 10-8 10-7 10"^  10"^  5 X 1 1 0 " ^ 
b) Effects of PiAR agonist/ antagonist with/ without TNF-a on cyclin D1 gene 
expression 
D O B treatment only (M) 
C 10-9 5X10-9 10:8 10-7 一 、 
CRP treatment 2h before TNF-a (M) 
TNF-a 10—9 10—8 10—7 10"^  lO—^  lO"' 10'' 
c) Effects of P2AR agonist/ antagonist with/ without TNF-a on cyclin D1 gene 
expression 
P R O C treatment only (M) 
C 10-9 5X10.9 10.8 10-7 10.6 10-5 10.4 
'mmfjmmm^ ‘'''""’等' 乂,巧二: , : ! 、 : ？ 丫、: 、《、:;： 
：會暴 /"、、‘ , ,、• -、 
, .rQl,么 , „‘,„. i':�/ ‘Z•：• / , , L ‘ - - �>-J^^SSih.-^、之:r；if 
ICI treatment 2h before TNF-a (M) 
TNF-a 10.9 5X10.9 q^-S 5X10"^ lO"' 5X10.7 10"^  
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4.2. Effects of P-AR agonists and antagonists on cyclin D2 gene expression 
a) Effects of common P-AR agonist/ antagonist with/ without TNF-a on cyclin D2 
gene expression 
ISO treatment only (M) 
C 10—9 5X10—9 10-8 10-7 10-6 10-5 10-4 
iiBiiiiliKilillilliiiiliiilli^  
PROP treatment 2h before TNF-a (M) 
TNF-a 10—9 10—8 10—7 10"' 10'' 5X10—4 lO"' 
, '1：：； ‘ ‘ ‘ ？雜 
b) Effects of PiAR agonist/ antagonist with/ without TNF-a on cyclin D2 gene 
expression 
D O B treatment only (M) 
C 10—9 5X10—9 10-8 10—7 10—6 10—5 10-4 
丨|_錢|丨錢缓錢I缀丨;:丨丨_驳錢鬆缀膝丨丨缀識ij丨丨：丨凝錢__ 
CRP treatment 2h before TNF-a (M) 
TNF-a 10-9 10-8 10:7 lO:'— :::<——JO:,:::::: 
C) Effects of P2AR agonist/ antagonist with/ without TNF-a on cyclin D2 gene 
expression 
P R O C treatment only (M) 
C 10—9 5X10-9 10-8 10-7 10-6 10-5 10-4 
ICI treatment 2h before TNF-a (M) 
TNF-a 10-9 5X10—9 q^-8 5X10"^ lO"' 5X10"' lO'' 
誦 擎霞m^.，.;九。…‘：鄉…〜•，…'、(c"'' '..".:、： ” ::::、 \ 、’：t:入、 
M m ： ^ 麵 ^ M k m : , 耐 ^ ^ ^ 比 … 气 ： … . , “ ‘ 。‘欲；、：：：減 
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4.2. Effects of P-AR agonists and antagonists on cyclin D2 gene expression 
a) Effects of common P-AR agonist/ antagonist with/ without TNF-a on cyclin D3 
gene expression 
ISO treatment only (M) 
C 10—9 5X10—9 10-8 10-7 10-6 10-5 10-4 
M^^^ii^i^i'^mMM^^^ 沒法键 _？丨资丨_ •“ •‘ 'mmmM ;)丨叙.::丨咨^ ^^ ps::::::!;::彩容：丨幻:::::丨::逸 
‘ ‘ ‘ ‘ ‘ “ “ ‘ ‘ ‘ ‘“ ‘ ''''''' ‘‘‘ 
P R O P treatment 2h before TNF-a (M) 
TNF-a 10-9 io_8 10—7 10"' 10"' 5X10"' 10"" 
, , :',々'''/''",/- ‘ '•. ‘ ：：'/ ..、,;• 夕/'' '/r'/f;' % , / 广 “ 心 : 々 . , : • ) 、 ‘ 
b) Effects of piAR agonist/ antagonist with/ without TNF-a on cyclin D3 gene 
expression 
D O B treatment only (M) 
C 10—9 5X10—9 10-8 10-7 10-6 10-5 10-4 
. 丨丨獲丨紹毅雜錄.. ...丨iiiil ：  :::殘iiiiP:丨. ..:.:.:.: .:•‘:.•.�".�..:丨※丨键錄丨^:丨::::::::::.::丨:::::丨:※：彳|丨_ 
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CRP treatment 2h before TNF-a (M) 
TNF-a 10-9 10-8 10-7 iq"' 10"' 10"' lO'' 
錢•露.^•：•••!•?；；!：*-!：：- iiii；： __iii_: i__i麗丨 ‘ - ‘ 
‘is； lllllf 111111 ‘ , 
C) Effects of P2AR agonist/ antagonist with/ without TNF-a on cyclin D3 gene 
expression 
P R O C treatment only (M) 
C 10—9 5X10-9 10-8 10-7 10-6 10—5 10-4 
ICI treatment 2h before TNF-a (M) 
TNF-a 10-9 5X10.9 q^-S 5X10'^ lO"' 5X10"' 10"' 
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4.2. Effects of P-AR agonists and antagonists on cyclin D2 gene expression 
a) Effects of common P-AR agonist/ antagonist with/ without TNF-a on cdk 4 gene 
expression 
ISO treatment only (M) 
C 10-9 5X10-9 10-8 10-7 10-6 10-5 10-4 
PROP treatment 2h before TNF-a (M) 
TNF-a 10—9 10-8 10-7 10"' SXIO'' 10"' 
一 ― ， , 、：;, “ • • 
b) Effects of Pi A R agonist/ antagonist with/ without TNF-a on cdk 4 gene expression 
D O B treatment only (M) 
C 10-9 5X10-9 10-8 10-7 10-6 iq-5 10-4 
Jf^ ^场^赢‘：^^ /！；拟；^〜臺，；^ "一'知，纖滅機^^嫩耀iS^:�':迭3厂衛旧..广〉’.、, 
CRP treatment 2h before TNF-a (M) 
TNF-a 10—9 10—8 10-7 q^"^  10"' 10"' 10"' 
c) Effects of P2AR agonist/ antagonist with/ without TNF-a on cdk 4 gene expression 
P R O C treatment only (M) 
C 10—9 5X10-9 10-8 10-7 10-6 10—5 10—4 
ICI treatment 2h before TNF-a (M) 
TNF-a 10—9 5X10-9 q^-S 5X10"^ 10"' 5X10—' 10'' 
一 】 > ___I__國___111111111|11 
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4.2. Effects of P-AR agonists and antagonists on cyclin D2 gene expression 
a) Effects of common p-AR agonist/ antagonist with/ without TNF-a on cyclin E 
gene expression 
ISO treatment only (M) 
C 10-9 5X10—9 10—8 10-7 10—6 10—5 10-4 
PROP treatment 2h before TNF-a (M) 
TNF-a 10-9 10-8 10-7 iq"' 10"' 5X10"' 10"' 
b) Effects of PiAR agonist/ antagonist with/ without TNF-a on cyclin E gene 
expression 
D O B treatment only (M) 
C 1(J9 5X10—9 10-8 10-7 10—6 10—5 10-4 
頃游II韓丨賴瘦商憩::丨丨：錢丨丨藝鐵丨殘丨：錢麗錢翁I鎮丨：籍III顯貌_鍋黨揮 
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CRP treatment 2h before TNF-a (M) 
TNF-a 10-9 10-8 10-7 iq"' 10"' 10"' 10"^  
i^iiiiiiiiis^  
C) Effects of P2AR agonist/ antagonist with/ without TNF-a on cyclin E gene 
expression 
P R O C treatment only (M) 
C 10—9 5X10-9 iq-8 10—7 10—6 10—5 10-4 
ICI treatment 2h before TNF-a (M) 
TNF-a 10-9 5X10-9 q^-S 5X10"^ 10'' SXIO'' 10"' 
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4.2. Effects of P-AR agonists and antagonists on cyclin D2 gene expression 
a) Effects of common P-AR agonist/ antagonist with/ without TNF-a on cdk 2 gene 
expression 
ISO treatment only (M) 
C 10—9 5X10-9 10-8 10-7 10-6 10—5 10-4 
PROP treatment 2h before TNF-a (M) 
TNF-a 10.9 10.8 10-7 iq"' 10"' 5X10"' 10"' 
.、、、、、:： ： X ” 、 ‘ 、 、 … 、 ： 、 」 • 、 “、為、、、、 、、；0、 
b) Effects of Pi A R agonist/ antagonist with/ without TNF-a on cdk 2 gene expression 
D O B treatment only (M) 
C 10-9 5X10-9 10-8 10-7 10-6 10-5 10-4 
< 感 i 悠 ‘ 献 臺 t 
CRP treatment 2h before TNF-a (M) 
TNF-a 10-9 10—8 10-7 lO"^  10；' 10；' 10"' 
c) Effects of P2AR agonist/ antagonist with/ without TNF-a on cdk 2 gene expression 
P R O C treatment only (M) 
C 10—9 5X10-9 10—8 10-7 10—6 10-5 10—4 
‘ “:、：：“：、、、、、:、、、：：、、、、£：、、；、hS^^^SSI；、 
ICI treatment 2h before TNF-a (M) 
TNF-a 10—9 5X10-9 q^-8 5X10-^ lO"' 5X10'' 10"^  
、 ： : : 、 ： 、 、 ： ^ 、：S: U 
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4.2. Effects of P-AR agonists and antagonists on cyclin D2 gene expression 
a) Effects of common p-AR agonist/ antagonist with/ without TNF-a on pi5 gene 
expression 
ISO treatment only (M) 
C 10-9 5X10-9 10-8 10-7 10-6 10—5 10-4 
：？：一 - , … . . 广 . ： 蓬 b � , ,一 狐 論 , 
PROP treatment 2h before TNF-a (M) 
TNF-a 10-9 10-8 10-7 iq"' 10"' 5X10—4 ^o"' 
b) Effects of Pi A R agonist/ antagonist with/ without TNF-a on pi 5 gene expression 
D O B treatment only (M) 
C 10-9 5X10-9 10-8 10-7 10-6 iq-5 10-4 
讓 _ _ _ _ _ _ _ | _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ 1 丨 _ _ 1 錢 | _ 禁丨:丨 I 丨丨淺赛：;丨丨丨 
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CRP treatment 2h before TNF-a (M) 
TNF-a 10-9 10-8 10-7 iq"' 10"' 10"' 10"' 
c) Effects of P2AR agonist/ antagonist with/ without TNF-a on pi5 gene expression 
P R O C treatment only (M) 
C 10-9 5X10—9 10-8 10-7 10—6 10—5 10-4 
顯 ： g l 纖 ; 巧 ？ ; ? ？ 、 ： ： “ 、：、： 
1 :.:’‘.、. ‘."、/ … ： 、 、 鲁 ， 德 
ICI treatment 2h before TNF-a (M) 
TNF-a 10-9 5X10-9 Q^-S 5X10"' 10"' 5X10—7 10'' 
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4.2. Effects of P-AR agonists and antagonists on cyclin D2 gene expression 
a) Effects of common P-AR agonist/ antagonist with/ without TNF-a on p27 gene 
expression 
ISO treatment only (M) 
C 10-9 5X10-9 10-8 10-7 10-6 10-5 10-4 
ii|iiliiiiilliiliiiiiiiiiiiil^  •^a；；: • •丨疑康！菌議_ii.-.二;;s__i蒙__擴____纖__顯_!_1_1菌_議____|1|1__嚷!_|;:_;麵__藝誦|| 
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P R O P treatment 2h before TNF-a (M) 
TNF-a 10-9 10—8 10-7 10"' 10"' 5X10—4 iq"' 
… 零 業 零 ’ “ ‘ * '''〜 
• ； ‘ ： 二 / " : 磨 多 、 ， te 、 、 、 、 、 • 、 、 、 、 “ . . ， 
b) Effects of Pi A R agonist/ antagonist with/ without TNF-a on p27 gene expression 
D O B treatment only (M) 
C 10-9 5X10-9 10-8 10-7 10-6 10-5 10-4 
CRP treatment 2h before TNF-a (M) 
TNF-a 10—9 10—8 10-7 10"^  10'^  lO"' 10'^  
雷 ' “ ‘ 麗 二 麗 ’ 翼 二 
C) Effects of P2AR agonist/ antagonist with/ without TNF-a on p27 gene expression 
P R O C treatment only (M) 
c 10-9 5X10-9 10-8 10-7 10-6 ^^  
霧 麵 • 〜 暴 潜 ；':〈:’ ’’’；’’，-、、;機〜、、-
’ 众'/^'''//v 么'….. ••••••••••••••••••••• ‘'•••'•^•‘‘ ‘ "X、、••狄、、、!Sx、、、、、V"、、o- W、、、、 、 、 \ 、 5 \ 、 " \ 、 V \ \ 、 N i W 、 • i J x 、 、 、 i > v 、 
ICI treatment 2h before TNF-a (M) 
TNF-a 10-9 5X10—9 q^-S 5X10"^ 5 X 1 1 0 — 6 
'瑪〜爾: "繁, -5； 丫；么…‘、-
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4.2. Effects of P-AR agonists and antagonists on cyclin D2 gene expression 
a) Effects of common P-AR agonist/ antagonist with/ without TNF-a on p21 gene 
expression 
ISO treatment only (M) 
C 10—9 5X10—9 10-8 10-7 10-6 10-5 10—4 
、，、, ''A 、！:•Ah: ,.„,, 二 , , ,，，， S h �〜广 , . J S ^ 〜 , , . / M L ： , !jr'::，分麥忍 
PROP treatment 2h before TNF-a (M) 
TNF-a 10-9 10-8 10-7 ^^ -e 5X10"^ 10'^  
b) Effects of Pi A R agonist/ antagonist with/ without TNF-a on p21 gene expression 
D O B treatment only (M) 
C 10-9 5X10-9 10-8 10-7 10-6 10-5 10—4 
“： "缚 
CRP treatment 2h before TNF-a (M) 
TNF-a 10-9 10-8 10-7 q^-s IQ"' 10"^  
c) Effects of P2AR agonist/ antagonist with/ without TNF-a on p21 gene expression 
P R O C treatment only (M) 
C 10—9 5X10-9 10—8 10-7 10—6 10—5 10—4 
::；：；：：*：：.：：：：：：! 
ICI treatment 2h before TNF-a (M) 
TNF-a 10—9 5X10—9 q^-s 5X10"^ 5X10"' 
’ 等 欲 , , - ‘ 
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4 . 2 . Effects of P-AR agonists and antagonists on cyclin D2 gene expression 
a) Effects of common P-AR agonist/ antagonist with/ without TNF-a on pi 30 gene 
expression 
ISO treatment only (M) 
C 10—9 5X10-9 10—8 10—7 10-6 10-5 10-4 
PROP treatment 2h before TNF-a (M) 
TNF-a 10-9 10-8 10—7 10"^  10"^  5X10—4 iq-4 
b) Effects of pi A R agonist/ antagonist with/ without TNF-a on pi 30 gene expression 
D O B treatment only (M) 
C 10—9 5X10-9 10-8 10-7 10-6 10-5 10-4 
謹聽：： •^•MMmMMMMi^m-. .11藝縫i: iisilss 議IS:. 麗i議： J藥鬚 IliiiligiiliwlsiiiHsp^  iiiiiitiiiiiliiii 
CRP treatment 2h before TNF-a (M) 
TNF-a 10—9 10—8 10_7 10"^  10"' 10"^  10"^  
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c) Effects of P2AR agonist/ antagonist with/ without TNF-a on pl30 gene expression 
P R O C treatment only (M) 
C 10-9 5X10-9 10-8 10-7 10-6 10-5 10—4 
:.•:—.‘..:..…..,.•..,..， .....^,,.................................；:；：：；；：；：<；；^；；；：：：：：：：：：：；：；；：：；：：：：：；：：；：：：：^：-：-：>^  ； 
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ICI treatment 2h before TNF-a (M) 
TNF-a 10—9 5X10—9 10'^  5X10"^ 10"^  5X10"^ 10"^  
；f ''''霍 % ‘‘：‘ <> ,‘々 ‘-VV-‘…'汉:"…‘,塔：、二、：广丫，、， 
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4 . 2 . Effects of P-AR agonists and antagonists on cyclin D2 gene expression 
a) Effects of common P-AR agonist/ antagonist with/ without TNF-a on Cak gene 
expression 
ISO treatment only (M) 
C 10—9 5X10-9 10-8 10-7 10-6 10—5 10—4 
P R O P treatment 2h before TNF-a (M) 
TNF-a 10-9 10-8 10-7 q^"^  10'' 5X10"' lO"' 
b) Effects of PiAR agonist/ antagonist with/ without TNF-a on Cak gene expression 
D O B treatment only (M) 
C 10—9 5X10—9 10—8 10—7 10—6 10-5 10-4 
霄:S擬:：署记:::巧�Y'.'、'；：级.丫：“ “ ‘ ：哪、，零 '、.“,::'〜'““雙','、？。、:八:::巧 
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CRP treatment 2h before TNF-a (M) 
TNF-a 10-9 10—8 10-7 10"^  lO"' 10'^  10"^  
_::„„、, 5|i|r •<»；• …… 
,, . :/券 \ . /Vlt • A:V； , . : ， , . . 7v->,-广 '”.，.,'/..、 
c) Effects of P2AR agonist/ antagonist with/ without TNP-a on Cak gene expression 
P R O C treatment only (M) 
C 10—9 5X10-9 10-8 10-7 10-6 10-5 10-4 
ICI treatment 2h before TNF-a (M) 
TNF-a 10-9 5X10-9 j^q-8 5X10"^ lO"' 5X10"' 10"^  
‘-r- '、 tv^  敬 \ …嫩、炉 
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4 . 2 . Effects of P-AR agonists and antagonists on cyclin D2 gene expression 
a) Effects of common P-AR agonist/ antagonist with/ without TNF-a on cyclin H 
gene expression 
ISO treatment only (M) 
C 10-9 5X10-9 10-8 iq-7 10-6 10-5 10-4 
P R O P treatment 2h before TNF-a (M) 
TNF-a 10—9 10—8 10-7 10'' 5X10—4 ^o"' 
1 ^^m ^^m i^ B,. ^^m ^ ^ 
b) Effects of piAR agonist/ antagonist with/ without TNF-a on cyclin H gene 
expression 
D O B treatment only (M) 
C 10—9 5X10—9 10—8 10-7 10-6 10-5 10-4 
CRP treatment 2h before TNF-a (M) 
TNF-a 10-9 IQ-8 10-7 10—6 10"' 10"^  lO"' 
IIIISIIIIIII* •SIPPLR^'-^^ ^ .…. 螺 翻珍•錢毅錢雜縫錢 JFG 
C) Effects of P2AR agonist/ antagonist with/ without TNF-a on cyclin H gene 
expression 
P R O C treatment only (M) 
C 10-9 5X10-9 10-8 10-7 10-6 10-5 10-4 
况一徵^P^rv ‘ ‘““ “‘ ‘：“’ ) 、 
ICI treatment 2h before TNF-a (M) 
TNF-a 10-9 5X10.9 10"^  SXIO"^ 10"^  5X10"^ 10"^  
—一, I — — � i r : : i « ! f ^ �、 
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4 . 2 . Effects of P-AR agonists and antagonists on cyclin D2 gene expression 
a) Effects of common P-AR agonist/ antagonist with/ without TNF-a on cyclin B 
gene expression 
ISO treatment only (M) 
C 10—9 5X10—9 10-8 10-7 10-6 10-5 10-4 
PROP treatment 2h before TNF-a (M) 
TKF-a 10-9 10-8 10-7 q^"^  10"' 5X10'"^  10"' 
' 脚 ‘ ^ f , 『 〒 “ ^ ^ ^ ^ ^ 纖 漏 
b) Effects of PiAR agonist/ antagonist with/ without TNF-a on cyclin B gene 
expression 
D O B treatment only (M) 
C 10-9 5X10—9 10-8 10-7 10-6 10-5 10-4 
CRP treatment 2h before TNF-a (M) 
TNF-a 10—9 10—8 10—7 10"^  10"^  10"^  10"^  
c) Effects of P2AR agonist/ antagonist with/ without TNF-a on cyclin B gene 
expression 
P R O C treatment only (M) 
C 10-9 5X10-9 10-8 10—7 10-6 10—5 10—4 
ICI treatment 2h before TNF-a (M) 
TNF-a 10-9 5X10-9 q^-8 5x10"^ ICT? 5X1 
； … 、 、 、 . 、 、 众 : 、 、 、 、 V . 泰 〉 
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4 . 2 . Effects of P-AR agonists and antagonists on cyclin D2 gene expression 
a) Effects of common (3-AR agonist/ antagonist with/ without TNF-a on bcl-XL gene 
expression 
ISO treatment only (M) 
C 10-9 5X10-9 10—8 10-7 10-6 10-5 10-4 
PROP treatment 2h before TNF-a (M) 
TNF-a 10-9 10-8 10-7 lO'' 5X10—4 
“ 丄 ‘ ； 〜 " ， ， , , 
b) Effects of PiAR agonist/ antagonist with/ without TNF-a on bcl-XL gene 
expression 
D O B treatment only (M) 
C 10—9 5X10-9 10-8 10-7 10-6 10-5 10-4 
CRP treatment 2h before TNF-a (M) 
TNF-a 10-9 10-8 10-7 iq'^  10"' 10"' 10"^  
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C) Effects of P2AR agonist/ antagonist with/ without TNF-a on bcl-XL gene expression 
P R O C treatment only (M) 
C 10—9 5X10—9 10-8 10-7 10-6 10—5 10—4 
— 一 
ICI treatment 2h before TNF-a (M) 
TNF-a 10—9 5X10-9 Q^-S 5X10"^ 10"' 5X10"' 10'^  
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4 . 2 . Effects of P-AR agonists and antagonists on cyclin D2 gene expression 
a) Effects of common P-AR agonist/ antagonist with/ without TNF-a on bcl-Xa gene 
expression 
ISO treatment only (M) 
C 10—9 5X10—9 10-8 10—7 10-6 10—5 10-4 
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PROP treatment 2h before TNF-a (M) 
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b) Effects of PiAR agonist/ antagonist with/ without TNF-a on bcl-Xa gene 
expression 
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c) Effects of P2AR agonist/ antagonist with/ without TNP-a on bcl-Xa gene expression 
P R O C treatment only (M) 
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4 . 2 . Effects of P-AR agonists and antagonists on cyclin D2 gene expression 
a) Effects of common P-AR agonist/ antagonist with/ without TNF-a on bcl-w gene 
expression 
ISO treatment only (M) 
C 10—9 5X10-9 10—8 10-7 10-6 10—5 10—4 
PROP treatment 2h before TNF-a (M) 
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b) Effects of pi A R agonist/ antagonist with/ without TNF-a on bcl-w gene expression 
D O B treatment only (M) 
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C) Effects of P2AR agonist/ antagonist with/ without TNF-a on bcl-w gene expression 
P R O C treatment only (M) 
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4 . 2 . Effects of P-AR agonists and antagonists on cyclin D2 gene expression 
a) Effects of common P-AR agonist/ antagonist with/ without TNF-a on Mcl-l gene 
expression 
ISO treatment only (M) 
C 10-9 5X10-9 10-8 10-7 10-6 10-5 10-4 
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b) Effects of PiAR agonist/ antagonist with/ without TNF-a on Mcl-l gene 
expression 
D O B treatment only (M) 
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C) Effects of P2AR agonist/ antagonist with/ without TNF-a on Mcl-l gene expression 
P R O C treatment only (M) 
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4 . 2 . Effects of P-AR agonists and antagonists on cyclin D2 gene expression 
a) Effects of common P-AR agonist/ antagonist with/ without TNF-a on P-actin gene 
expression 
ISO treatment only (M) 
C 10-9 5X10-9 10-8 10-7 10-6 10-5 10-4 
P R O P treatment 2h before TNF-a (M) 
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b) Effects of PiAR agonist/ antagonist with/ without TNF-a on P-actin gene 
expression 
D O B treatment only (M) 
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